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ABSTRACT
Peripheral neuropathy is estimated to afflict 20 million people in the United States. Most cases
of neuropathy result from physical injuries and trauma arising from automobile accidents and war.
Peripheral nerves have the intrinsic ability to regenerate over time, bridging the injury gap. However
native regeneration is limited to a distance of only a few millimeters. Current methods utilized to assist
in the regeneration of peripheral nerves over distances exceeding those amenable to native repair
include nerve autografts and allografts, and implantation of conduits. Nerve autografts are regarded as
the most effective method but require a second surgical site to access a donor nerve. Allografts are
similar to autografts except the donor nerve is from another individual and the patient therefore
requires a prolonged regimen of immunosuppressant medication. Conduits currently on the market
have equal or lower success rates relative to nerve autografts. Issues that arise with the use of the
current generation of conduits involve foreign body reaction, and the potential need for second
surgeries to remove the conduit. It is proposed that a biocompatible material such as nanocellulose may
serve as a viable alternative conduit construction material. The current work determined means by
which conduits comprising cellulose nanofibrils may be produced and evaluated their efficacy in
regeneration after a sciatic nerve injury in a murine model. Development of a GMP compliant process to
produce such cellulose nanofibril conduits was completed and a tolerability study was conducted in nonhuman primates.
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CHAPTER ONE
PERIPHERAL NERVOUS SYSTEM ANATOMY, PHYSIOLOGY AND NATIVE
REPAIR MECHANISMS
1.1 PERIPHERAL NERVOUS SYSTEM
The human nervous system comprises two elements: the central and the peripheral nervous
systems. The central nervous system (CNS) consists of the brain and the spinal cord, while the nerves
branching from the CNS are defined to be components of the peripheral nervous system (PNS) [1, 2].
Differences exist in the regenerative abilities of the CNS and PNS, due largely to the presence of
Schwann cells in the PNS [3, 4]. Injuries to the CNS can be life threatening, or lead to paralysis, as the
CNS lacks the ability to regenerate [5, 6]. In contrast, injuries to the PNS can often be repaired either
through native recovery, largely led by Schwann cells, or through surgical intervention [7]. The focus of
the current work is to improve the efficacy and distance over which peripheral nerve injuries may be
repaired through surgical intervention and via leveraging of the native ability of the PNS to regenerate.

1.2 PERIPHERAL NERVE ANATOMY
The structure of a peripheral nerve may be viewed as a bundle of bundles arrangement in which
each bundle is encapsulated in a sheath that separates it from its surroundings, see Figure 1 [8]. The
smallest fiber in a peripheral nerve is the axon (the functional unit of the nerve) which is encapsulated
by the endoneurium [9, 10]. A bundle of several axons, each encapsulated by endoneurium, constitutes
a fascicle [10]. The fascicle is encapsulated by the perineurium. A bundle of fascicles comprises the
nerve as a whole which is wrapped by the epineurium [10].
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As stated above, the smallest functional unit of a nerve is the axon [9]. Axons conduct electrical
signals known as action potentials and are typically surrounded by an insulating layer of myelin which
comprises a mixture of proteins and phospholipids. Myelin is deposited around the axons via Schwann
cells in relatively short, repeating segments. Gaps between the myelin segments are known as nodes of
Ranvier [9]. Interestingly, the myelin sheath of a given axon is deposited by a singular Schwann cell [11].
Efficient transfer of action potentials through an axon is dependent on the presence of both the myelin
sheath and the Nodes of Ranvier and occurs via the phenomenon of saltatory conduction [12].

Figure 1: Peripheral Nerve Structure
Adapted from Grinsell et al [104]

1.3 ACTION POTENTIALS AND PROPAGATION
Action potentials are electrical signals that are produced by the CNS and PNS to communicate
and to coordinate anatomical functions [13]. All cells possess a resting membrane potential that is
maintained through the action of ion channels resident in the plasma membrane [14]. Propagation of an
action potential occurs due to depolarization and repolarization of a membrane as a result of a stimulus
that alters the membrane potential to a value that exceeds a threshold depolarization value. There are
several key stages in action potential development and propagation that are summarized below and
depicted in Figure 2 [11].
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Figure 2: Action Potential Propagation
Stages of an action potential, adapted from [105]

When the threshold voltage is exceeded due to action of the stimulus, a depolarization cascade
ensues that drastically increases the membrane voltage (often resulting in membrane voltage changes
from of the order of negative 70 mV to positive values of the order of 30 mV). Depolarization occurs due
to an influx of sodium ions into the cell and the concomitant loss of potassium ions from the cell. The
shift towards a positive membrane potential during depolarization is due to the differential rate of
transport of sodium and potassium ions. Specifically, the diffusion rate of sodium exceeds that of
potassium and as such sodium ions enter the cell at a much higher rate than potassium ions leave,
resulting in an increasingly positive membrane potential. At the peak of the action potential (greatest
membrane potential), the repolarization phase is initiated via closing of the sodium ion channels and the
opening of potassium ion channels. Potassium ions are expelled from the cell and the membrane
potential returns to a negative, polarized, potential. Indeed, during repolarization, potassium ions may
leave the cell so rapidly that the membrane becomes hyperpolarized, that is temporarily assumes a
potential below that of the resting membrane potential. The resting membrane potential is however,
gradually restored [11, 14].
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In the time period after an action potential and during the hyperpolarization phase, the plasma
membrane has decreased sensitivity to stimuli, a phase referred to as the refractory period. The
refractory period may be broken into two stages. The first stage is termed the absolute refractory period
and is characterized by a complete lack of sensitivity to changes in the cellular membrane potential; no
additional action potentials may be initiated during this stage [14, 15]. The second stage is termed the
relative refractory period and is characterized by the fact that a second action potential may be
activated, but the threshold is greatly increased relative to that pre-action potential. Successive action
potentials are delivered through nerves via saltatory conduction.

1.4 SALTATORY CONDUCTION
Action potentials are propagated along both myelinated and unmyelinated nerve fibers of axons
[16]. The potentials are transferred without any decrease in magnitude. Each action potential stimulates
an adjacent area of the axon membrane to produce a new action potential. Therefore, each action
potential causes the production of additional action potentials sequentially along the nerve fiber, that is,

Figure 3: Saltatory Conduction of Action Potentials
Comparison of myelinated and unmyelinated axons [106]
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the action potential is propagated serially by making ‘copies’ of itself. Propagation of action potentials
along nerve fibers consequently differs from the flow of an electrical current through a wire, see Figure
3.
In unmyelinated axons, secondary (generated) action potentials are located immediately
adjacent to the initial action potentials. In myelinated axon nerve fibers however, the action potential
generated at one node of Ranvier may propagate rapidly or ‘jump’ (note the Latin word saltare – to
leap) across the myelinated nerve segment to the next node of Ranvier [11, 12]. Myelinated axons
propagate action potentials more efficiently than unmyelinated axons as fewer action potentials are
required to span the length of a given axon. Efficient propagation of action potentials is possible due to
the insulation provided by the proteins and phospholipids of the myelin sheath. In addition, it is noted
that the nodes of Ranvier contain a high concentration of sodium ion channels which aid in propagation
through efficient recreation of the action potential at each junction [16]. The speed of action potential
propagation is dependent upon the extent of myelination and on axon diameter. Specifically, thicker
and more abundant myelination as well as greater axon diameter result in increased rates of action
potential propagation [16].

1.5 WALLERIAN DEGENERATION
Peripheral nerve repair following an injury occurs via a complex pathway that may be broken
down into degeneration of the affected neural tissue (known as Wallerian degeneration), followed by
various phases of axonal regeneration, see Figure 4. Wallerian degeneration is the first major phase of
peripheral nerve repair and entails degeneration and removal of the damaged neural tissue to create an
environment amenable to nerve regeneration [17].
Interestingly, Schwann cells, which are responsible for generation of the myelin sheath of
peripheral nerves, and whose presence differentiates the regeneratable PNS from the non5

regeneratable CNS, are also crucial in the early stages of the repair process of peripheral nerve injuries
[18]. When subjected to physical trauma, peripheral nerves fragment and release a variety of cell types,
growth factors, and debris in the afflicted area. The segment of the axon distal to the injury site
commences disintegration/degeneration within a 24-36 hour period post injury, degeneration occurs
until the nearest node of Ranvier is reached [12]. During this time period, factors pertaining to
myelination are downregulated, while factors attributed to nerve cell adhesion and support are
upregulated. An immune response cascade is initiated at the distal stump by Schwann cells through
upregulation of a variety of cytokines [19, 20].

Figure 4: Wallerian Degeneration and Axonal Regeneration
Stages of reinnervation following a peripheral nerve injury [107]

Removal of degenerated neural tissue, myelin in particular, is key to repair as myelin is
inhibitory for the regeneration of axons [21]. Macrophages clear the debris via phagocytosis, whilst
6

simultaneously excreting factors that aid in Schwann cell migration to the site of the injury [22]. During
the initial phases of Wallerian degeneration Schwann cells aid in removal of debris. Wallerian
degeneration acts to remodel the surrounding tissues and provide an environment conducive to nerve
regeneration across the neural gap. The process is critical for neural repair as the distal stump is
prepared for reconnection to the proximal stump, and inhibitory debris is removed. Four factors have
been identified that dictate the efficacy of Wallerian degeneration: 1) the successful recruitment of
Schwann cells, 2) secretion of neurotrophic factors, 3) existence of the basal lamina (specialized
extracellular matrix), and 4) preservation of the distal nerve [23]. As the process of Wallerian
degeneration nears completion, axonal regeneration is initiated.

1.6 AXONAL REGENERATION
Whilst debris is cleared, primarily by phagocytosis via Schwann cells and macrophages, a
population of Schwann cells migrate to the distal end of the injury site, undergo a cell type transition to
a non-myelinating form, proliferate, and begin to form bands of Bunger [19, 24]. Bands of Bunger,
comprising longitudinally aligned Schwann cells, form inside each basal lamina tube which previously
held myelinated axons, thereby creating a columnar pathway that directs axonal growth to achieve
regeneration [22, 25]. Axonal growth cones in the form of filopodia, sprout from the proximal nerve
stump and extend towards the bands of Bunger, which provide support for the regenerating nerve [26,
27]. Axonal elongation is promoted through upregulation of both neural and vascular growth factors. It
is noted that successful regeneration may be impeded by an excessive distance required to bridge the
neural gap, and if the microenvironment is not amenable to regrowth. The regenerated nerve is remyelinated by Schwann cells, however distinct differences exist between the original nerve and the
regenerated one in terms of the thickness of the myelin sheath, and the length of nerve covered by each
myelin segment (i.e. the distance to the node of Ranvier) [17].
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1.7 LIMITATIONS OF NATIVE PERIPHERAL NERVE REGENERATION
As outlined above, peripheral nerves have the innate ability to self-repair, however several
factors dictate the extent to which regeneration is successful, and determine if surgical intervention is
necessary [28]. The response of the proximal stump to injury is dependent upon the location of the
transection/crush; if the damage is in the proximity of the neuronal body, then apoptosis may occur,
otherwise the stump will sprout growth cones and extend toward the residual distal stump. Ideally, the
response of the distal stump to injury follows the process of Wallerian degeneration leading to neural
tissue degeneration back to the nearest node of Ranvier, phagocytosis of cellular debris, and the
formation of bands of Bunger [12, 18].
Optimal recovery occurs for injuries that result in short axonal disruptions and limited damage
to the surrounding tissue. Compression and blunt-transection injuries however disrupt the endoneurial
tubing and create scar tissue which makes it difficult for bands of Bunger to form, leading to
disorganized tissue growth and poor recovery [12]. Full remyelination of axons may not occur after
regeneration due to poor stimulation of growth factors and hence limited activity by Schwann cells [29].
The length of the neural injury is negatively correlated with successful regeneration, that is, the greater
the length of neural transection/crush the poorer the prognosis for functional recovery. Unfortunately,
reinnervation and complete functional recovery are not synonymous. For example, even if neural
reconnection is successful, for large injuries the time required for repair may be too great and the
targeted, denervated muscle, may have atrophied beyond recovery [8, 30]. It is noted that muscle
atrophy may occur in as little as 3 weeks, however structural integrity of the muscle may be maintained
for up to a year. Fortunately, sensory end organs may maintain their integrity for two to three years
without enervation, potentially allowing sensory recovery even after functional muscle has been lost.
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It may be appreciated therefore that native nerve regeneration is possible, but for optimal
results is limited to specific injury types and extents, and requires the careful orchestration of a range of
degeneration and regeneration processes [18, 21]. It should not be surprising then that a range of
surgical interventions have been developed to aid in restructuring the injury site. For example, neural
transplants are a common approach, as are implants such as conduits that are employed to encase the
site, isolating it from the surrounding tissue, and concentrating necessary cell types/factors within the
neural gap [31, 32]. The various surgical methodologies for peripheral nerve repair, and their advantages
and disadvantages, are presented in the following chapter.
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CHAPTER TWO
SURGICAL INTERVENTIONS TO PROMOTE PERIPHERAL NERVE REPAIR
2.1 FREQUENCY AND SEVERITY OF PERIPHERAL NERVE INJURIES
Approximately 200,000 surgical procedures are performed each year in the United States to
address peripheral nerve injuries [33]. Less than 50% of such interventions result in full functional
recovery, and account for $150 billion of health-care expenditures annually [8, 34]. Most peripheral
nerve injuries occur in the upper limbs of young men (from 16-38 years old) and are the result of
traumatic events such as automobile accidents, sport injuries, or occupation-related accidents [35].
Common nerves that are affected by these traumas are the brachial plexus, ulnar, median and peroneal
nerves [35]. Peripheral nerve injuries are commonly graded using the Seddon-Sunderland classification
system which differentiates injuries via the severity of damage to the nerve (scale of I-V with V being the
most severe), see Table 1 [9].
Table 1: Nerve Injury Classifications
Summary of Seddon-Sunderland nerve gradations [8, 9, 36]

Grade

Classification

I

Neurapraxia

II

III

Axonotmesis

IV
V

Neurotmesis

Description
Internal neural compression, no Wallerian degeneration, address via
physical therapy
Axonal disruption, surroundings intact. Surgery generally not necessary.
Observe, recovery anticipated in months.
Compression injuries, endoneurium disruption. Wallerian degeneration
expected. Observe for up to 6 months and if poor recovery, surgery will be
necessary.
Blunt transection injury. Epineurium is only structure intact. Delay repair to
assess neural damage. Surgical exploration and reconstruction typically
necessary.
Lacerating injury, whole nerve is transected. Immediate repair required

Investigation of Table 1 reveals that severe peripheral nerve injuries occur via two means; blunt
trauma (crush) and laceration. Traumatic crush injuries are classified as grade IV in the Seddon10

Sunderland system and typically result in only the epineurium remaining intact. Frequently there is a
need to surgically intervene and debride the injury site to remove necrotic tissue and debris in order to
promote repair [28]. Lacerated nerve injuries (grade V in the Seddon-Sunderland system) are
characterized by complete neural discontinuity and require immediate surgical intervention, including at
a minimum debriding the injury site [36].

2.2 CURRENT APPROACHES TO PERIPHERAL NERVE REPAIR
2.2.1 NEURORRHAPHY
Neurorrhaphy, also known as end-to-end, or direct, repair is a surgical technique employed
when there is no loss of neural tissue and the two severed nerve stumps can be sutured together
without inducing excessive tension on the nerves [28, 36]. It is a common and generally successful
surgical method with several variants which are dependent upon the specifics of the neural injury as
presented in Figure 5 [37].

Figure 5: Methods of Neurorrhaphy
a) epineural repair, b) fascicular repair, c) Epineural sheath repair, d) single fascicle repair [108]

Figure 5a depicts epineural repair in which the epineurium of the severed nerve is reconnected
via sutures. Figure 5b presents fascicular repair in which the epineurium is retracted, and individual
fascicles are sutured together. Epineural sheath repair (Figure 5c) extends the intact epineural sheath of
one neural stump over the other stump, where it is sutured in place. In order to accomplish the overlap
of sheaths, a portion of neural tissue of the receiving stump must be resected. Lastly, Figure 5d depicts
single fascicle repair, a technique in which a single donor fascicle is sutured between the proximal and
distal nerve stumps. It is noted that all four of the surgical methods presented in Figure 5 require a great
deal of intricate suturing and have the potential to cause further damage to the injury site [9, 36].
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2.2.2 GRAFTS
For peripheral nerve injuries in which the neural gap is sufficiently large that the nerve stumps
cannot be reconnected without imposing significant tension, neural grafts are commonly utilized. Neural
graft repairs generally have very good regenerative outcomes, and have been termed the ‘gold
standard’ in peripheral nerve repair [38, 39]. The graft tissue may be sourced from the patient
themselves (autograft), from another individual (allograft), or be a modified natural material. For an
autograft, the donated nerve is sourced from a location of the patient deemed less important than the
injury site [33], and is often the sural nerve, which renders the relevant region of the leg sensationless
but not functionless [40]. Allografts are sourced from an individual other than the patient and as such
require a regimen of immunosuppressant treatment to reduce the likelihood of rejection of the
transplanted nerve [41]. Modified natural material grafts, such as AxoGen’s Avance Nerve Graft, are
produced from human peripheral nerve allografts processed to create an acellular extra cellular matrix
derived scaffold [28, 42]. Prior to implantation the grafts are sterilized via gamma irradiation to reduce
the likelihood of immunogenic responses, however such treatment has been shown to reduce the
efficacy of regeneration [41].

2.2.3 CONDUITS
Neural conduits are an alternative option for repair of severe injuries, and are typically
employed for neural gaps of 20 mm and less [41]. Conduits are advantageous in relation to nerve grafts
in that a second surgical site is not required, and immunosuppressant regimes are generally not needed.
Neural conduits are typically hollow cylinders into which the proximal and distal neural stumps are
inserted, as illustrated in Figure 6. Conduits are sutured in place to ensure that the nerve stumps remain
within the conduit throughout the regeneration process. The surgical methodology of employing a
conduit for peripheral nerve repair is referred to as entubulation [36].
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Figure 6: Method of Entubulation
Phases for peripheral nerve repair using conduit assisted repair [109]

The process of entubulation and the various phases of neural regeneration are depicted in
Figure 6 [41]. The first phase, known as the fluid phase, occurs on the day of surgical implantation and is
characterized by the presence of neurotrophic factors in the fluid filling the void within the conduit.
During the following week, a scaffold of extracellular matrix forms between the proximal and distal
stumps in preparation of cellular migration, a process known as the matrix phase. During the second
week post implantation various cell types are recruited into the luminal space, perhaps most notably
Schwann cells which accumulate at the distal stump, in what is known as the cellular phase, in
preparation of bands of Bunger formation and axonal regeneration. The final phase, referred to as the
axonal phase, is characterized by axonal sprouts occurring at the terminus of the proximal stump which
extend via the bands of Bunger to the distal end to effect neuronal repair.
When designing a neural conduit, the objective is to create a microenvironment surrounding the
injury site that is conducive to native regeneration, as outlined above. That is, to create an environment
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that promotes isolation and containment of specific growth factors and cells critical to the regeneration
process, whilst preventing an influx of inflammatory species [31]. Consequently, characteristics of
conduits that should be considered include selective permeability, biocompatibility, biodegradability,
structural stability and flexibility. In addition, the conduit should comprise a material amenable to
sterilization [28]. The neural conduits employed in early studies were typically comprised of silicon
(1982) [43] or Gore-tex (ePTFE, 1988) [44]. In the decades since these pioneering studies the number of
materials used in the production of neural conduits has increased dramatically, as summarized below in
the context of commercially available products:
a) Neurotube
Neurotube comprises polyglycolic acid (PGA), a highly crystalline and rigid polymer with low
solubility in organic solvents [45]. PGA is resorbable and has beneficial mechanical
properties for neural regeneration. Of the various FDA approved neural conduits, Neurotube
has the greatest amount of clinical data available [41]. Neurotube has been highly successful
in terms of clinical outcomes, surpassing neural grafts in certain studies, and has been
employed for the repair of neural defects in the range of 2-40 mm, with a few studies
performed on defects as large as 65 mm [46, 47].
b) NeuraGen, Neuroflex, NeuroMatrix, Neuromend and Neurawrap
NeuraGen, and associated conduits, are comprised of type 1 collagen, which is one of the
few naturally occurring materials employed in neural conduit production [41]. Collagen is
the most abundant protein in mammals, is easily isolated and purified, and presents a
minimal risk for immunogenic responses [41, 48]. NeuraGen and associated conduits have
performed well clinically, with outcomes that have been comparable to those obtained from
neural grafts for defects up to 20 mm [49, 50, 51].
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c) AxoGuard/Surgisis Nerve Cuff
AxoGuard/ Surgisis nerve cuffs comprise porcine small intestine submucosa (SIS) which is a
strong, yet pliable, collagen matrix. Submucosa grafts are cell free and therefore minimally
immunogenic [52]. SIS has been observed to assists in local tissue remodeling, and to induce
a systemic response to resist infection [53]. Comparatively little data has been published
regarding the efficacy of SIS in neural repair, however evidence of enhanced neural
regrowth has been reported [54].
d) Neurolac
Neurolac conduits comprise poly D,L lactide-co-ε-caprolactone (PCL), which is a hydrophobic
semi-crystalline polymer that is both straightforward and inexpensive to produce [41, 55]. It
is noted that Neurolac conduits are the only FDA approved transparent products available,
and are biodegradable, with non-toxic degradation products [55, 56]. Extensive pre-clinical
data suggests that PCL conduits approach the efficiencies of grafts in the repair of neural
defects up to 20 mm in length [41, 57, 58, 59, 60]. Clinical data of Neurolac conduit
entubulation has been reported for defects in the 5-20 mm range with positive results
observed [46, 61].
e) Salutunnel and Salubridge (PVA)
Salutunnel and Salubridge conduits comprise a non-biodegradable material, Salubria, which
is a synthetic polyvinyl alcohol hydrogel (PVA). The hydrogel mimics the water content of
human tissue, yet is readily sterilized and is mechanically stable [41, 62]. No data have been
published regarding pre-clinical nor clinical studies employing Salutunnel or Salubridge [41].

2.3 LIMITATIONS OF CURRENT METHODS OF PERIPHERAL NERVE REPAIR
As seen above, peripheral nerve repair requires the orchestration of multiple processes to
efficiently regenerate a nerve [21]. Natural regeneration of peripheral nerves is effective for minor
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injuries and for those occurring on short length scales, an injury that exceeds the capabilities of the
native regenerative processes however requires surgical intervention [9]. As would be expected, each of
the surgical repair methods outlined in the preceding section have limitations and associated
complications, which are reviewed below.

2.3.1 NEURORRHAPHY
Epineural sutures are employed when the damaged nerve has little or no tissue that has been,
or needs to be, removed. Such injuries often arise from a clean sever of the nerve [32, 37]. Direct repair
via epineural suturing is generally employed for neural gaps of less than 20 mm, and in scenarios where
the two neural stumps can be aligned end-to-end without the introduction of excessive tension [9]. The
process of epineural suturing can however subject the neural stumps to excessive handling and induce
greater damage than caused by the original injury [8, 9]. Though direct end-to-end repair via epineural
suturing is a common technique for the repair of minor nerve gaps, the success of the operation is
heavily reliant on the skill of the surgeon in correctly aligning the nerve stumps and executing effective
and minimally invasive sutures [9, 32]. Interestingly, some studies have demonstrated that implantation
of a conduit over a small neural gap had better regenerative results than direct repair via epineural
sutures, suggesting that conduit implantation may in the future become the preferred surgical repair
methodology for such injuries. [37]

2.3.2 GRAFTS
Neural grafts are often considered the preferred means of peripheral nerve repair, although
they are not without significant limitations [38, 41]. As stated above, there are two primary methods of
neural graft repair, autograft and allograft. Autografts are the generally preferred choice as the neural
tissue is donated by the patient that is receiving the graft and as such tissue rejection and immune
system responses are rare [42]. However, a significant issue with autografts is that they require an
additional surgical site and concomitant loss of sensation in the region of donation. If large numbers of
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grafts are necessary the stocks of lesser-important nerves are diminished and one must resort to more
impactful donor nerves, or employ alternate methodologies [42]. Conversely, allografts are neural grafts
donated by an individual other than the patient who is receiving the nerve [41]. Allografts require an
intense regimen of immunosuppressant medication for a period of approximately 18 months, a process
which renders the patient susceptible to numerous opportunistic infections, or in some cases, tumor
formation [41, 63]. Modified natural material grafts are an alternative that may be used to avoid the
issues associated with donor donation sites and immunosuppressant side effects [42]. Synthetic grafts
are donated tissues that have been processed to remove cells and hence decrease their
immunogenicity, such as the product Avance. Limitations that have been observed in the use of acellular
grafts include increased scarring and fibrosis attributed to host cell rejection, and reduced performance
as a result of degradation during neural processing and sterilization [41]. As such it may be appreciated
that while the degree of neural regeneration that can be achieved via grafts may be superior to other
surgical interventions, they are not without limitations, including those related to availability,
immunogenic responses, and potential performance issues due to degradation.

2.3.3 CONDUITS
Neural conduits are a viable alternative to neural grafts, particularly for neural gaps of 20 mm or
less. However, the performance of conduits decreases rapidly at larger neural gaps, a major limitation of
the technology, and one investigated in the present work [41]. Since conduits are a non-native
construct, the material of choice can be a major determinant of clinical success, or failure. As noted
above, conduits can be constructed employing natural or synthetic materials, and further, can be
designed to be biodegradable. Commercially available conduits and their specific limitations are outlined
below:
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a) Silicon/Teflon
Conduits comprising silicon and polytetrafluoroethylene (ePTFE) were employed in the
formative investigations of neural conduit entubulation. Performance of the conduits were
deemed acceptable for neural gaps of below 15 mm for silicon and 6 mm for ePTFE conduits
[43, 44]. Although both materials are considered biocompatible, neither biodegrade in vivo,
and as such a second surgery was required to remove the conduit post-regeneration.
Removal of the conduits was necessary as they were observed to restrict and compress the
regenerating nerve, creating a poor environment for full recovery [41].
b) Neurotube
Neurotube conduits, as stated above, comprise the synthetic polymer polyglycolic acid
(PGA). The mechanical properties of PGA conduits are favorable for regeneration in terms of
structural stability and the conduits biodegrade comparatively quickly, obviating the need
for a second surgery to remove the conduit post-regeneration. However, the degradation of
PGA produces acidic byproducts that are harmful to the surrounding tissues in the body [41,
46]. Consequently, while it has been observed that Neurotube conduits aid in the
regeneration of peripheral nerve injuries with neural gaps in the range of 10-30 mm, the
surrounding tissue is irritated and damaged upon conduit degradation thereby requiring
conduit removal despite its biodegradable nature [46, 64, 65].
c) NeuraGen, Neuroflex, NeuroMatrix, Neuromend and Neurawrap
The NeuraGen and associated conduits comprise collagen, which is a natural and abundant
protein [41]. Collagen is both biocompatible and biodegradable, making it a logical and
compelling choice for conduit production [48, 49]. The time scale for conduit degradation is
specific to the various associated conduits. NeuraGen for example has been found to remain
intact for up to 4 years in vivo, leading to unfavorable nerve compression comparable to
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that seen in silicon/ePTFE conduits. Other conduits comprising collagen have been found to
degrade in as few as 8 months [41, 51]. It should also be noted that instances of collagen
conduits eliciting an immune response, which have required the implementation of an
immunosuppressant regimen, have been observed [50].
d) AxoGuard/Surgisis Nerve Cuff
AxoGuard/Surgisis nerve cuffs comprise porcine small intestine submucosa (SIS) which have
been processed to create an acellular matrix comprising primarily collagen [53]. A major
limitation of SIS conduits is the incidence of immune responses (despite the removal of the
native cellular species), interestingly the responses appear to be dependent on the species
from which the material was harvested [41, 53]. The production process of SIS conduits is
lengthy and relatively expensive. In addition, the resultant conduits have large variability in
a range of physical/chemical properties, and indeed have a finite risk of infectious disease
transmission. There are minimal pre-clinical and clinical data for use of SIS conduits, so
assessments of efficacy are not currently possible [52].
e) Neurolac
Neurolac conduits comprise the polymer poly D,L lactide-co-ε-caprolactone (PCL) and, as
stated above, are the only FDA approved conduits that are transparent, an attribute that
aids in visualization of the surgical field during entubulation [41, 57]. PCL is however a very
rigid material, a fact that has resulted in difficulties in implantation including the inability of
surgeons to penetrate the conduit walls with needles during suturing, and associated
disturbances of the injury site [41, 66]. As such, surgeons often use larger needles and
sutures when implanting Neurolac vs other conduits, which has been observed to result in
tearing of the neural tissue during implantation or afterwards if the neural stumps are under
tension. Other issues that have been reported in association with Neurolac conduit
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implantation include severe swelling, fragmentation of the conduit, and conduit collapse
[58].
f)

Salutunnel and Salubridge
Salutunnel/Salubridge conduits comprise a synthetic polyvinyl alcohol hydrogel called
Salubria which is intended to mimic the high water content of human tissue [62, 67]. Though
mechanically stable, Salubria is non-biodegradable and has been shown to lead to neural
compression and potential tension of the suture attachment sites, further damaging neural
tissue. To date there have been no clinical studies published on Salutunnel/Salubridge
conduits making it difficult to gauge its efficacy in neural regeneration [41].

Table 2: FDA Approved Peripheral Nerve Repair Devices
Summary of positive attributes and limitations of device materials

Material

Tradename

Positive Attributes

Acellular Graft

Avance

Readily available
No donor site morbidity
Reduced surgical times

PGAPolyglycolic
Acid

Neurotube

Excellent degradability
Very good mechanical
properties
High cell viability
Comparable to grafts (20 mm)
Good efficacy up to 30 mm

Type I
Collagen

Neuragen
Neuraflex
Neurawrap
Neuramatrix
Neuramend

Abundant and easily isolated
Biocompatible
Supports cell adhesion
Supports tissue regeneration
Comparable to grafts (20 mm)
Good efficacy up to 40 mm

Porcine

Surgisis
AxoGuard

Physically supportive
Supports tissue regeneration
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Limitations
Increased scarring/fibrosis
Chance of host rejection
Requires
immunosuppression
High rate of degradation
Degradation products are
acidic
Low solubility
Slow degradation time
may lead to compression
(Neuragen only)
Most degenerate in 8
months
Undesirable immune
response
Immune response can
vary
Very high cost
Risk of infectious disease
transmission

Table 2 Continued

PCLPolylactidecocaprolactone

Neurolac

Only FDA-approved
transparent conduit
Comparable to grafts (20 mm)

PVA-Polyvinyl
Alcohol

Salubridge
Salutunnel

Tissue-like water content
Mechanically stable
Easily sterilized

High rigidity, difficult to
implant
Requires large
needles/sutures
Greater chance of neural
damage and foreign body
reactions
Non-resorbable, may
cause
tension/compression
No published studies on
efficacy of material

2.4 DESIRED PROPERTIES OF NEURAL CONDUITS
It is evident that the conduits currently used for entubulation vary greatly in their positive
attributes and in their limitations. Further, it may be seen that many of the positive aspects and the
limitations stem from the physical properties of the materials used to create the conduits [41]. In order
for entubulation to match and/or surpass the regenerative outcomes achieved via neural grafts,
conduits must be created that have been optimized in terms of their mechanical, biodegradation and
biocompatible/non-immunogenic properties. The relevant properties of currently available conduits,
and the areas yet to be fully optimized are addressed below.
The ability of a conduit to biodegrade in vivo in a manner that is safe, occurs on the relevant
timescale and that enables the maintenance of favorable mechanical properties during neural
regeneration is critical. Of the current FDA approved conduits, none meet all of these degradation
requirements. For example, Salubridge/Salutunnel conduits are non-resorbable and as such cause
compression of the nerve in the end-stages of regeneration leading to neural degeneration. Other
conduits, including those comprising PLC, collagen, and PGA do undergo degradation in vivo, but do so in
non- ideal processes, or on timescales that are incompatible with the regeneration process. For
example, Neurolac, composed of PLC, is biodegradable but is so rigid that the conduit is difficult to
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implant, and may fragment during degradation. Collagen conduits have a range of degradation times;
Neuragen, for example, degrades so slowly (4 years) that it essentially behaves as a non-degradable
conduit and engenders compression of the regenerating nerve. Neurotube, composed of PGA, degrades
on a favorable time scale and maintains excellent mechanical stability over the desired time period,
however the products of the degradation process are acidic, and are detrimental to surrounding tissue.
Therefore, a material has yet to be identified that has the required mechanical properties, undergoes
degradation in a timeframe comparable to that of neural regeneration, and whose degradation products
are benign.
Material selection for conduit construction must consider its biocompatibility/immunogenicity
and likely response of the body to its presence. Synthetic materials, such as polylactide-co-caprolactone
and polyglycolic acid have been observed to promote a foreign body response, and /or to produce tissue
inflammation upon degradation, as such use of man-made materials is often avoided. Conversely,
natural materials, such as collagen, which is a native protein in humans, may in fact elicit an immune
response and require an immunosuppression regimen which may have unintended consequences.
Attempts have been made to decrease the immunogenicity of naturally derived neural conduits by
making acellular variants, for example Avance (acellular nerve allograft) and Surgisis (acellular porcine
small intestine submucosa). The decellularization process employed to create the Avance grafts has
been shown to decrease the performance of the graft and to result in scarring and fibrosis, characteristic
of rejection. Surgisis is marketed as a non-immunogenic implant derived from porcine small intestine
submucosa; however, patient responses to entubulation have been shown to be dependent upon the
species of pig the conduit was harvested from. In addition, such implants have the potential to transmit
infectious diseases.
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2.5 TESTING OF THE EFFICACY OF CONDUIT ENTUBULATION FOR PERIPHERAL NERVE
REPAIR
Many animal studies have been performed to investigate the efficacy of conduit entubulation in
promoting peripheral nerve repair. Such studies have employed a wide range of animal models, and an
equally wide range of nerve types distributed throughout animals under investigation. To gauge the
effectiveness of nerve regeneration several forms of analysis have been employed, including grip
strength, gait analysis, tissue microscopy and histology. The wide variety of animal model, nerve type
and analytical methodology employed has made inter-experimental comparisons challenging, a fact
commonly acknowledged in the literature. Broad consensus has been reached, however, that several
specific conduits have been shown to perform as well as grafts up to a given injury length, and that
epineural suturing has been determined to be inferior to conduit implantation for small neural gap
injuries. Beyond these two broad conclusions however, little consensus has been reached. Indeed,
several sources have stated that there is a dire need for a large-scale experiment to be performed in
which all conduits available are tested, alongside grafts and neurorrhaphy, in the same animal trial to
ensure consistency in analytical methods and injury models to provide translational results for interexperimental comparisons [23, 33, 41]. Such a large-scale experiment could also provide a standard for
future conduit development such that new products could be tested in the same manner to create a
consistent database of products and techniques.
Table 3 provides a summary of several pre-clinical studies that have been performed to
determine the efficacy of specific neural conduits in the regeneration of peripheral nerve injuries.
Investigation of Table 3 highlights the fact that direct comparison of studies using the same animal
model, conduit, nerve type and analysis methodology is currently infeasible.
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Table 3: Sample of Pre-Clinical Studies Using Neural Conduits
MAP-Muscle Action Potential, SAP-Sensory Action Potential, EMG-Electromyography; adapted from Kehoe et al [41]

Author
Tyner
(2007)

Animal Model

Conduit Used

Rat

Neuragen

Archibald

Nonhuman

(1995)

primate

Archibald

Rat and

(1991)

primate

Waitayawinyu
(2007)
Dellon
(1988)
Meek
(2009)
Meek
(2009)
Meek
(2001)
Meek
(1996)

Rat

Nerve Used

Analysis Techniques

Sural,

Histology and autonomy

peroneal, tibial

scoring

Median and

MAP, SAP,

ulnar

histomorphology

Neuragen

Sciatic and

Neuragen

median

Neuragen

Sciatic

Neurotube

Monkey

Neurotube

Ulnar

Rat

Neurolac

Sciatic

Rat

Neurolac

Sciatic

Rat

Neurolac

Sciatic

Rat

Neurolac

Sciatic

MAP and SAP
Isometric contraction,
muscle weight, histology
Morphometric analysis and
electrophysiology
Functional analysis and
light microscopy
Microscopy
EMG and video gait
analysis
Walking track analysis and
electrostimulation

2.6 THE POTENTIAL OF CELLULOSE NANOFIBER FOR NEURAL CONDUIT PRODUCTION
It is evident from the preceding sections that an opportunity and a need exists for the
development of a neural conduit that minimizes immunogenicity whilst maximizing the characteristics of
biocompatibility, biodegradability and mechanical stability. Further, such development work should
employ a common animal model, a readily accessible nerve type, and standardized analysis
methodologies. Given that the materials employed to construct current neural conduits have all been
found to be deficient in one or more aspects, an alternate material, one not yet employed for conduit
production, should be evaluated.
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Cellulose nanofibrils (CNF) are an emerging natural material which is being evaluated for an
exponentially increasing number of applications in a large variety of fields. In the biomedical realm it has
been shown that CNF is relatively bio-inert [68], has excellent mechanical properties [69], degrades over
time in vivo [70], and is flexible [71]. CNF consists of cellulose fibrils of the order tens to hundreds of
nanometers in diameter, and hundreds of nanometers to many µm in length. The Process Development
Center (PDC) of the University of Maine has become one of the top suppliers of cellulose nanomaterials
in the world and is the only facility in the United States with 1 ton per day production capability [72].
CNF may be produced via a range of methodologies from a vast array of cellulosic and lignocellulosic
feedstock materials. At the University of Maine, CNF is generally produced from a Kraft bleached
softwood pulp with fiber diameters of tens of µm and is refined through means of mechanical
defibrillation in an aqueous slurry to attain fibril diameters on the nanoscale.
Preliminary work by the author demonstrated that CNF can be readily employed in slurry form
to produce thin sheets without additional treatment or functionalization, as presented in Section 4.1.
The sheets had sufficient pliability to enable the ready formation of a tube, or conduit. It is evident
therefore that CNF has the potential to be a viable material for neural conduit production, and that such
conduits may address many of the deficiencies of current conduits. The following chapters present the
work performed to develop, produce and characterize CNF neural conduits, to assess their efficacy in
neural regeneration in a common animal model using standardized testing methods, and to model their
facilitation of the diffusion of pro-regenerative species into the luminal space to shed light on the results
of the regenerative studies.
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CHAPTER THREE
EXPERIMENTAL METHODS
3.1 PULP PREPARATION
Wood pulp is the primary feedstock employed to produce CNF via mechanical defibrillation and
segmentation of cellulose fibers. Bleached softwood Kraft pulp was acquired through the University of
Maine Process Development Center from Resolute Forest Products. Oven-dried pulp (280 grams) was
cut into pieces approximately 15.2 cm x 15.2 cm and placed in an 18.9 L bucket containing 13.72kg of DI
water (17.4 MΩ-cm) and left overnight. The sheets of pulp were subsequently broken apart manually to
release fibers and fiber aggregates. The resulting aggregates were less than 1 cm in diameter.

3.2 CONFIGURATION OF CONTINUOUS REFINEMENT VIA A SUPERMASSCOLLOIDER
A supermasscolloider was purchased from Masuko Sangyo Co., Ltd (model MKCA6-2J). The
system was a benchtop model designed for batch refinement in which the lower of two stones (rotor) is
rotated by an electric motor, and the feed material is pumped into the space between the rotating stone
and a parallel, static, upper stone (stator). Coarse deep ditch stones (MKE6-46) of 15.2 cm diameter
were employed to refine CNF from the pulp slurry prepared as described above. It is noted that the
stones are generally used commercially to create pastes from fruits, vegetables, seeds, beans, rice etc.
and are constructed of a combination of silicon carbide and aluminum oxide.
In typical operation, the supermasscolloider (SMC) was designed for batch refining in which the
slurry makes a single pass through the system. If the desired slurry consistency was not achieved with a
single pass, additional passes of the slurry through the system would be implemented manually. The
refining of cellulose pulp to cellulose nanofiber however requires many passes through the SMC, as such
modifications were made to the supermasscolloider to enable continuous refinement. Specifically, an
extended hopper was added to increase the volume of feed material to the colloider, a recirculating
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pump and reservoir (14 L) system were installed, and an overflow line connecting the hopper to the
pump reservoir was implemented. The system was designed and built to contain a total slurry volume of
14 L between the overflow and the pump reservoir.
A

B

Figure 7: Supermasscolloider Refining System
(a) SMC refining system and (b) schematic view
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As shown in Figure 7, cellulose pulp slurry was gravity fed into the hopper at the highest point of
the SMC. The feed was directed into the gap between the rotor and stator stones where fibers were
defibrillated, prior to passing out of the discharge port of the SMC. The gap between the rotor and
stator was controlled via a manual adjustment with units of µm. The rotor was driven by an electric
motor (Masuko, 208V 1.5kW) with rotational speed of 800-3000 rpm set via a digital control system.
Cumulative electrical energy consumed by the motor driving the rotor for a given refining run was
monitored via both a cumulative and instantaneous wattmeter (Load Controls Inc, KWH-3 cumulative
meter and DM-100 instantaneous meter). The slurry discharged from the SMC was fed vertically into the
reservoir of a positive displacement pump (Moyno Sanitary Pump FB1D-SSF-SAA, Baldor General Severe
Duty 2HP/3-phase Gearmotor), the speed of which was controlled via a SMVector variable frequency
drive (Lenze AC Tech, ESV152N04TXC). Slurry exiting the pump was subsequently fed into a recirculation
line that led back to the feed hopper, thus completing a single refining cycle. Valves were incorporated
into the recirculation line at two separate locations to facilitate removal of slurry from the system.
Specifically, at the lowest point of the recirculation line a waste port and valve were installed to enable
complete drainage of the system prior to cleaning. A sampling port and valve were installed
approximately halfway up the recirculation line and were used to remove aliquots of the slurry as
desired. As the flow rate of the pump was greater than the observed flow rate of slurry through the
SMC, an overflow line was installed to direct excess slurry from the feed hopper to the pump reservoir.
All piping, valves and fittings were 316 stainless steel and approved for food grade applications. The
SMC was equipped with a water jacket for removal of excess heat generated during refining; cold
municipal water was fed through the jacket at a rate of 5.1 L/minute. An image and a process flow
diagram of the supermasscolloider configured for continuous refining may be seen in Figures 7a and 7b,
respectively. Figure 8 presents detailed images of specific components of the system.
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In order to provide a consistent and clean environment for CNF production, the SMC system was
constructed within a temperature-controlled ISO 7 class cleanroom which included four HEPA filters and
a custom recirculation chamber, see Appendix A1. The cleanroom was divided into a gowning area and a
working area, with designated zones for each stage of the CNF and conduit production process, see
Appendix A2. All procedures used in CNF production and neural conduit construction were developed,
implemented and documented employing Good Manufacturing/Laboratory Practices (GMP/GLP) [73].
Appendix A3 provides Standard Operating Procedures (SOP) for all facets of CNF and conduit
production.

Figure 8: Supermasscolloider Refining System Components

3.3 SMC OPERATION
SMC operation was initiated by opening the gap between the refining stones (via the clearance
adjustment) prior to turning on the drive motor; failure to separate the stones prior to engaging the
drive motor could result in damaging them and/or the motor. The rotational speed of the stones was
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initially set at 2,000 rpm, once this was achieved the gap between the stones was gradually decreased
until there was a tonal change in the system characteristic of grazing stone contact. The inter-stone
distance was set to zero under this condition via locking the gauging sleeve, and was used thereafter as
a reference point, termed the zero point. Once the zero point had been determined and set, the interstone gap was opened to positive 50 µm in preparation for introduction of the pulp suspension to the
system via the feed hopper. Feeding the system with an open but restricted gap ensured that all of the
pulp that passed into the system experienced a preliminary refining period and that all fiber aggregates
were subsequently broken down to dimensions less than the 50 µm inter-stone gap. When sufficient
pulp suspension had been fed to the system to fill the intake line of the pump (14 L), circulation of the
suspension was commenced via energizing the pump (set to 14.4 L/min). The system was filled to its 14
L capacity, at which point the slurry in the hopper continuously passed into the overflow passage for
recirculation. Once the system was full and recirculation had commenced, a slurry sample, referred to as
a zero-time sample, was taken from the recirculation line entering the hopper, via filling a 100 mL
container; the inter-stone gap was subsequently reduced to negative 100 µm. There is intentional
flexibility in the positioning of the stones such that when they are adjusted to a negative distance
setting, the fluid between the stones will keep them flexed outward preventing harmful contact of the
stones whilst providing pressure for grinding.
At each 15-minute time interval beyond the zero-time of the run, a 100 ml sample was removed
from the system (with care taken to ensure that the total volume removed for the run did not exceed 1
L). When sampling from the SMC system, the gap was opened for one minute to positive 100 µm to
allow the slurry to circulate freely throughout the system and to mix with the contents of the pump
reservoir. The gap was subsequently returned to negative 100 µm, the cumulative electrical energy
consumption of the run was recorded from the power meter, and the 100 ml sample was taken for offsite morphological analysis. It is noted that the SMC was typically run to a targeted cumulative energy
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consumption value, which was demonstrated to correlate with reproducible CNF fiber morphology, see
Section 3.5. A final sample was collected before removing the CNF from the system by opening of the
waste valve on the recirculation line to allow the pump to force the slurry out of the system versus into
the hopper. The pump was shut off prior to its inlet line being emptied (which would have risked
damage to the pump). The system was subsequently cleaned by running a copious amount of DI water
through it; the system was deemed clean when no fibers were visible in the waste stream.

3.4 CNF SLURRY CHARACTERIZATION
During the refining process, the viscosity of the pulp slurry increases dramatically as the
percentage of fines (fibers less than 200 m) increases, see Figure 9. The increase in viscosity is
attributed to the progressively greater fiber/fibril entanglements that occur as the pulp fibers are
increasingly segmented and defibrillated. The dramatic increase in viscosity (several orders of
magnitude) makes refining a challenge as it becomes increasingly difficult to pump the slurry.
Fortunately, however the CNF slurry is shear thinning, a fact that does enable processing if great care is

Figure 9: Viscosity Characteristics of CNF Production by Percent Fines
Viscosity of refined cellulose nanofiber slurries, at ~2% solids by weight, over a range of percent fines
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taken in system design and operation. It is noted that the high viscosity of the CNF slurry also impedes
mixing, care must therefore be taken to avoid inconsistencies throughout CNF slurry production, and
other downstream processes. The viscosity of a CNF slurry is also heavily dependent upon the solids
content. Care must therefore be taken to ensure CNF slurry production is performed at a solids content
that enables appropriate fluid flow (typically 3wt% CNF or less).

3.5 CNF MORPHOLOGICAL DETERMINATION/DEVELOPMENT OF CALIBRATION CURVES
The MorFi Fiber and Shiv Analyzer (Techpap MorFi Compact) is the standard device employed in
the pulp and paper industry to measure fiber size, fiber diameter, distribution of these values, kink
angle, etc. The MorFi Fiber and Shiv Analyzer, referred to hereafter as the MorFi, housed in the Pilot
Plant of the UMaine Process Development Center was employed throughout the present work for CNF
fiber analysis. Specifically, a 25 g sample of CNF slurry produced by the supermasscolloider was diluted
via addition of DI water bringing the solution up to 1 L, followed by a subsequent 1:100 dilution with
deionized water to produce a 50 mg/L CNF slurry. The diluted suspension was circulated through the
MorFi where several images of the fibers were taken. The MorFi performed several calculations on the
images of the fibers in the diluted suspension and determined arithmetic means, distributions etc. of
fiber physical parameters. Fibers that were greater than 200 µm in length may be measured by the
MorFi; fibers of smaller dimensions that are not able to be measured are termed ‘fines’ and are
reported as such. Consequently, a CNF slurry that had been measured by the MorFi as containing 90%
fines comprised particulates, 90% of which had lengths less than 200 µm.
MorFi analysis was employed to track the progress of the refining of cellulose pulp to cellulose
nanofiber through progressive segmentation and defibrillation, see Figure 10. It is important to note
that the feedstock softwood pulp has a significant native percentage of fines (23%), prior to refinement
in the SMC. Development of a consistent method to produce CNF resulted in the adoption of a 90% fines
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slurry at a solids content of 2 wt% as the standard material for production of CNF sheets and hence
conduits.

Figure 10: MorFi Fiber Characteristic Analysis
MorFi fiber analysis of the transition of fiber into fines through refinement of wood pulp (left) into cellulose nanofibers
(right)
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Cumulative energy consumption of the drive motor for the rotor of the SMC system (i.e. not
including the recirculating pump energy consumption) was shown to be strongly correlated with the
resultant cellulose fiber size, and the fiber distribution. As such, desired fiber distribution values were
achieved through establishment of calibration curves, in triplicate, between fiber size/distribution and
cumulative energy consumption values, see Figure 11.

Figure 11: Correlation of Energy and Fines
Calibration of improved refining system to correlate fines with energy input for three trials

3.6 SHEET FORMATION
CNF was employed at 2 wt% solids and 90% fines to create sheets by spreading onto stainless
steel plates. A casting knife film applicator was used to spread CNF into a wet sheet of 75 thousandths of
an inch (~1.9 mm) thickness. The sheets were left to dry overnight on the stainless-steel plates under
ambient conditions. The dried sheets were removed using razor blades to gently trim the sheets’ edge
from the plate followed by lifting the sheets from the top to the bottom as the edges were trimmed.
After sheet removal, the sheets were left to adjust to standard temperature and humidity (23ºC and
50%RH) in the Process Development Center (PDC’s) TAPPI room.
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3.7 CNF SHEET THICKNESS MEASUREMENTS
The thickness (caliper) of dried CNF sheets was measured employing a benchtop digital
micrometer (TMI, 49-85) housed in the TAPPI room of the Pulp and Paper Process Development Center.
Prior to making thickness measurements, CNF sheets were allowed to acclimatize for a 24-hour period in
the 23 ºC, 50% relative humidity conditions of the TAPPI room. Individual sheets were measured in
twelve locations in a 3 row by 4 column configuration in the landscape orientation, with measurements
evenly spaced. A mean and standard deviation were calculated from the twelve measurements of each
sheet.

3.8 TENSILE STRENGTH MEASUREMENTS
The tensile strength of CNF sheets was measured employing a combination of TAPPI standard
methods 220 (pulp handsheets) and 494 (paper and paperboard). Specifically, the sample size was as
defined in TAPPI standard method 220 (10 cm in length by 1.5 cm in width), and the rate of elongation
remained constant as per TAPPI standard method 494 (25 mm/min). CNF sheets were acclimatized to
the temperature and relative humidity of the TAPPI room for 24 hours prior to measurements being
made. An Instron model 5564 running the Instron Bluehill software package was employed to perform
tensile strength measurements. Samples were cut to the specified dimensions and clamped within the
upper and lower grips of the Instron machine, extension and load were recorded until the sample broke.
It is noted that when casting the CNF sheets the action of the draw knife spreading the slurry potentially
creates a ‘machine direction’; as such samples for tensile testing were cut both parallel to, and
perpendicular to, the machine direction.
To calculate the Young’s modulus of each sample, load and extension were converted to stress
and strain, respectively. Stress was found through dividing load by the cross-sectional area of the test
strip. Strain was calculated as the ratio of the deformed length to the original length of the test strip.
Stress was plotted on the y-axis as a function of strain on the x-axis. Young’s modulus is defined as the
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initial, linear, slope of the stress-strain curve and was determined by maximization of the R-squared
value of the fitted trend line for each sample [74].

3.9 AIR PERMEABILITY MEASUREMENTS
Air permeability of CNF sheets was measured employing a Gurley 4340N Automatic Densometer
and Smoothness Tester equipped with an air filter and desiccator to ensure the input air was clean and
had a low moisture content. The Densometer was housed in the TAPPI room of the Process
Development Center; all CNF sheets were acclimated in the TAPPI room for 24 hours prior to
measurements being undertaken. The Densometer measured the amount of time required to pass 100
cubic centimeters of air through the material being tested, with data reported in Gurley Seconds. The
greater the number of Gurley Seconds measured for a given sample, the less permeable it was. The
measurement was performed by placing a CNF sheet into the Densometer where it was clamped in
place over a charged cylinder that released air onto one surface of the sheet. Air that passed through
the sheet flowed through an exit chamber equipped with a flow meter. The results from each test were
recorded manually from the instruments display.

3.10 OXYGEN PERMEABILITY MEASUREMENTS
The oxygen permeability of CNF sheets was determined employing a MOCON OXTRAN 2/22 OTR analyzer. CNF sheets were cut and double masked with aluminum foil to an area of 5
cm2 and adhered to the lightly greased sample cell of the analyzer. The two halves of the sample cell
were brought together on the respective sides of the sample to hold it in place and were pneumatically
sealed during testing. Sample cells were subsequently loaded into the analyzer and 8 oxygen
transmission rate tests were performed at four relative humidity values (duplicate measurements were
performed at each relative humidity value). The temperature of the sample was maintained at 37ºC and
the permeant concentration of oxygen was set to 100%. The relative humidity was altered by
modification of the test and carrier gas humidities permeating the sheet. The relative humidities
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employed in the present work were 0%, 50%, 80%, and 90%. The duration of the measurement varied as
the test was performed until a transmission rate was converged upon. Measurements were terminated
when five consecutive transmission rates differed by less than 1%. The final value of transmission rate
was converted into a permeation rate via normalization by the thickness of the CNF sheet. The resulting
data at the four relative humidities were plotted and a value for the permeation rate of the CNF sheet at
100% was obtained via extrapolation. Oxygen permeability was measured by Dr. Mehdi Tajvidi of the
University of Maine on CNF sheets provided by the author.

3.11 DIFFUSION COEFFICIENT OF GLUCOSE IN A CELLULOSE NANOFIBER SHEET
The diffusion coefficient of glucose in the cellulose nanofiber conduit wall was determined
experimentally in the present work. Specifically, a series of tanks were designed and constructed that
were equipartitioned via a cellulose nanofiber sheet comparable to those employed to create the
conduits (~ 50 m in thickness (dry)). One chamber per tank was filled with a phosphate buffered saline
(PBS) solution of known glucose concentration (referred to as the donor chamber), the other chamber
was filled with a PBS solution of zero glucose concentration (referred to as the receiver chamber). Due
to the concentration gradient, glucose diffused across the CNF sheet from the donor to the receiver
chamber; glucose concentrations in the receiver container were monitored as a function of time to
enable calculation of a diffusion coefficient. Specifically, the diffusion coefficient was calculated via a
method adapted from that of Suhaimi et al. [27], represented by Equation 1:
Equation 1: Fick's First Law Adaptation

𝜕𝐶𝑑
𝐶𝑑 − 𝐶𝑟
= −𝐷𝑒 𝐴 ∙
𝜕𝑡
𝑙 ∙ 𝑉𝑑

1

→
𝐴∙

𝐶𝑑 − 𝐶𝑟
𝑙∙𝑉

∙

𝜕𝐶𝑟
= 𝐷𝑒
𝜕𝑡

where 𝐶𝑑 and 𝐶𝑟 are the initial glucose concentrations of the donor and receiver chambers, respectively,
in mol/m3. 𝑙 is the thickness of the CNF sheet in meters, 𝐴 corresponds to the area of the CNF sheet in
m2, 𝑉 represents the volume of the donor/receiver chambers (which were equivalent) in m3, 𝜕𝐶𝑟 is the
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difference in glucose concentration measured in the receiver chamber in mol/m3 for a given time
interval of 𝜕𝑡 in seconds. Finally, 𝐷𝑒 is the effective diffusion coefficient of CNF to glucose in m2/s. It is
noted that all parameters in Equation 1 are known from the experimental design, or may be measured,
to yield a diffusion coefficient.
The bi-chambered tanks, see Figure 12, were constructed from 3.175 mm thick polycarbonate
with internal dimensions of 50 mm H x 50 mm W x 80 mm L; an acrylic plastic cement adhesive (SciGrip
16) was employed to glue and seal all joints. A central divider was implemented to separate the tanks
into two equal sized chambers. The divider was constructed of two 50 mm x 50 mm pieces of
polycarbonate from which approximately a 40 mm x 42.5 mm rectangle of polycarbonate had been
removed from the center. A 50 mm x 50 mm sheet of CNF was placed between the two polycarbonate
divider components and sandwiched in place employing SciGrip 16 adhesive. The divider was
subsequently glued in place, again employing SciGrip 16 adhesive. After all the joints had cured (24

Figure 12: Glucose Diffusion Experiment
Glucose diffusion tank experimental setup for elucidation of the glucose diffusion coefficient of CNF sheets
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hours), the chambers of a given device were filled with PBS solutions containing, or not, a defined
concentration of glucose and subsequently sealed from the atmosphere employing Parafilm®.
Glucose concentration was measured in the receiving chamber employing a glucose hexokinase
assay kit (Sigma Aldrich GAHK20). The assay kit operates via a two-step enzymatic reaction. Specifically,
glucose and ATP are enzymatically phosphorylated to glucose-6-phosphate and ADP by hexokinase.
Subsequently, glucose-6-phosphate dehydrogenase converts glucose-6-phosphate and NAD into 6phosphocluconate and NADH. Each reaction is equimolar and consequently the concentration of NADH
(which may be measured spectroscopically at 340nm) is directly proportional to the amount of glucose
present in the original sample.

Figure 13: Glucose Hexokinase Assay Standard Curve
Standard Curve for known glucose concentrations using a glucose hexokinase assay kit, error bars
included using one standard deviation

A calibration curve for NADH absorbance at 340 nm vs glucose concentration was developed
employing the assay kit and standard solutions prepared with known glucose concentrations in 1x PBS.
Glucose concentrations spanned the biologically relevant range of 0 – 6 mmol/L in increments of
1mmol/L. The measured NADH absorbance at 0 mmol/L was invariant from the reference and was
hence was determined a single time. The remaining 6 standards were tested in triplicate. A linear
calibration curve resulted from the measured absorbance values with an r-squared value of 0.9997, see
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Figure 13. Four bi-chambered diffusion tanks were created, resulting in a total of 12 absorbance values
(and hence glucose concentrations) spanning a measured time range of 3 hrs to 96 hrs, see Appendix
A4.
All parameters in Equation 1 were either defined by the experimental design, or readily
measured, with the exception of CNF sheet thickness. The dry thickness of the sheet was readily
determined using a digital caliper as 50 ± 2 m. However, the relevant sheet thickness is that in the
hydrated state. As such wet sheet thickness was measured via a digital caliper as approximately 70 m,
indicating significant swelling, an observation confirmed via determination of the mass of water uptake.
A sheet thickness of 70 m was consequently used when employing Equation 1. Employing the data
gathered from the bi-chambered diffusion experiments the glucose diffusion coefficient in CNF sheets
was determined to be 1.7 ± 0.9 x 10-11 m2/s, a value employed in subsequent COMSOL modeling.

3.12 CNF SHEET POROSITY
The porosity of CNF sheets was determined via the technique of mercury porosimetry
employing a Micromeritics Autopore IV porosimeter. Specifically, the mass of a sample of a CNF sheet of
approximately 0.02-0.03 g was measured to four decimal places and the sample mounted in the
penetrometer. The penetrometer was subsequently sealed and inserted into the pressure chamber of
the porosimeter. The pressure exerted on a reservoir of mercury in contact with the sample was
progressively increased, thereby altering the characteristic contact angle of the mercury and forcing it
into progressively smaller pores within the sample. The inverse relationship between pore size and
applied pressure enabled calculation of pore size, pore size distributions, cumulative volume etc. The
resulting data was exported in both numerical and graphical form. Mercury porosimetry measurements
were performed by Dr. Lisa Weeks of the University of Maine on CNF sheets provided by the author.
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3.13 CNF SHEET TOPOGRAPHY
The topography of CNF sheets was measured employing a Tencor Alphastep 500 mechanical
profilometer. Specifically, CNF sheets were cut into strips approximately 38 mm long by 6 mm wide.
Samples were cut in both the machine and cross-machine directions to check for variability. Each sample
strip was fixed to a glass slide using double-sided tape. Samples were attached with either the side that
dried in contact with the stainless-steel plate during sheet formation up, or the side that dried exposed
to air up. Individual samples were loaded into the profilometer such that the stylus could scan from left
to right, parallel to the length of the sample and centered on the width of the sample. The stylus
position was set to zero at approximately ¼ of the sample length from the left edge. The profilometer
was set to scan a 2 mm length and record the average surface roughness. The measurement was
repeated for a total of three measurements per sample. It is noted that samples were taken from sheets
cast on two different plates. Each combination of plate used for casting, machine or non-machine
direction, and exposed surface during drying were tested 6 times.

3.14 CONDUIT FORMATION
In early work, conduits were made by employing a simple rectangular pattern of CNF sheet to
roll cylinders comprising 2 to 7 layers; 2 layers became the standard over time based on feedback from
surgeons regarding rigidity and transparency. Typically, conduit patterns were cut with dimensions of
1.5 x 2.5 cm. The pattern was rolled around a mandrel with a diameter of 1.65 mm to produce a 2layered conduit that was 2.5 cm in length. Initially, conduits were sealed on the final wrap using water to
leverage the native hydrogen bonding properties of cellulose. It was discovered however that as the
diameter of the conduits increased 2 to 3-fold, the water seal was insufficient, and conduits had a
tendency to delaminate and completely unroll. Improvements were made to the conduit design by
employing CNF slurry instead of water to seal the final wrap. The slurry seal proved to be a dramatic
improvement for smaller diameter conduits, however inconsistent results were obtained at the largest
diameters.
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To address the inconsistency of seal effectiveness at large diameters, i.e. 3-fold and larger, a
mechanical interlock was developed for the outer layer. The interlocks consisted of tabs and
corresponding slits. The interlocks proved so effective that they were adopted for all diameter conduits,
and in later work interlocks were applied to the interior layer as well, see Figure 14. CNF slurry was
applied to the exterior tabs after they had passed through the exterior slits in order to adhere the tabs
to the conduit wall.

Figure 14: Mechanical Interlock Design
Conduit design with exterior and interior interlocks to aid in retention of structural stability

An additional coating of CNF was applied postproduction to improve the structural integrity of
the conduits. Specifically, after the slurry seal of the conduit and its tabs had dried, and before removal
of the conduit from the mandrel, an outer coating of 2 wt% CNF was applied to the conduit by
submerging it in an aliquot of slurry. The coating was allowed to dry overnight whilst undergoing
constant rotation, thereby creating a seamless final layer on the conduit.

3.15 PACKAGING
Completed conduits were packaged in polypropylene bags in preparation for shipping. Fully
dried conduits were removed from the mandrels and inspected for any visible defects. It was common
that residual CNF coating had to be removed from the ends of the conduit in order to provide a perfectly
smooth and regular conduit. Conduits that passed visual inspection were bagged and sealed using an
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impulse sealer under ambient conditions (ULINE H-161). Each polypropylene bag was labeled with the
following information: conduit interior diameter, conduit length, description of conduit pattern, initials
of producer, date produced, as well as a customized identification code. The identification code allowed
tracking of production parameters such as pulp changes, slurry changes, which sheet the conduits were
cut from, as well as additional notes as necessary. After each conduit had been packaged, they were
sent to an off-site sterilization center where the conduits were subjected to ethylene oxide sterilization.

3.16 ETHYLENE OXIDE STERILIZATION
Conduits were sterilized using ethylene oxide gas (Anprolene, model number AN74i). Heatsealed packages containing individual conduits were opened and each wrapped in a non-woven fabric
sheet (Dynarex, CSR wrap) and placed in a resealable plastic bag. Each pouch was equipped with an
Andersen package closure indicator strip to verify sufficient exposure to ethylene oxide gas upon
treatment. Progressive exposure to ethylene oxide resulted in migration of a blue indicator bar from the
left side of the strip toward the right side. Correct exposure to ethylene oxide had been achieved when
the indicator bar reached a triangular mark on the strip. The resealable pouches, complete with
indicator strips were left open, packed in a single liner bag and placed into the sterilization chamber.
Care was taken to ensure that as the pouches were loaded into the liner bags, all pouches remained
opened and if stacked they were not stacked on the opening of another. An additional indicator strip
was inserted into approximately the center of the liner bag. One ampoule of ethylene oxide, in a gasrelease bag, was inserted into the top of the liner bag followed by the purge probe. The opening of the
liner bag was then sealed around the neck of the probe with a Velcro strap. With the door of the
chamber open, the liner bag was purged for 1.5 minutes, removing some but not all air from the liner
bag. The ampoule at the top of the liner bag was then carefully broken manually and the sterilization
cabinet door was quickly closed and locked. The ethylene oxide gas released then filled the liner bag as
well as the individual resealable pouches. The sterilization cycle proceeded for a 24-hour period; upon
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completion, a two-hour air purge process was undertaken. All indicator strips were examined to confirm
sufficient ethylene oxide exposure. Subsequently the chamber was unloaded and the resealable
pouches were sealed while in the liner bag prior to disconnecting the purge probe from the liner bag.
The sealed pouches containing the sterilized conduits were removed from the liner bag and set aside for
future implantations. Ethylene oxide sterilization was performed by Dr. Paul Sweetnam of Redux
Therapeutics on CNF conduits provided by the author.

3.17 CELL CULTURE AND CELL GROWTH STUDIES
Three cell types were employed to assess their ability to grow on CNF sheets. Motor neurons,
Schwann cells, and macrophages were individually cultured to be seeded on polystyrene cell culture
dishes, and separately, cellulose sheets. Schwann cells (ScienCell Research Laboratories, 1700) were
purchased and cultured according to supplier specifications using Schwann cell medium (ScienCell
Research Laboratories, 1701). Macrophages (ATCC, RAW 264.7 TIB-71) were purchased and cultured
according to supplier instruction in Dulbecco’s modified eagle’s medium (ATCC, 30-2002). Motor
neurons were differentiated from human embryonic stem cells (Harvard University, HuES-3 HB9::GFP) in
mTeSR1 (STEMCELL Technologies, 85850) media [75]. All cells were incubated at 37ºC in a 5% CO2
environment.
Three substrates were employed in the cell growth study: standard polystyrene cell culture
plastic, untreated CNF sheets, and laminin-infused CNF sheets. Prior to seeding cells on the plastic
substrate, the surface was coated with Matrigel (VWR, 47743-706). CNF sheets were used without
surface modifications. Laminin infused CNF sheets were formed via the addition of 1 mg of laminin, from
a 1.19 mg/mL solution (Gibco, 23017015), to 20 mL of CNF slurry prior to sheet formation; no surface
modifications were employed. Cells were seeded individually on each of the substrates and the
respective growth media added. Cells were grown for 7 days before staining with Calcein AM
(ThermoFisher, C1430) and fluorescently imaged. Calcein AM is a cell-permanent dye that is only
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fluorescent in viable cells. Living cells cleave acetoxymethyl groups by intracellular esterases that
converts the dye to a green fluorophore. Live cells of all 3 types on each of the substrates were imaged
employing a fluorescence microscope at a wavelength of 520 nm. Cell culture studies were performed
by Dr. Paul Sweetnam of Redux Therapeutics using CNF sheets provided by the author.

3.18 CONDUIT IMPLANTATION
Two murine studies were performed, in addition to a single non-human primate study, in the
course of the present work. Murine studies were performed by the Eggan Laboratory at Harvard
University. The non-human primate study was performed at the Southwest National Primate Research
Center of the Texas Biomedical Research Institute. All experimental protocols and procedures were
approved by the Animal Care and Use Review Office (ACURO) and the local Institute of Animal Care and
Use Committee (IACUC).
For murine studies, the subjects were anesthetized with either a 1.25% (w/v) injection of
tribromoethanol-tert-amyl alcohol in DI water (0.5 mL/25 g mouse) or 1-2% (v/v) isoflurane in an oxygen
flow. The site of implantation was shaved and disinfected with a combination of betadine swabs and
alcohol. The subjects also received a preemptive dose of buprenorphine, 0.05-0.1 mg/kg, to relieve pain.
For the surgeries, only the left hindlimb was operated on and the right leg of each subject was left
unaffected as a control leg. The hindlimbs were secured making a right angle at the knee joint relative to
the body. An incision was made across the midline of the disinfected area, the skin was gently cut and
folded back revealing the underlying musculature. The sciatic nerve was revealed in the left hindlimb
through opening the plane between the gluteus maximus and the anterior head of the biceps femoris.
Removal of the surrounding fascia allowed for clear access to the nerve to begin excision and
implantation of the conduit.
The procedure for conduit implantation began with placement of two polypropylene sutures
through the nerve at approximately 6 mm apart centered between the sciatic notch and the distal
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bifurcation, as observed under a light microscope. The neural conduit was subsequently placed over the
uncut sciatic nerve and the two suture ends at one terminus of the conduit were run axially through the
interior of the conduit and out of the opposite terminus. Once conduit placement was confirmed and
the suture ends appropriately positioned, the nerve was transected, creating a neural gap. The conduit
was subsequently gently worked into the gap and over the nerve stumps by moistening the surgical area
with sterile saline and inserting the neural stumps into the conduit. Upon successful placement of the
nerve stumps within the conduit, the sutures were tied together on the outside of the implant. The
suturing technique allowed for the conduit to remain centered over the neural gap, whilst also ensuring
that the neural stumps could not be removed from the interior of the conduit. The musculature was
subsequently sewn together with absorbable sutures, and clips were used to close the external wound.
The wound clips were removed 7 days post-surgery.
Due to different objectives (discussed in Chapter 5), the two murine studies varied in several
surgical details. The first study comprised two separate groups. The first group consisted of mice for
which the sciatic nerve was transected, but no tissue was deliberately removed from the resulting nerve
stumps, a conduit was implanted as described above. The second group consisted of mice for which the
same sciatic nerve transection was performed, but with nerve stumps bridged by a single polypropylene
suture to maintain neural alignment in the absence of a conduit. The second murine study comprised
neural gaps created by deliberate excision of 1 mm or 3 mm segments of neural tissue, achieved by
transection of both neural stumps. Additionally, the second study employed several minor variants of
repair techniques that were necessitated via the experimental design, the specifics are detailed in
Section 5.4.
The non-human primate study employed a radial nerve versus a sciatic nerve model due to the
accessibility of the radial nerve and anticipated observations of digit mobility as an indicator.
Comparable surgical methodologies to those employed for the murine study were adopted for the non46

human primate study. Three subjects were included in the study. Subjects 1 and 3 received conduits
over a severed nerve, with no tissue removed. Subjects 1 and 2 received sutures at the site of injury to
assist in alignment of the neural stumps. The results of this study are detailed in Section 5.6. Conduit
implantation was performed by Dr. Joanie Mok and Dr. Maura Charlton of Harvard University using
conduits provided by the author.

3.19 GRIP STRENGTH ANALYSIS OF MICE
The grip strength of the hindlimbs of mice was measured using a Bioseb grip strength testing
device (Bio-GS3). The device was equipped with a T-handle bar attachment. Mice were positioned with
the hind limb of interest over the bar, which they instinctively gripped. The mice were subsequently
pulled backwards in the horizontal plane with respect to the device, until they released the bar. The
peak tensile force recorded by the device was considered the maximum grip strength of the limb.
Measurements were made in triplicate, and for both limbs, allowing normalization of the data from the
limb that had been operated on by the control limb. Grip strength analysis was performed by Dr. Joanie
Mok and Dr. Maura Charlton of Harvard University.

3.20 END OF LIFE ANALYSIS
At the completion of the murine studies (approximately 40 weeks for study one, and 20 weeks
for study two), the mice were prepared for end of life analysis. Each mouse was weighed, a video taken
to observe hindlimb locomotion, and the grip strength of the hindlimb, with and without the implant,
measured. Grip strength was measured in triplicate as described above. Humane euthanasia was
performed using 100% (v) isoflurane followed by transcardial perfusion with 4% (w/v) paraformaldehyde
in phosphate buffered saline (PBS) to prepare for dissection and tissue removal. The hindlimbs were
dissected to reveal the sciatic nerve in the control limb as well as the conduit and nerve in the opposing
limb. An image was taken of the surrounding tissues prior to resection to allow for qualitative
assessment of the surgical site. Both the control nerve and the conduit-repaired neural segment were
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resected from the respective hindlimbs for tissue processing. As the neural segments were removed,
each received a suture on the proximal end of the segment to ensure consistent alignment and
orientation during tissue embedding.
Neural segments were immersed in 4% (w/v) paraformaldehyde in PBS for 24 hours before
undergoing several saline wash cycles. Pairs of control and conduit-repaired segments from each animal
were blotted dry and set into HistoGel (ThermoFisher, 22-110-678} with care taken to ensure proximal
end correlation, and parallel alignment. The HistoGel-embedded neural segments were placed in a
biopsy cassette (Globe Scientific, 1090W) to facilitate the paraffin-embedding process. Specifically, the
samples were subjected to multiple alcohol washes of increasing concentration in order to progressively
dehydrate the tissues. The samples were subsequently washed with xylene three times (with the
residence time of each wash progressively increasing from 30 to 60 minutes), and finally washed twice
with paraffin with a residence time of one hour per wash.
Embedding of the tissues in paraffin allowed for the neural segments to be sectioned employing
a microtome (Leica RM2255). Each tissue block was assigned three zones, labeled A - C as indicated in
Figure 15, to denote the proximal stump, the conduit region, and the distal stump, respectively. Crosssectional samples were collected by floating 4 µm thick sections in triplicate on the water surface in a
heated water bath and then collecting the sections on a slide submerged at an angle into the water
bath. Five slides were collected serially per 100 µm of tissue to be analyzed using a variety of histological
techniques. Excess tissue sections per 100 µm regions were either mounted for test-staining or disposed
of appropriately. End of life analysis was performed by Dr. Joanie Mok and Dr. Maura Charlton of
Harvard University.
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Figure 15: Zone Analysis of Tissue Sections
Division of zones for tissue sectioning to separate the proximal stump (A), the conduit and regeneration zone in the
neural gap (B), and the distal stump (C)

3.21 SLIDE PREPARATION AND STAINING
Once sectioned and mounted on slides, the paraffin wax in which the tissues were embedded
had to be moved, and the samples rehydrated, to facilitate staining. Histoclear II (VWR, 64111-04) was
employed to remove paraffin from the tissue sections. Specifically, slides were washed two times with
Histoclear for 5 minutes each wash. Samples were subsequently washed with alcohol solutions of
deceasing concentration to gradually rehydrate the tissues. After two 1-minute washes, in each of the
three descending alcohol concentrations (100%, 95%, 70%), the slides were washed in DI water for 2
minutes to fully rehydrate the neural sections. The hydrated tissues were subsequently stained for
histological analysis.
Three histological staining systems were employed on the neuronal tissue sections; Hematoxylin
and Eosin (H&E) for visualization of cellular structure and cell types (Sigma-Aldrich, HHS128 and
HT1101128), Luxol Fast Blue for identification of myelin (VWR, KT022), and Calcofluor White for
localization of cellulose (Sigma-Aldrich, 18909). The H&E staining procedure was performed as follows:
first, hematoxylin was applied to the tissues to stain the nuclei of cells a red-purple color. An acid wash
was subsequently employed to remove excess hematoxylin from surrounding tissues. Scotts bluing
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agent was then applied to darken the hematoxylin stain. Lastly, eosin was employed as a counter stain
to color non-nuclear elements of the tissue with various shades of red/pink which were viewed via
brightfield microscopy. The staining procedure for H&E required significant optimization in order to
maximize contrast, see Table 4.
Table 4: Hematoxylin and Eosin Staining Procedure
Adaptations performed on general Hematoxylin and Eosin procedures to increase contrast

Stain/Step
Hematoxylin
Water
Acid Alcohol
Water
Scott’s Blue
Water
Eosin
95% EtOH
100% EtOH
Histoclear

Alterations in timing to improve staining
Test #1
Test #2
Test #3
3 min
4 min
4 min
2 min
2 min
2 min
2 quick dips
1 quick dip
1 quick dip
1 min
1 min
1 min
3 min
3 min
3 min
1 min
1 min
1 min
1 min
2 min
3 min
1 min x2
1 min x2
1 min x2
1 min x3
1 min x3
1 min x3
1 min x3
1 min x3
1 min x3

The presence and distribution of myelin in the tissue samples was determined via application of
the myelin-specific stain Luxol Fast Blue. First, a coplin staining jar was filled with approximately 55 ml of
Luxol Fast Blue, the container was subsequently placed in an oven that had been pre-heated to 60 ºC.
Once the stain had reached the target temperature, the dewaxed slides were immersed in the solution,
where they remained for a period of 4 hours at 60 ºC. The slides were subsequently removed from the
Luxol Fast Blue solution and rinsed with copious amounts of DI water to remove excess stain. The tissues
were subsequently differentiated using a dropper to apply lithium carbonate to the tissue section for 30
seconds. Finally, the slides were rinsed again with DI water to remove residual lithium carbonate and
then placed in clean container for storage. Stained slides were viewed via brightfield microscopy. It is
noted that a counterstain procedure was not performed, as such myelin in the tissue samples was
stained deep blue.
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Calcofluor White is a non-specific fluorochrome that binds to cellulose and chitin in cell walls
and is typically used for detection of yeast and pathogenic fungi. In the present work Calcofluor White
was employed for identification of cellulose nanofiber comprising the neural conduits. Calcofluor White
was deposited directly onto the dewaxed tissue sections via a dropper, covering the surface of the tissue
section. The stain was allowed to equilibrate for 60 seconds before excess was removed from the slide
by wicking into an absorbent material from the edge of the slide. After removal of excess stain, the
slides were immediately imaged via fluorescence microscopy. Preliminary histology was performed by
the author, in addition to Dr. Joanie Mok, and Dr. Maura Charlton of Harvard University.
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CHAPTER FOUR
CELLULOSE NANOFIBER SHEET CHARACTERIZATION AND NEURAL
CONDUIT DEVELOPMENT
4.1 CNF SHEET CHARACTERIZATION
CNF sheets were created by casting 100mL of 2 wt% CNF slurry directly onto stainless steel
plates, as per the methodology detailed in Section 3.6. It should be noted that in the development phase
of CNF sheet production, a variety of materials were trialed as casting plates with mixed results.
Specifically, plastic and plastic-coated metal plates created deformed and inconsistent sheets, aluminum
plates resulted in metal particulate contaminants in the sheet upon removal, and glass plates bound the
CNF sheets to the extent that they could not be removed intact. CNF sheets were successfully cast on
stainless steel plates and characterized in a variety of manners as detailed in the following sections.

4.1.1 SHEET THICKNESS
A series of 12 CNF sheets were created, 6 each on two different stainless steel plates. The
thickness of each sheet was measured in order to assess the consistency of sheet formation. Thickness
Table 5: Sheet Thickness Analysis
Sheet thickness consistency of 12 CNF sheets cast on two separate stainless steel plates, all values reported in µm.
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measurements were made employing a benchtop digital caliper as per the methodology described in
Section 3.7. The 12 sheets were measured to have an average thickness of 56.2 m with a standard
deviation of less than 1.5 m (less than 3% of the sheet thickness), see Table 5. It should be noted that
sheet thickness was found to be readily adjustable through variation of the solids content of the CNF
slurry employed to cast the sheet.

4.1.2 TENSILE STRENGTH TESTING
Tensile strength testing was performed on the CNF sheets in order to ascertain the Young’s
modulus, or the modulus of elasticity under tension – defined as the ratio of the stress acting on a
material to the strain produced. Tensile testing was performed as described in Section 3.8 and the
Young’s modulus was taken as the gradient of the linear portion of each stress vs strain curve, as may be
seen in Figure 16. Tensile data were recorded for CNF sheets oriented parallel to the machine (blade)
direction, with Young’s modulus values observed to range from 4.99-5.71 GPa. Tensile data recorded for
CNF sheets oriented perpendicular to the machine direction (cross machine direction) resulted in
Young’s modulus values in the range of 4.62-5.10 GPa. Statistical analysis via Minitab (two sample t-test,
P< 0.001, see Appendix A5) revealed that the average Young’s modulus of samples taken in the parallel
direction was statistically greater than the average of samples taken in the perpendicular direction.

4.1.3 SURFACE PROFILOMETRY MEASUREMENTS
Due to the casting method employed to create the CNF sheets, as described in Section 3.6, the
resultant sheets possessed two markedly different surfaces. Specifically, the face that dried in contact
with the stainless steel plate was smoother and had a greater sheen relative to that which dried exposed
to air, as evidenced by both visual and tactile investigation. To quantify the surface roughness of the
sheets, sample strips were collected from sheets cast on two different stainless-steel plates (designated
P1 and P2). Strips were cut in both the machine (blade) and cross-machine direction, (designated M and
C, respectively). The surface roughness of all strips was measured employing a Tencor Alphastep 500
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Figure 16: Tensile strength testing of CNF sheets
Samples taken in the machine and cross-machine directions

mechanical profilometer, as described in Section 3.13. The surface roughness of both sides of each sheet
was tested with the side that was dried in contact with the steel plate designated S, and the side that
was dried exposed to air designated A. For each combination of parameters, two individual CNF strips
were cut and analyzed (a and b), each individual measurement was performed in triplicate. Figure 17
presents the surface roughness data obtained. It is evident from examination of Figure 17 that neither
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the direction that the CNF strip was cut relative to the casting process, nor the individual stainless steel
plate employed for casting, had any significant effect on the surface roughness of the sheets. However,
the air-exposed, and stainless steel plate contacting, surfaces were consistently statistically different
(see Appendix A5, 2 sample t-test with p<0.001). Indeed, the surface dried exposed to air had an
average surface roughness across all sheets of 3.17 µm, while the surface dried in contact with the
stainless steel plate had an average surface roughness across all sheets of 0.70 µm.

Figure 17: Surface Roughness Measurement Results
Average surface roughness (Ra) of two distinct sheet sides. P1-plate 1, P2-plate 2, C-cross machine direction, M-machine
direction, A-air exposed, S-steel contacting, a-sample one, and b-sample 2

4.1.4 CNF SHEET TRANSPARENCY
CNF sheets, and hence neural conduits constructed from CNF sheets, inherently possess a
degree of transparency; a significant attribute that aids surgeons visualize the surgical field. In order to
ascertain the extent to which CNF sheet transparency could be controlled, sheets of varying thickness
were created via modification of the solids content of the slurry cast on the stainless steel plates, and by
variation of the height of the casting knife applicator. The resulting dried sheets were conditioned in a

55

temperature and humidity-controlled environment, in compliance with TAPPI standards, prior to
measurement of their thicknesses. All sheets were made in duplicate. One of each duplicate CNF sheet
was hot calendared in the UMaine Process Development Center via two passes through the nip of two
heated steel rollers. Figure 18 presents the solids content of the slurry employed, the thickness of the
sheets resulting from variation of the height of the casting knife applicator, and images depicting the
transparency of the calendared and non-calendared sheets. Investigation of Figure 18 reveals that the
thinner the initial CNF sheet the greater the transparency, and that the transparency is significantly
increased via calendaring.

Figure 18: CNF Sheet Transparency
The effect of varying sheet thickness and calendaring on transparency.

4.1.5 AIR PERMEABILITY OF CNF SHEETS
The air permeability of CNF sheets was determined employing a Gurley 4340N Automatic
Densometer and Smoothness Tester via the methodology described in Section 3.9. The densometer
measures the amount of time required to pass 100 cm3 of air through a sample and reports in units of
Gurley Seconds over a range of 0-50,000. Testing of CNF sheets consistently resulted in an output of
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“Too dense to read”, implying that the sheets were highly impermeable to air and required in excess of
50,000 seconds for the passage of 100 cm3 of air.

4.1.6 MERCURY POROSIMETRY OF CNF SHEETS
The porosity of CNF sheets was determined employing a mercury porosimeter, as described in
Section 3.11. A representative plot of cumulative pore volume vs pore diameter is presented in Figure
19. Investigation of Figure 19 reveals that the CNF sheet possess no pores with diameters between 0.01
and 10 m. It is noted that a spurious data point occurs at a pore diameter of ~10 m which is
attributed to a mechanical switch in pressure made by the operator to increase the pressure in the
sample chamber. At extremely small pore diameters, Figure 19 possesses an anomalous peak (in the
0.01-0.03 m range). Measurements in this pore diameter regime are known to be affected by the
surface roughness of the sheet. As evidenced by the profilometer measurements, presented earlier in
this section, the surface of the CNF sheet that was dried in contact with air was statistically rougher than
the surface that was dried in contact with the stainless steel plate, likely giving rise to the inconsistent

Figure 19: Mercury Porosimetery Results
Pore volume analysis of a CNF sheet
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mercury porosimetry data at very low pore diameters. Taken in combination, the mercury porosimetry
and the air permeability data suggest that the CNF sheets do not have any pores that completely
traverse the thickness of the sheet, only small surface vacancies resulting from surface roughness.

4.1.7 OXYGEN PERMEABILITY OF CNF SHEETS
The oxygen permeability of CNF sheets was determined employing a MOCON OX-TRAN analyzer
at relative humidity values of 0, 50, 80, and 90% via the methodology described in Section 3.10. Two
CNF sheet samples were tested at each humidity, the resultant plot of oxygen permeation rate as a
function of relative humidity is presented in Figure 20. It is evident from investigation of Figure 20 that
the CNF sheets are permeable to oxygen and that the permeation rate increases in an exponential
manner as the relative humidity increases above a value of 50%. Indeed at a relative humidity value of
90% the oxygen transmission rate of the CNF sheets was measured to be ~ 181 cc/(m2day), not
dissimilar to the literature value for polyvinyl chloride of 150 cc/(m2day) [76]. It is noted that polyvinyl
chloride is widely used as a food wrap due to its semi-permeability to oxygen.

Figure 20: MOCON Oxygen Permeability Results
CNF sheet oxygen permeability measurements made on a MOCON Ox-Tran from 50-90% relative
humidity. Initial measurements (blue) and duplicate measurements (orange)
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4.2 CNF CONDUIT DEVELOPMENT
Various options were considered for initial development of CNF conduits, including casting
methods such as drying the slurry in between an inner and an outer cylinder. However, due to the large
amount of water that is removed upon drying (~98% of the slurry’s wet weight), and the concomitant
shrinkage, few methods were deemed viable. Indeed, the simplest, most robust method was
determined to be rolling multi-layer tubes from sheets of dried CNF. Such a method enabled the
shrinkage resulting from drying to occur in the sheet formation process, giving rise to changes in sheet
thickness that could be controlled by the solids content, and the thickness of the slurry spread by the
casting knife applicator. Once a CNF sheet of suitable thickness had been cast and dried, it was a
straightforward process to cut the sheet into a rectangular form and roll it into a multilayer conduit
employing a mandrel.
It was determined that in order to seal the outer flap of the CNF sheet to the wall of the conduit,
and thereby produce a self-supporting, robust implant, a method should be developed that avoided the
use of an adhesive. The decision to avoid the use of an adhesive was made based on the desire not to
introduce an additional material into the CNF conduit construct that might require regulatory approval.
As such a range of methods of sealing the outer flap of the CNF sheet to the conduit were evaluated.
Numerous additional CNF conduit geometries and CNF devices are presented in Appendix A6.

4.3 CONDUIT SEAL EMPLOYING NON-MECHANICAL MEANS
The simplest method to seal the outer flap of the CNF sheet was to wet the inner face of the
sheet with water and press it onto the conduit wall, thereby using the well-known hydrogen bonding
nature of CNF to seal the conduit layers together [77]. Initial inspection and qualitative testing of the
water sealed conduits suggested however, that they were not as stable when exposed to an aqueous
environment (such as that found in vivo) as was hoped for. An alternative method of sealing the outer
flap of the conduit was therefore evaluated. Specifically, rather than applying solely water to the inner
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surface of the flap, 2 wt% CNF slurry was applied thereby enhancing the hydrogen bonding capabilities
of the seal by including suspended cellulose nanofiber. A final methodology developed to aid in sealing
the CNF conduit layers was to coat the entire construct in CNF (post construction, with the outer flap
sealed with CNF slurry) by submerging it in 2 wt% CNF slurry and allowing it to air dry. The coating was
intended to provide a seamless final layer which would function to prevent delamination of the external
layer of the conduit.

4.4 EVALUATION OF CONDUIT SEAL INTEGRITY
In order to assess the integrity of the outer seal of the conduits made via water, CNF slurry, and
CNF slurry coupled with an external CNF coating, a static immersion test was developed. Specifically,
conduits were immersed in vials containing aqueous solutions of biological relevance, namely water,
saline solution (9 g NaCl in 1 L water), ringer’s solution (7.2 g NaCl, 0.37 g KCl, and 0.17 g CaCl2 in 1 L
water), and PBS buffer (1X concentration) and their structural integrity assessed as a function of time. In
order to determine if the number of CNF sheet wraps employed to construct the conduits factored into
the stability of the outer seal, conduits employing 1, 2 and 3 wraps were evaluated. Two conduits were
employed for each of the nine conditions (1 wrap water seal, 2 wraps water seal, 3 wraps water seal, 1
wrap CNF seal, 2 wraps CNF seal, 3 wraps CNF seal, 1 wrap CNF seal-dip coated, 2 wraps CNF seal-dip
coated, 3 wraps CNF sealed dip-coated) in each of the four solutions, resulting in a total of 72 conduits.
Once the pairs of conduits were placed in the relevant vials, they were left undisturbed for the duration
of the test.
The structural integrity of each conduit was assessed at three time points: 24 hours (1 day), 2
weeks (14 days), and 1.5 months (46 days). Conduits that were observed to have delamination of the
outer layer were assigned a score of 0. A score of 1 was given to conduits that were intact and stable.
The results for each conduit at the 24-hour time point are presented in Table 6. Investigation of Table 6
reveals that conduits sealed with water performed poorly with only 25% of the conduits remaining
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intact. The CNF sealed, and CNF sealed and CNF coated, conduits performed significantly better with
62.5% and 75% remaining intact, respectively. It was concluded therefore that the water seal was
inferior to the CNF seal. No clear trend with regard to the stability of the conduits as a function of the
number of wraps was evident at the 24-hour time point.
Table 6: First Conduit Stability Study Results at 24 Hours
Analysis of conduits composed of varying number of layers and seal techniques after 24 hours in various solutions
Scoring of 1 means the conduit passed inspection, 0 indicates structural failure

Table 7 presents data for conduit stability at the 14 day and 1.5-month time points.
Investigation of Table 7 reveals that only 8% of the water sealed conduits remained intact after 46 days:
not a surprising result given the 24 hour and two-week data. As at the earlier time points, the CNF
sealed conduits performed better than the water sealed conduits, although only 25% remained intact
after 1.5 months. The CNF sealed and CNF coated conduits performed significantly better than the other
variants at the 1.5-month time point with ~46% of conduits remaining intact. The data of Table 7
indicate that the stability of the conduits is not a strong function of the number of wraps of CNF sheet
employed in their construction, although 2-wrap conduits were consistently either the most stable, or
equal most stable, versus 1 and 3-wrap conduits.
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Table 7: First Conduit Stability Study Results at 14 and 46 Days
Analysis of conduits composed of varying number of layers and seal techniques after 14 and 46 days in various solutions
Scoring of 1 means the conduit passed inspection, 0 indicates structural failure

4.5 EVALUATION OF THE EFFECT OF CNF SHEET THICKNESS ON CONDUIT INTEGRITY
A potentially important parameter in the stability of CNF conduits is the effect of the thickness of
the sheet employed in their construction. CNF sheet thickness was considered to be potentially
important as the stiffness of the sheet increases with thickness, and the flexibility and pliability decrease
accordingly. As such a study was performed to determine the effect of CNF sheet thickness on the
stability of conduits. Employing the findings from the conduit seal investigation, 2 wrap conduits were
constructed employing the CNF seal and CNF coating method. Sheets of four different thicknesses, 52,
59, 76, and 86 m were employed to create pairs of conduits which were subsequently placed in vials
containing the same aqueous solutions employed in the seal integrity study. The stability of the conduits
was assessed at time points of 24 hours and 18 days, with the binary scoring system of 0 for a
delaminated conduit and 1 for an intact conduit applied.
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Table 8: Second Conduit Stability Study Results at 24 Hours
Analysis of conduits composed of varying sheet thicknesses after 24 hours in various solutions
Scoring of 1 means the conduit passed inspection, 0 indicates structural failure

Table 8 presents data for conduit stability as a function of CNF sheet thickness at the 24-hour time
point. Investigation of Table 8 reveals that conduit stability decreased monotonically with increasing
sheet thickness, with conduits constructed from 52 and 59 m CNF sheets remaining largely intact while
conduits constructed of 76 and 86 m CNF sheets largely failing. Little if any effect of variation of the
aqueous solution on conduit stability was observed. Table 9 presents data for conduit stability as a
function of CNF sheet thickness at the 18-day time point. Comparison of the data of Table 9 with those
of Table 8 reveals very little change. Specifically, the number of structurally intact conduits constructed
from the two thinnest CNF sheets remained unchanged, while one additional conduit constructed from
each of the thicker CNF sheets failed. It was concluded from the study that conduits are most stable
when constructed of thinner CNF sheets, preferably in the ~ 50 m range. It is noted that it is
challenging to reproducibly create defect free CNF sheets with thicknesses less than 50 m, hence the
lower limit of the study.
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Table 9: Second Conduit Stability Study Results at 18 Days
Analysis of conduits composed of varying sheet thicknesses after 18 days in various solutions
Scoring of 1 means the conduit passed inspection, 0 indicates structural failure

4.6 MECHANICAL INTERLOCKING CNF CONDUITS
The investigations of the effect of CNF seal methodology and sheet thickness on conduit stability
were highly informative, however it is noted that even the optimized conduit designs had a portion of
the samples that failed. It was determined therefore that an alternate method of conduit construction
should be developed, while adhering to the premise that no additional materials should be introduced
to the design. To achieve this objective, a series of mechanically interlocking closure devices were
implemented to physically prevent delamination of both the inner and outer CNF layers.
Specifically, the previously rectangular CNF form was modified to contain tabs on both the top
and bottom edges, with corresponding slits in the body of the sheet, see Section 3.14, Figure 14. When
the CNF sheet was rolled around the mandrel to form a cylinder, the tabs were passed through the slits
to provide a mechanical interlock, thereby preventing unravelling. The interior interlocks were held in
place by the tension imparted by the rolling of the conduit. The exterior tabs were folded to pass
through the slits and then unfurled to provide a profile broader than the slit and hence a mechanical
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interlock. The tabs were subsequently adhered to the exterior surface of the conduit with CNF slurry,
and the entire conduit coated in CNF to form a continuous, seamless outer surface.

4.7 EVALUATION OF THE STABILITY OF MECHANICALLY INTERLOCKED CNF CONDUITS
In order to evaluate the stability of the mechanically interlocked CNF conduits relative to their
non-mechanically interlocked predecessors, and to do so in a relatively short time frame, a more
intensive stability assay was developed. Specifically, conduits were immersed in DI water within 50 mL
plastic centrifuge tubes and placed horizontally on an orbital shaker table (Innova 2000). The table was
set to an agitation speed of 140 rpm and run for a 24-hour period. At the completion of the agitation
cycle each conduit was evaluated with regard to mechanical stability/integrity.
The newly developed agitation assay was employed to perform a study of the effectiveness of
the mechanical interlock in maintaining the structural integrity of the CNF conduit. Specifically, three
types of conduits were assessed: mechanical interlock with a CNF coating, mechanical interlock without
a CNF coating, and a non-mechanically interlock CNF sealed conduit with a CNF coating. Three conduits
were constructed for each condition. Figure 21 presents an image of the nine conduits within their
respective centrifuge tubes upon completion of the 24-hour agitation cycle. Investigation of Figure 21
reveals that the conduits created employing a mechanical interlock and a CNF coating (A-C) maintained
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Figure 21: Third Conduit Stability Study Results at 24 hours
Third conduit stability study 24-hour analysis of three groups: mechanical interlock with CNF coating (AC), mechanical interlock without CNF coating (D-F), and non-mechanical interlock with CNF coating(G-I)
that were graded by retention of structure
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their mechanical stability and experienced only occasional lifting of the external tabs. The conduits
created employing a mechanical interlock but without a CNF coating (D-F) universally lost their
mechanical integrity, as did the non-mechanical interlock conduits created with a CNF seal and CNF
coating (G-I). It is evident therefore that conduits created employing a mechanical interlock and a CNF
coating are remarkably stable, even under extreme conditions.

4.8 CONCLUSION
Neural conduits comprising CNF were successfully created from sheets of CNF. To create well
defined and consistent conduits the precursor CNF sheets were thoroughly characterized. Specifically,
sheets were cast on stainless steel plates and were determined to have a dried thickness of 56.2 ±1.3
m. A mechanical profilometer was employed to determine that the two sides of the CNF sheets had
very different surface roughnesses; the side dried with exposure to air had an average roughness of 3.17
m, while the side dried in contact with the stainless steel plate had an average roughness of 0.70 m.
The sheets were determined to be non-porous via both Gurley densometer and mercury porosimetry
measurements. The CNF sheets were found to be semi-permeable to oxygen, with permeability
increasing with relative humidity. The tensile strength of the CNF sheets was comparatively high with a
Young’s modulus average of approximately 5.3 GPa in the machine direction and 4.9 GPa in the crossmachine direction. It was determined that the transparency of the CNF sheets increased with decreasing
sheet thickness, and increased with the application of hot calendaring.
Conduits were created from the CNF sheets by wrapping a CNF form around a mandrel. Various
means of closing the outer flap of the conduit were evaluated and tested. Adhering the outer flap to the
conduit via wetting with water was found to result in loss of conduit structural integrity in aqueous
solutions. Adhering the outer flap with CNF slurry gave improved results, but still led to a large
proportion of conduit failures. Adding a coating of CNF to CNF sealed conduits further improved conduit
stability, however with extended immersion times conduit failures were still observed. It was
66

determined that a CNF sheet of approximately 50 m thickness was optimal for conduit stability.
Conduits closed with internal and external mechanical interlocks were developed to promote structural
integrity. It was determined that conduits created with the interlocking tabs adhered with CNF slurry,
and the entire conduit coated in CNF were extremely stable, even under testing conditions far more
rigorous than found in vivo.
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CHAPTER FIVE
CELLULAR COMPATIBILITY WITH CELLULOSE NANOFIBER AND IN VIVO
STUDIES
5.1 CELLULAR PROLIFERATION ON, AND COMPATIBILITY WITH, CELLULOSE NANOFIBER
SHEETS
In order to determine if CNF is in fact a viable material from which to construct neural conduits,
a study was performed to evaluate the ability of various relevant cell types to be cultured on CNF. In
addition, CNF sheets were modified via the inclusion of the extracellular matrix protein laminin to
ascertain whether cellular interaction with the sheet could be tailored/enhanced. Three cell types were
investigated: macrophages, Schwann cells and motor neurons. Macrophages were selected as they are
one of critical cell types associated with a foreign body/inflammatory response and their interaction
with CNF could be an indicator of the potential of CNF to induce a negative in vivo reaction. Schwann
cells were investigated since they are the primary non-neural cell type associated with peripheral nerve
regeneration and their interaction with CNF could potentially be predictive of the likelihood of CNF to
directly support Schwann cell proliferation. Motor neurons were studied to determine if CNF could
directly support neural regeneration.
CNF sheets were prepared via the procedures outlined in Section 3.6. Laminin containing CNF
sheets were prepared by adding 1 mg of murine-derived laminin (Gibco, 23017015) to 20 mL of CNF
slurry at 2 wt% solids and proceeding with sheet formation as per the standard procedure. Cell culture
was performed via the methodologies presented in Section 3.17. As quantified in Section 4.1.3, the CNF
sheets produced in the present work were distinctly ‘sided’; cell culture was performed on the side dried
with exposure to air given its comparatively high surface roughness (RMS average ~ 3.17 m) and hence
greatest likelihood of cellular attachment. Cellular number, distribution and morphology were
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determined in a qualitative fashion employing fluorescent image analysis. Images were collected on a
fluorescence microscope after cells were fluorescently labeled employing Calcein AM via methodologies
presented in Section 3.16. Each cell type was cultured directly on standard cell culture plastic
(polystyrene coated with Matrigel), on an untreated CNF sheet, and on a laminin-infused CNF sheet.
Representative images of each condition are presented in Figure 22.

Figure 22: Cellular Attachment Modification Study
Analysis of cellular attachment of Schwann cells, macrophages, and motor neurons on a plastic substrate, a CNF
sheet, and a Laminin-infused CNF sheet. Motor neuron on plastic adapted from Moakley et al. [113]

Investigation of Figure 22 reveals that macrophage growth was greatest on the plastic substrate,
and further, that the cellular morphology was elongated/non-spherical indicating activation.
Macrophage growth on the CNF sheet was negligible, with a single cell in the field of view. It is
interesting to note that the single cell is comparatively spherical, indicating a non-activated state. The
addition of laminin to the CNF sheet resulted in greater macrophage growth relative to the neat CNF
sheet, although the numbers were comparatively low; a non-spherical morphology indicated a degree of
activation. It is evident from Figure 22 that Schwann cell proliferation on the plastic substrate was
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significant and that the cellular morphology was elongated indicating activation. Schwann cells had a
comparable proliferation on the CNF sheet as on the plastic substrate, however their morphology was
largely spherical suggesting an inactive state. The proliferation of Schwann cells on the laminin infused
CNF substrate was extensive and the morphology was elongated. Motor neurons of the same cell line
were cultured on the plastic substrate by Moakley et al. As may be seen in Figure 22, the cell culture
plastic did support modest motor neuron growth and neurite extension. Unmodified CNF did not
support motor neuron growth as may be seen from their absence in Figure 22. However, infusing a CNF
sheet with laminin did lead to the growth and neurite extension of motor neurons, as evidenced by the
lower right panel of Figure 22.
It may be concluded from the cellular proliferation and compatibility study that the plastic cell
culture substrate led to macrophage proliferation and activation, an undesirable result. The plastic
substrate did however promote Schwann cell proliferation and extension, in addition to modest motor
neuron growth and neurite extension. CNF sheets were shown to be non-supportive of macrophage
proliferation and extension-likely meaning that CNF would not elicit a significant foreign
body/inflammatory response in vivo, a very important and positive finding. Schwann cells and motor
neurons were largely not effective in proliferation and extension on CNF sheets, suggesting that CNF will
likely not play an active role in neural regeneration, but rather may be present as an inert material
construct. Interestingly, laminin infused CNF was largely non-supportive of macrophages, suggesting it
may elicit only a weak foreign body/inflammatory response, but was highly successful in promoting
Schwann cell and motor neuron proliferation and extension. The latter findings are extremely
interesting and provide a path forward if in fact a conduit is desired that actively promotes and
participates in neural regeneration.
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5.2 INTRODUCTION TO IN VIVO STUDIES
With confidence that macrophages have very little if any interaction with CNF, and were
certainly not activated by the material, and further, that Schwann cells and motor neurons experienced
limited interactions with CNF, it was determined that in vivo studies of conduit implantation were viable.
Two murine studies were performed to determine the efficacy of CNF neural conduits in promoting
regeneration of peripheral nerves. A single, preliminary, non-human primate study was performed to
determine the tolerance of the animal to CNF conduits. The murine studies were performed in
collaboration with the Eggan Laboratory of Harvard University, while the non-human primate study was
performed in collaboration with the Southwest National Primate Research Center of the Texas
Biomedical Research Institute. All experimental protocols and procedures were approved by ACURO and
local IACUC.

5.3 MURINE STUDY ONE: SCIATIC NERVE TRANSECTION WITH NO TISSUE RESECTION
The first murine study was aimed at determining the efficacy of implantation of CNF conduits
over a severed sciatic nerve when no neural tissue was resected. Twenty, 8-week old female mice were
employed. Female mice were used as age-related decline in motor nerve conduction has been shown to
be less than that of male mice [78]. The cohort was broken into two groups, the first group comprised
five animals which underwent surgery to have the sciatic nerve in the left leg severed and the nerve
stumps sutured to surrounding tissues to keep them in place; no conduits were implanted in these
animals. The second group comprised fifteen animals which underwent surgery to have the sciatic nerve
in the left leg severed and a conduit sutured over the neural gap as per the methodology detailed in
Section 3.18. The conduits used were 1 mm in diameter, 2 mm in length, approximately 100 m in
thickness, and sealed with water. In both groups, the sciatic nerve was severed in the left leg, therefore
the right leg was used as a control to provide initial/maximum grip strength data. Over the course of 40
weeks the grip strength of the left and the right leg of each animal (both groups) were measured at 4-
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week intervals employing the methodology described in Section 3.19, see Figure 23. Grip strength data
are presented in Appendix A7.
Investigation of Figure 23 reveals that sciatic nerve regeneration within an implanted CNF
conduit was far superior to regeneration when a conduit was not employed (sham surgeries). The grip
strength of the conduit implanted legs increased monotonically to a maximum value at approximately
30 weeks and was of the order of six times the grip strength of legs that underwent the sham surgeries
at the same time point. Indeed, comparison of the strength of the left leg with the right leg (control)
enabled calculation of the percent recovery for each group. The conduit-implanted group obtained
approximately 66% of the initial grip strength, while the sham surgery group obtained approximately
11% of the initial grip strength.

Figure 23: First Murine Study Grip Strength Results
Grip Strength measurements for first murine study over 40 weeks. Weeks 2-40 were measured from the left hindlimb
whereas the control leg measurements were taken from the right hindlimb for both conduit and sham groups
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The study was concluded at the 40-week time point when it became clear that grip strength
recovery had plateaued for mice that had received a CNF conduit implant. It may be concluded from the
data of the study that CNF does serve as a viable material from which to construct peripheral nerve
conduits, and that such implants are highly effective in promoting neural regeneration. It should be
noted however that in some respects the first murine study was, by design, limited. First, the number of
animals employed was low, a decision made for ethical reasons given the uncertainty associated with
implantation of a new material. Second, no neural tissue was resected; the nerves were transected and
then the stumps abutted resulting in minimal neural gap. Third, no variation in the dimensions (length in
particular) of the conduit was investigated. As such, and with the knowledge that CNF conduit
implantation does indeed promote neural regeneration, a second murine study was undertaken to
address these observations.

5.4 MURINE STUDY TWO: SCIATIC NERVE TRANSECTION WITH TISSUE RESECTION AND
CNF CONDUIT LENGTH VARIATION
The second murine study was conducted to determine the efficacy of CNF conduits in promoting
peripheral nerve repair when various amounts of neural tissue were resected. In addition, the study
aimed to determine the effect of varying the conduit length on neural repair. One hundred and ten, 8week old female mice were employed and were broken into five groups of twenty mice and one group
of ten mice. The latter group served as a control in which the animals underwent no surgery. As per the
first murine study, a sciatic nerve model was employed with mice in groups 1 through 5 having surgeries
performed on the left leg, with the right leg serving as a control. Neural tissue of 1mm or 3 mm length
was excised, and conduits were either not employed, or were employed in lengths of 3 or 5 mm. The
specifics of the surgeries performed on each group were as follows: 3mm excision of neural tissue
without a conduit or suture (Group 1), 3 mm excision of neural tissue without a conduit and with a
suture connection (Group 2), 3 mm excision of neural tissue with a 5 mm conduit (Group 3), 1 mm
excision of neural tissue with a 5 mm conduit (Group 4), and a 1 mm excision of neural tissue with a 3
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Suture

Figure 24: Second Murine Study Group Characteristics
Groupings for second study picturing variation in repair techniques, neural gap size, and conduit length for five groups

mm conduit (Group 5). Figure 24 provides a graphical depiction of the surgeries performed on each
group.
The surgical configurations of Groups 1 and 2 were selected to provide baseline data for neural
regeneration with significant tissue rescission (3 mm) versus that employed in the first study (no
rescission). Specifically, Group 1 investigated regeneration in the absence of any intervention, while
Group 2 investigated regeneration when a suture was employed to stabilize the relative positions of the
neural stumps. The surgical configuration of Group 3 was selected to investigate the effect of employing
a 5 mm long conduit over the same 3 mm neural gap employed in Groups 1 and 2. The surgical
configuration of Group 4 was selected to study neural regeneration using a fixed conduit length (5 mm)
but a shorter neural gap (1 mm) by comparison with Group 3. The configuration of the surgery
performed on Group 5 was selected to approximate that of the first murine study, that is use of a 3 mm
conduit and a minimal neural gap (nominally zero in the first study and 1 mm in the second study).
Group 5 therefore provided some continuity between the two studies. In addition, the configuration of
the surgery performed on Group 5 enabled study of the effect on neural regeneration of shortening the
conduit employed over a fixed neural gap (1 mm) by comparison to Group 4.
The grip strength of the left and right leg of each mouse was measured every two weeks for the
20-week duration of the study and is presented in Figure 25 in the same manner as the data from the
first murine study. It is noted that the second murine study was half the length of the first murine study,
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a fact dictated by the more rapid obtainment of a maxima/plateau in the data of the second study.
Investigation of Figure 25 reveals that the neural regeneration of mice in Group 1 was lowest, not a
surprising result given the large tissue excision (3 mm) and the lack of any surgical intervention. Indeed,
the magnitude of the grip strength approximates that observed for mice undergoing the sham surgeries
of the first murine study. The addition of a suture bridging the 3 mm gap between the two neural
stumps resulted in a modest increase in the average grip strength of mice in Group 2 vs those in Group
1, indicating that even a minor surgical intervention fixing the position of the neural stumps has
regenerative advantages. Comparison of the grip strength for mice in Group 3 with those in Groups 1
and 2 indicates that the implantation of a 5 mm long CNF conduit over a 3 mm neural gap does indeed
promote greater neural regeneration than either no surgical intervention (Group 1), or a suture bridging
the nerve gap (Group 2). The observation that implantation of a CNF conduit supports neural
regeneration is consistent with the findings of the first murine study, but importantly extends the work
to large neural gaps. Indeed, application of allometric scaling laws indicates that a 3 mm neural gap in a
mouse is equivalent to approximately a 9 cm gap in a human, a fact that emphasizes the importance of
the data of Figure 25. It is noted that the grip strength data of Group 3 has an apparent plateauing trend
in the 12 to 20-week time period, potentially indicating the maximum extent of regeneration possible
with the surgical configuration employed.
The grip strength data of mice in Group 4 (1 mm nerve gap and 5 mm conduit) approximated
those of mice in group 3 (3 mm nerve gap and 5 mm conduit), a somewhat surprising result that appears
to indicate that the extent of neural regeneration within a conduit is independent of the extent of tissue
excision, at least at the length scales employed in the present study. Investigation of the grip strength
data of Group 5 (1 mm nerve gap and 3 mm conduit) reveals that a maximum value of approximately
10g was reached at the 16-week time point, the greatest value observed in the entire study. Given the
uncertainty in the data it is unclear if the maximum value was maintained for the remainder of the time
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course of the study, or if a minor decrease occurred. Interestingly, comparison of the data for Groups 4
and 5 indicates that for a fixed nerve gap (1 mm) decreasing the length of the conduit from 5 to 3 mm,
respectively, increases the maximum extent of neural regeneration. Comparison of the data of Group 5
of the second murine study with the approximately 20 week data of the first murine study reveals that
the average grip strength of mice that underwent a 1 mm nerve resection was considerably less than
those without a recession when both received a 3 mm long conduit implant. Analysis of the weight of
each mouse indicated that each group (1-5) gained weight over the course of the study. Available grip
strength and weight data are presented in Appendix A7.

Figure 25: Second Murine Study Grip Strength Results
Grip strength measurements for five groups in the second murine study over 20 weeks, error bars are standard deviation

Two major conclusions may be drawn from the second murine study. First, CNF conduits
promote neural regeneration and do so over gaps that scale to very large injuries in humans. Second,
the extent of neural regeneration is dependent upon the length of the conduit employed and appears to
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be greatest for shorter conduits. The cause for the greater neural regeneration engendered by shorter
conduits is not known, but it may be hypothesized that it could relate to the rates of diffusion in and out
of the conduit of pro and anti-regenerative species, a possibility that is investigated in silico in Chapter 6.

5.5 HISTOLOGICAL ANALYSIS
A preliminary histological analysis was performed on select tissue samples from the second
murine study. The aim of the work was to optimize the staining methods to facilitate investigation of
neural tissues, and to determine cell types and distribution within the conduit. Hematoxylin and Eosin
(H&E) stains were employed for visualization of cellular structure and to aid in identification of cell
types, Luxol Fast Blue was used for identification of myelin, and Calcofluor White was employed to
facilitate localization of cellulose. The tissue sectioning, mounting and staining methods employed are
detailed in Section 3.21. Images of cross sections of conduits/tissues were taken in quadrants to enable
assembly of the images and hence construction of a complete image of the full cross section. Images
were overlaid manually by identification and alignment of distinct features within the tissue/conduit.

Suture
CNF Conduit

Lumen
200 μm
Figure 26: Hematoxylin and Eosin Stain of Conduit Containing Tissue Section

A representative image of an H&E stained cross section is presented in Figure 26, the cross
section was located 600 µm into zone B from the proximal side. It is evident from investigation of Figure
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26 that there are extensive tissues within the lumen of the conduit, as may been seen from the large
number of cellular nuclei that were stained purple by the Hematoxylin stain, each surrounded by the
non-nuclear cellular material stained pink by the Eosin stain. Interestingly the non-stained, light regions
of the image are identified as the CNF sheet comprising the conduit. The two-layer wrap structure of the
conduit is evident, as are some minor cellular populations in between the CNF layers themselves, and on
the outside of the conduit. On the left side of the image the outer flap of the conduit may be seen, and
in the center of the lumen it appears that the inner flap may have delaminated, a possibility that will be
investigated more fully with the Calcofluor White stain. The light blue anomaly observed in upper right
of the image is the suture employed for implantation. The sutures ran through the length of the conduit
in sets of two in opposite directions such that 2-4 sutures were commonly identified in each tissue
section. Suture segments were observed to be subject to shifting within the tissue section during
microtoming, an unfortunate phenomenon that left gouges in the tissue section and clear vacancies.

Delaminated
Conduit Flaps

Sheet
Fragmentation

200 μm
Figure 27: Calcofluor White Stain of Conduit Containing Tissue Section

In order to clearly identify and characterize the condition of the CNF conduit, Calcofluor White
staining was performed, see the representative image of Figure 27. Investigation of Figure 27 confirms
the impressions gained from analysis of Figure 26, that is, that the conduit had largely retained its
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tubular conformation, however the outer flap had commenced delamination, and the inner flap was
extensively detached. It should be noted that the conduits used in the second murine study were nonmechanically interlocked and used solely CNF on the outer flap, followed by coating the full conduit in
CNF. Detailed investigation of Figure 27, particularly at the edges of the CNF sheets, reveals a loss of
integrity of the sheets themselves, that is, the onset of an apparent fraying/degrading process. Given
that the intent of the CNF conduit is to promote neural regeneration and then to degrade in vivo,
thereby obviating the need for a second surgery to remove the conduit, the apparent CNF degradation
at the 20-week time point is highly encouraging.
Myelinated
Axons

Conduit
Layers

50 μm
Figure 28: Luxol Fast Blue Stain of Peripheral Nerve Section

In order to determine if Luxol fast blue was a suitable stain for the myelin sheath surrounding
nerve fibers of axons, a preliminary test was performed on a tissue section from the first murine study.
The tissue section was taken approximately one-third of the conduit length from the proximal end in
order to ensure the presence of myelinated nerves. Figure 28 presents an image of the resultant stained
tissue. Investigation of Figure 28 reveals the presence of a large number of dark blue annuli that
represent the cross sections of the myelin coatings of healthy nerves. Also evident in Figure 28 is the
non-stained wall of the CNF conduit in the lower left of the image. It is concluded therefore that Luxol
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fast blue is indeed an appropriate stain for the myelin sheath of the nerve fibers of axons and could be
employed in future studies to elucidate the presence and distribution of nerves.

5.6 NON-HUMAN PRIMATE STUDY: CNF TOLERABILITY
The non-human primate (baboon) study was conducted to assess the ability of the animal to
tolerate the CNF implant and to thereby determine the extent of biocompatibility of the CNF conduits in
an animal closely related to humans. The study and all protocols were approved by ACURO and the local
IACUC. In order to minimize the invasiveness of the surgery, the radial motor nerve in the forearm was
transected versus the sciatic nerve in the hind limb as was done in the murine studies. The initial study
employed a single animal. The radial nerve was severed and a 1.5 cm long mechanical interlocked CNF
conduit of ~3.2 mm diameter was implanted employing a comparable methodology to that employed in
the murine studies, see Section 3.18. It should be noted that the sutures used to implant the conduit
were non-resorbable polypropylene Surgipro sutures, as were employed in the previous murine studies.
Vicryl 2-0 sutures, commonly used in nonhuman primate surgeries, were used to close the exterior
wound.
Observation of the baboon in the days and weeks post-surgery indicated that there was no
significant difference in the motor function of the arm/wrist/fingers relative to that prior to the
procedure. It was concluded therefore that transection of the radial nerve resulted in a decrease in
sensory function rather than motor function. In addition, it was noted that the wound site was inflamed,
a fact that could potentially be attributed to poor hygiene, self-mutilation, a response to the suture
and/or the conduit, or a combination of these factors. As such, the animal was taken down for
histopathological analysis. Histological analysis revealed elevated levels of neutrophils localized around
the Surgipro sutures. Additionally, giant cells were found to be present, and to contain an unidentified
foreign material, again indicative of an inflammatory/foreign body response.
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Based upon the available data, it was determined that the baboon had likely experienced a
foreign body response to the Surgipro sutures used to implant the CNF conduit. To test this hypothesis a
two animal, follow-on study was performed to identify the source of inflammation. Specifically, subjects
2 and 3 had the same radial nerve severed as the initial animal (subject 1), however alternate repair
techniques were employed. For subject 2 a Surgipro suture was employed to bridge the neural gap
between the nerve stumps. For subject 3 a 1.5 cm long, ~2.4 mm diameter mechanical interlock CNF
conduit was placed over the nerve gap, however it was not sutured into place. Vicryl 2-0 sutures were
employed to close the external wound of both animals.

A

B

C

Figure 29: Histology of Non-Human Primate (Subject #2) Neural Tissue and Suture Material
A) Hematoxylin and Eosin stain showing suture material and surrounding neutrophils and Giant cells. B) Polarized light
demonstrating foreign material (suture). C) Closer look of extreme neutrophil invasion (blue arrow) at site of active
inflammation surrounding suture (Red arrow)

Subjects 2 and 3 were monitored for four weeks post-surgery before being taken down for
evaluation. No changes in behavior were observed post-surgery in the subjects. Histological analysis of
the tissues of subject 2 revealed extensive neutrophil and Giant cell infiltration at the site of the
Surgipro suture, see Figure 29, an observation consistent with that of the first study. Analysis of the
tissues of subject 3, revealed no evidence of neutrophil or Giant cell infiltration in the region of the
conduit. It was concluded therefore that the inflammation observed in initial non-human primate study
arose from the suture employed to implant the CNF conduit, and was not attributable to the conduit
itself. Indeed, the second study demonstrated that the CNF conduit was well tolerated and elicited no
foreign body/inflammatory response.
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5.7 CONCLUSION
In order to determine if cellulose nanofiber is a viable material from which to construct neural
conduits, an ex vivo cellular proliferation and compatibility study was performed in cell culture. It was
determined that macrophages had very little interaction with CNF, a fact that likely means implants
comprising CNF will not elicit a strong foreign body/inflammatory response. In addition, it was shown
the neither Schwann cells nor motor neurons proliferate well on CNF, suggesting that a CNF conduit
would likely be a non-participatory material in a neural conduit. Importantly, CNF infused with the
extracellular matrix protein laminin had a significantly stronger macrophage response, but also was
highly supportive of both Schwann cell and motor neuron attachment and proliferation - thereby
potentially providing a ready means of modifying the behavior of a CNF conduit from non-participatory
to strongly participating in neural regeneration.
Two murine studies and one non-human primate study were performed to determine the
efficacy of CNF conduits in peripheral nerve repair. The first murine study employed a sciatic nerve
model where the nerve was transected, but no tissue was excised. The nerve ends were abutted and
entubulated within a CNF conduit; the conduit was subsequently sutured in place. Neural regeneration
was assessed via functional recovery of grip strength of the hind limb. Conduit implant results were
compared to those of sham surgeries where the nerve was transected, but no conduit was implanted. It
was found that at 30 weeks the grip strength of the hind limb with the implanted conduit was 6 times
greater than that of the limb that underwent the sham surgeries, representing an approximately 66%
recovery of initial grip strength and indicating that CNF conduits were very effective in promoting
peripheral nerve regeneration.
The second murine study was undertaken to determine the efficacy of CNF conduits in
promoting peripheral nerve repair when various amounts of neural tissue were resected. In addition,
the study aimed to determine the effect of varying the conduit length on neural repair. A comparable
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experimental approach to that of the first murine study was employed with additional controls
implemented. It was concluded from the study that CNF conduits promote neural regeneration and do
so over gaps that scale to very large injuries in humans. In addition, and somewhat surprisingly, it was
shown that the extent of neural regeneration is dependent upon the length of the conduit employed
and appears to be greatest for shorter conduits. Histological analysis revealed the presence of significant
tissue in the luminal space of the conduit. Treatment with a cellulose specific stain revealed that the CNF
conduit largely retained its tubular geometry, although delamination of the inner and outer flaps was
evident, suggesting the need for a mechanical interlock design rather than solely a CNF slurry seal and
coating. The cellulose specific staining also revealed the onset of CNF conduit degradation at the 20
week time point, an important observation consistent with the desire to create a biodegradable conduit
that would obviate the need for a second surgery to remove it post neural regeneration.
The non-human primate study was undertaken to determine the ability of an animal species
known to be very sensitive to foreign bodies to tolerate the CNF conduit. It was determined that
conduits comprising CNF were very well tolerated and histological examination showed no evidence of a
foreign body/inflammatory response, a finding consistent with the cell culture study. The suture
employed in both the murine and the non-human primate surgeries to implant the conduit, however,
engendered a strong foreign body/inflammatory response. It is recommended that future in vivo studies
in non-human primates employ an alternate suture.
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CHAPTER SIX
FINITE ELEMENT ANALYSIS OF DIFFUSION AND DISTRIBUTION OF
OXYGEN AND GLUCOSE WITHIN CNF PERIPHERAL NERVE CONDUITS
6.1 INTRODUCTION
Functional recovery data from the second murine study revealed that implantation of a 3 mm
long conduit over a 1 mm neural gap was more efficacious in promoting regeneration than implantation
of a 5 mm conduit (see Section 5.4). It was hypothesized that the increased conduit length may have
altered the diffusive path of molecules known to be beneficial, and conversely detrimental, to peripheral
nerve regeneration; for example oxygen, calcium, glucose, and carbon dioxide [24, 31]. Indeed, it is
known that a critical aspect of conduit performance is facilitation of diffusion of pro-regenerative
molecules into the interior of the conduit, and promotion of diffusion of waste materials out of the
conduit [31]. In addition to length, other conduit parameters considered likely to be relevant to
molecular diffusion include wall permeability and nerve to conduit diameter ratio.
One of the primary molecules of interest in the present work was oxygen, arguably the most
critical chemical species required for homeostasis. In addition, it is noted that while necessary for
successful nerve regeneration, the detailed role of oxygen in nerve regeneration is unclear [79, 80]. For
example, Cho et al. found that intermittent hypoxia may be beneficial to nerve regrowth as the lack of
oxygen triggers the activation of Hypoxia-Inducible Factor (HIF) [81]. When activated, this transcriptional
mediator recruits co-activators and modifies the chromatin structure of the injured nerve, which
controls gene expression for the transcriptional response. It was discovered that the absence of HIF
resulted in impaired nerve regeneration, suggesting that hypoxia may potentially enhance nerve
regeneration [81]. In addition, Yao et al. have shown that hypoxic conditions indirectly improve neural
regeneration by enhancing cell migration to the injury, particularly Schwann cells [82].
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Conversely, other studies have indicated that hyperbaric oxygen (HBO) therapy (inducing
hyperoxygenation) may be an effective treatment for nerve injuries [83, 84]. Indeed, HBO studies
employing a murine sciatic nerve model demonstrated greater nerve regeneration with less evidence of
edema, coupled with enhanced conservation of cytostructural features versus controls [85]. HBO is a
method of treatment that has been employed for more than 30 years and promotes regeneration
through hyperoxygenation as well as several secondary mechanisms [85]. For example, increased
oxygen concentration is known to be correlated with increased ATP and GTP levels. HBO is also known
to reduce the inflammatory response and aids in the conservation of healthy tissue by reducing
oxidative stress and preventing apoptosis [85]. Interestingly, Lim et al. have demonstrated that the
regenerating proximal nerve consumes approximately twice as much oxygen as a healthy nerve,
supporting the concept that elevated concentrations of oxygen may be beneficial [86]. Clearly such
findings are, however, contrary to those indicating that hypoxic conditions support repair, and highlight
the need for a greater understanding of the role of oxygen in nerve regeneration.
Perhaps equally important as oxygen for the regeneration of peripheral nerves is the
concentration and distribution of glucose, the primary energy source for neural function [87, 88].
Indeed, it has been estimated that at homeostasis, 60-70% of the energy derived from glucose is used
for maintenance of the membrane potential required for neural signal propagation (see Section 1.3)
[89]. Under conditions of nerve regeneration, however, glucose consumption is expected to be far
greater and may potentially be rate limiting [90]. It is important to ensure that glucose concentrations
are maintained above ~4 mol/m3, as concentrations lower than this value are considered hypoglycemic
and are associated with deleterious effects on tissues [91]. As such, knowledge of the concentration and
distribution of both oxygen and glucose within a peripheral nerve conduit during regeneration is critical
to the design of effective and efficient neural conduits. Consequently, COMSOL Multiphysics®, a finite
element analysis software package, was employed to model the diffusive behavior of oxygen, and
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separately, glucose within a peripheral nerve conduit system as a function of conduit length, the nerve
to conduit diameter ratio, and the permeability of the conduit wall.

6.2 COMSOL MULITPHYSICS® FINITE ELEMENT ANALYSIS
COMSOL Multiphysics® is a powerful finite element analysis programing suite which employs
various supplemental physics packages to study phenomena such as heat transfer, fluid flow, acoustics,
etc. The specific package employed in the present work was Transport of Diluted Species. A model of a
CNF conduit implanted over a peripheral nerve injury was constructed in COMSOL to replicate select
conditions of the second murine study. Specifically, the larger of the two nerve gaps employed in the in
vivo study (3 mm), was chosen in order to maximize the concentration gradients. The nerve diameter
was set to be 3 mm and conduit diameters were ranged from 3 mm to 4.28 mm. The conduit wall
thickness was selected to be twice the thickness of the CNF sheet employed to construct the physical
conduits since two layers of CNF sheet were used in creation of the conduits. The conduit length and
conduit diameter were varied during the analyses as presented in Table 10. It is noted that the conduit
diameter was varied to give progressive, specific, values of the ratio of the diameter of the nerve to the
diameter of the conduit. The ratio ranged from 1.00:1.00 to 0.75:1.00 and was referred to as the nerve
to conduit diameter ratio. It is noted that at a nerve to conduit diameter ratio of 1.00:1.00 the nerve and
conduit were the same diameter and no luminal space existed between them. At a nerve to conduit
diameter ratio of 0.75:1.00 however the nerve had a smaller diameter than the conduit and significant
Table 10: Physical Parameters of Nerve-Conduit Model
Dimensions of neural tissue, conduit, and interstitial space in COMSOL model

86

luminal space existed between the outer surface of the nerve and the inner wall of the conduit. Such
space, and the space existing between the nerve ends, was modeled to be filled with interstitial fluid.

Figure 30: COMSOL Nerve and Conduit Model
Model view of neural stumps and conduit. Solid angled view (top) and
transparent side view (bottom)

The nerve-conduit system was modeled to comprise 3 components; the nerve stumps were
modeled as two cylinders spaced by the neural gap, while the conduit was considered a hollow cylinder
centered over the neural gap, see Figure 30. COMSOL Multiphysics was employed to determine the
concentration of oxygen, and separately glucose, at three locations within the conduit; at the center of
the distal stump (Location 1), the center of the gap between the nerve stumps (Location 2), and at the
center of the proximal stump at the intersection of the regenerating tip (a 1 mm long segment at the
end of the stump) and baseline sections (Location 3), see Figure 31. Location 1 was chosen as a
representation of a region with normal, baseline oxygen and glucose consumption by a nerve. Location 2
was chosen to be the center of the nerve gap, and the center of the conduit. At Location 2 there was no
direct oxygen or glucose consumption by the nerves (due to their absence), however oxygen and
glucose could potentially be depleted from this region due to consumption by the two neighboring
nerve stumps. Location 3 was selected because initial testing indicated that the interface between the

Figure 31: COMSOL Modeling Locational Analysis
Three locations observed during modeling (top) and sample
concentration profile (bottom)
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regenerating nerve and the baseline proximal stump consistently had the lowest oxygen concentration
in the system. Analysis of the oxygen and glucose concentration at each location as a function of time
provided insight into how these species diffused into the luminal space, and how variation of system
parameters altered concentration profiles.

6.3 OXYGEN DIFFUSION AND DISTRIBUTION
In order to model the concentration of oxygen at the three locations within the nerve-conduit
system as a function of time, a series of parameters required quantification. In addition to the physical
dimensions of the neural stumps and conduits derived from the murine studies and defined in Table 10,
values for initial concentrations of oxygen at the three locations, the diffusion coefficient of oxygen
through the conduit wall, neural tissue and interstitial fluid, and the rates of oxygen consumption at the
three locations required definition. Appropriate values were derived from literature, calculated, or
determined experimentally as described below.
The baseline oxygen concentration in the ISF was taken to be that of the average partial
pressure of oxygen in arterioles (PO2 = 26.4mmHg) [92] and was assumed to be constant since the
vasculature continuously replenishes it. The oxygen diffusion coefficient for ISF was estimated to be
equivalent to that for water and was obtained by extrapolating data of oxygen diffusion coefficient vs.
temperature reported by Han et al. [93] to physiologic temperature. The oxygen diffusion coefficient
through mouse peripheral nerve tissue was assumed to be equivalent to that through rat peripheral
nerve tissue as reported by Lagerlund et al. [94]. Oxygen consumption rates were based on the premise
that the only entities consuming oxygen in the system were the nerve stumps, and that consumption
was through both normal metabolic processes [93], and through active repair mechanisms [86]. Two
studies ( [86] and [93]) provided values for baseline metabolic consumption that were almost identical
(within a few percent), the higher value was adopted for use in the present work.
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A critical parameter that was determined experimentally in the present work was the diffusion
coefficient of oxygen through the conduit wall. Since the in vivo experiments involved implantation of
the conduits in an aqueous environment, the diffusion coefficient of oxygen under comparable
conditions had to be determined. As described in Section 4.1.7, a MOCON OX-TRAN Model 22/2 (L)
instrument was employed to measure the oxygen permeability of CNF sheets at a series of relative
humidity (RH) values over the range of 50-90% and a value for the oxygen permeability of CNF at 100
%RH obtained via extrapolation. Specifically, two oxygen permeability values were obtained at 50, 80
and 90 %RH and plotted versus relative humidity, see Figure 32. A linear extrapolation to 100%RH was
performed by plotting the inverse of the permeability values on the y-axis versus the relative humidity
on the x-axis. A trendline with an R2 value of 0.969 was fit to the data points which, when extrapolated
to 100 %RH, resulted in a permeability of 1.41 x 10-13 m2/s. When the data were replotted with the
inclusion of the value obtained from the extrapolation however it was evident that the projected value
was a low estimate. A secondary extrapolation of the data was therefore performed using only the data
points from the 80 and 90 %RH permeability measurements; a value of 2.22 x 10-13 m2/s was obtained at
100 %RH via a trendline with an R2 value of 1.00. The latter value was considered a high estimate for the

Figure 32: Extrapolation of Oxygen Permeability from MOCON Analyses
Extrapolated data from oxygen permeability through CNF sheets
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value of the permeability of the CNF sheet at 100 %RH, as such the average value of the two
extrapolated numbers was employed, namely 1.8 x 10-13 m2/s. Table 11 presents a summary of the
oxygen diffusion coefficient, concentration and consumption values employed in the modeling work.
Table 11: Oxygen Diffusion Related Parameters
Initial oxygen concentration, diffusion coefficient and consumption rate for the
conduit neural tissue and interstitial fluid

The COMSOL model was run for a simulated time range of 1500 minutes by which time oxygen
concentrations throughout the conduit had either plateaued or reached a value of 0. The mesh that was
employed for the COMSOL analyses was ‘extra fine’ to ensure accurate iterative calculations.

6.3.1 EFFECT OF CONDUIT DIAMETER ON OXYGEN CONCENTRATION AND DISTRIBUTION
One of the major variables of interest was the effect of nerve to conduit diameter ratio on
oxygen concentration profiles. In order to evaluate the effects, the COMSOL Multiphysics® model was
run at the six different nerve to conduit diameter ratio values over the time period required to reach
equilibrium, or until oxygen concentrations at Location 1 reached the minimum possible value of 0
mol/m3. Figure 33 presents the final oxygen concentration profile of the model run for the lowest and
highest nerve to conduit diameter ratios and is presented as an axial-cut plane on a continuous color
scale of blue (0 mol/m3) to maroon (1.4 mol/m3).
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Proximal End
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Figure 33: Oxygen concentration profiles for lowest and highest nerve to conduit diameter ratios
The conduit was 15 mm long and the model was run for 30 minutes and 50 minutes respectively

It may be seen from investigation of Figure 33 that the regions of lowest oxygen concentration
were located toward the end of the nerve stumps within the conduit, and that the lowest overall
concentration was at the interface of the regenerating region and the baseline region of the proximal
stump where oxygen consumption is twice that of baseline nerve consumption. It is further evident from
Figure 33 that varying the ratio of the nerve to conduit diameter does not change the general oxygen
distribution profile, however the actual oxygen concentration at given points is affected. Specifically,
lower oxygen concentrations are observed within the conduit for higher nerve to conduit diameter
ratios (that is, when the conduit diameter approaches that of the nerve diameter), a fact likely
attributable to decreased axial diffusion due to the reduced volume of luminal interstitial fluid (ISF). The
oxygen concentration in the center of the nerve gap is greater than toward the ends of the nerve
stumps, an observation which is consistent with the lack of consumption. At the ends of the conduit
where the nerve stumps transition from being enclosed to non-enclosed, the oxygen concentration is
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Figure 34: Oxygen Modeling with Variable Nerve to Conduit Diameter Ratio
Oxygen concentration profiles of a 16 mm length conduit with variable nerve to conduit diameter
ratio at (A) Location 1, (B) Location 2, and (C) Location 3

observed to rapidly increase to that of the exterior oxygen concentration present in the ISF. The
qualitative representation of the oxygen concentration data of Figure 33 may be presented in a
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quantitative manner employing the three locations described above and plotting oxygen concentration
vs time at each, see Figure 34.
Investigation of the graphs of Figure 34 reveals several interesting attributes of the model and
its relationship to conduit oxygen permeability. First, it is noted that at Location 3 the oxygen
concentration for all nerve to conduit diameter ratios reached a concentration of 0 mol/m3 in the
shortest time period of the three locations (under 60 minutes for all nerve to conduit diameter ratios), a
finding that is consistent with the observation from the qualitative data of Figure 33 that the oxygen
concentration at Location 3 was lower than at locations 1 and 2. Additionally, analysis of the
concentration vs time curves of Figure 34 (A), (B) and (C) indicates that the curves for locations 1 and 3
are of similar shape, although of different scale, with a rapid, near linear, initial decline followed by a
transition to a more gradual decay. Conversely the curves for Location 2 have a shallower initial decline
followed by a transition to a slightly more rapid decay. For each location a clear trend in the oxygen
concentration at a given time as a function of the nerve to conduit diameter ratio is evident, with
concentration decreasing at all locations as nerve to conduit diameter increases. Figure 35 presents a
plot of oxygen concentration vs nerve to conduit diameter ratio at an arbitrary time point of 25 minutes.
From investigation of Figure 35 it is evident that there is a relatively linear relationship between
decreasing oxygen concentration and increasing nerve to conduit diameter ratio at all locations.
Location 2 has the highest overall oxygen concentration, a fact attributable to the lack of oxygen
consumption in the region between the two nerve stumps. Location 3, conversely, has the lowest overall
oxygen concentration, an observation that is consistent with the proximal stump terminating with a
region that consumes twice the oxygen of a non-regenerating nerve. The observed relationship of
decreasing oxygen concentration within the conduit with increasing nerve to conduit diameter ratio may
be understood via consideration of the resultant decrease in luminal ISF volume that results from a
more closely matched nerve and conduit diameter (i.e. greater nerve to conduit diameter ratio).
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Specifically, as the nerve to conduit diameter ratio increases, the distance between the nerve and the
conduit inner wall (filled with ISF) decreases and hence the cross sectional area through which oxygen
within the ISF can diffuse axially into the conduit decreases, leading to lower oxygen concentrations at
locations within the conduit. The high linearity of the relationship between oxygen concentration and
nerve to conduit diameter ratio suggests that there is very little influence of radial diffusion of oxygen
through the walls of the conduit (or that it is invariant with nerve to conduit diameter ratio).

0.70:1.00

0.80:1.00

0.90:1.00

1.00:1.00

Figure 35: Oxygen Concentration with Varied Nerve to Conduit Diameter Ratio
Nerve to conduit diameter ratio at t=25 min for all 3 Locations

6.3.2 EFFECT OF CONDUIT WALL PERMEABILITY ON OXYGEN CONCENTRATION AND
DISTRIBUTION
To determine the sensitivity of the model predictions to the permeability of the conduit walls to
oxygen, simulations were run employing CNF permeabilities one order of magnitude above and one
order of magnitude below the value listed in Table 11. The results of this analysis are presented in Figure
36 as plots of oxygen concentration vs time at the three locations within the conduit employing CNF
permeabilities spanning two orders of magnitude.
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Investigation of Figure 36 reveals that varying the oxygen permeability of the CNF conduit walls
by two orders of magnitude has only a minimal effect on the oxygen concentration within the conduit.
As such, it is concluded that the value employed for the oxygen permeability of CNF in the present work
is likely sufficiently accurate to give the COMSOL Multiphysics® model reliable predictive power. It is
noted however that the majority of the model predictions trend to zero oxygen concentration within the
conduit in a timeframe that is very short (typically hours) relative to the implant durations (weeksmonths), a continuously hypoxic scenario that is likely not favorable for nerve regeneration in vivo. It
was therefore determined that simulations should be run with significantly greater conduit wall
permeability in order to verify the veracity of the model itself, and to provide insight into how radial
diffusion pathways affect the resultant oxygen concentration profile when employing conduits with
greater wall oxygen permeability.
In order to determine an appropriate range for testing the effect of the oxygen permeability of
the conduit wall on oxygen concentrations within the conduit, the permeability of materials currently
used for conduit construction were reviewed, and related to the limiting case of a conduit wall with the
permeability of the surrounding media, i.e. interstitial fluid (ISF). Specifically, the oxygen permeability of
a material commonly employed for peripheral nerve conduit fabrication, collagen, is of the order of 10-10
m2/s [95]. By comparison, the oxygen permeability of interstitial fluid is reported to be 2.7269x10-9 m2/s
[93], approximately an order of magnitude higher than that of collagen. It is noted that the oxygen
permeability of CNF is approximately an order of magnitude lower than that of collagen. As such, a
range of oxygen permeabilities was selected from 10 times lower than ISF (1 order of magnitude 
collagen) to 100 times lower (two orders of magnitude  CNF). Specifically, the oxygen permeability of
the conduit wall was modeled employing values of 10x, 20x, 50x, and 100x less than that of ISF. The
resultant oxygen concentration vs time graphs for each conduit permeability (not shown) were very
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similar to those presented in Figure 34, however it is noted that as the conduit became progressively
less permeable, the curves took longer to plateau and plateaued at significantly lower oxygen
concentrations. Figure 37 presents the plateau values for oxygen concentration as a function of nerve to

Figure 36: Oxygen Concentrations with Variation of Measured Conduit Permeability
Employing a CNF oxygen permeability value as per Table 11 (standard), a permeability on order of magnitude
lower (low), and a permeability one order of magnitude higher (high). Shown for (A) Location 1, (B) Location 2, and
(C) Location 3 from t=0min to t=100min
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Figure 37: Oxygen Concentration with Variation of ISF-Based Conduit Permeability
Nerve to conduit diameter ratio at Locations 1 (A), 2 (B) and 3 (C) for varying conduit wall oxygen permeabilities of 10
(blue), 20 (orange), 50 (grey) and 100 (yellow) times less than ISF
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conduit diameter ratio for the 10, 20, 50 and 100 times less than ISF wall permeability values at
locations 1, 2 and 3. Figure 37 was generated in a manner comparable to that employed to create Figure
35.
It is evident from investigation of Figure 37 that the 10, 20, and 50 times less permeable than ISF
wall variants maintained oxygen concentrations greater than zero at all nerve to conduit diameter
ratios, at all three locations. Further, it is noted that the oxygen concentrations were consistently lower
at all locations at comparable nerve to conduit diameter ratios with progressively decreasing wall
permeability. Taken together these two findings suggesting that oxygen diffusion radially across the wall
of the conduit does indeed impact concentrations within the conduit and is modulated by the
permeability of the wall. The data for the 100 times less than ISF wall permeability variants have oxygen
concentrations that trend to 0 mol/m3 as the nerve to conduit diameter ratio approaches 1, an
observation made at all three locations. As such, for the 100 times less permeable than ISF wall variants,
the interior of the conduit is completely hypoxic at all nerve to conduit diameter ratios once the oxygen
concentration plateaus, a finding consistent with the CNF modeling results.
It may also be seen from investigation of Figure 37 that for the 10 times less permeable than ISF
wall variants there is little to no effect on the oxygen concentration at a given location as the nerve to
conduit diameter ratio increases, suggesting that the wall is so permeable to oxygen that radial diffusion
dominates over axial diffusion irrespective of the volume of ISF between the inner wall of the conduit
and the nerve stumps. It is noted however that the baseline oxygen concentrations at the three
locations do follow the expected trend of highest at Location 2 where there is no consumption, lowest
at Location 3 where there is twice the baseline oxygen consumption, and intermediate at Location 1. As
the wall permeability is decreased to 20 times less permeable than ISF, the oxygen concentration vs the
nerve to conduit diameter curves at Locations 1 and 3 (where there is oxygen consumption) trend
negatively, indicating that radial diffusion of oxygen across the conduit wall is less dominant, and that
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axial diffusion in the ISF filled space between the nerve and the inner wall of the conduit becomes
progressively more important. Interestingly at Location 2 the oxygen concentration remains invariant
with nerve to conduit diameter ratio at the 20 times less permeable than ISF wall permeability, an
observation potentially attributable to the fact that there is no oxygen consumption at this location
making it less susceptible to restricted supply and that radial diffusion remains dominant. A further
decrease in wall permeability to 50 times less permeable than ISF results in negative trends in the
oxygen concentration vs nerve to conduit diameter ratio curves at all locations, indicating dominance of
axial diffusion over radial diffusion, driven by the restricted oxygen diffusion across the conduit wall. It is
noted however that radial diffusion of oxygen does occur at this wall permeability value and is critical to
maintaining an oxygenated environment within the conduit; a finding exemplified by the hypoxic
environment at all locations observed at the 100 time less permeable than ISF wall variants. A summary
of the findings derived from Figure 37 is presented in Table 12. Specifically, the conduit wall
permeability and location in the model are paired in order to provide an overview of the mode of
diffusion that is dominant.

Table 12: Summary of the Dominant Diffusion Regimes
Observed for paired conduit wall permeabilities (relative to ISF) and locations within the conduit. All combinations apply to
conduits of any length in the tested range of 12-16mm.

10x

20x

50x

100x

Location 1

Radial Wall
Diffusion

Axial Gap
Diffusion

Axial Gap
Diffusion

Axial Gap
Diffusion

Location 2

Radial Wall
Diffusion

Radial Wall
Diffusion

Axial Gap
Diffusion

Axial Gap
Diffusion

Location 3

Radial Wall
Diffusion

Axial Gap
Diffusion

Axial Gap
Diffusion

Axial Gap
Diffusion

99

6.3.3 EFFECT OF CONDUIT LENGTH EFFECT ON OXYGEN CONCENTRATION AND DISTRIBUTION
Due to the data from the second murine study indicating that for a fixed nerve gap the length of
the conduit employed has a significant effect on peripheral nerve regeneration (see Section 5.4),
modeling was performed to explore the effect of conduit length on oxygen concentration and
distribution. Five different conduit lengths were tested, ranging from 12 mm to 16 mm in 1 mm
increments. The base CNF permeability of Table 11 was employed, and the model was run until the
oxygen concentration reached 0 mol/m3. Figure 38 presents the resultant oxygen concentration vs time
data as a function of conduit length for a nominal nerve to conduit diameter ratio of 0.70:1.00.
Investigation of Figure 38 indicates that as the conduit length increases the time required for the
oxygen concentration to reach 0 mol/m3 progressively decreases, a trend observed at all three locations
and attributable to impaired axial diffusion due to enhanced luminal distances. The data at Location 1
show greater dependence of the gradient of the curves at varying conduit lengths relative to those at
Locations 2 and 3, a fact attributable to the shorter axial diffusion distance for Location 1 vs that at
either Location 2 or 3 and hence a greater sensitivity of oxygen concentration to conduit length. It is
noted that these observations are specific to conditions promoting dominance of axial diffusion over
radial diffusion (low nerve to conduit diameter ratio, and low conduit wall permeability). Finally,
comparison of the data for the 16 mm conduit (dark blue line) of Figure 38 with the comparable data of
Figure 34 (red line) reveals complete agreement, implying internal consistency of the model.
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Figure 38: Oxygen Modeling with Variable Conduit Length
Oxygen concentration profiles of a conduit with a 0.70:1.00 nerve to conduit diameter ratio and
variable conduit length at (A) Location 1, (B) Location 2, and (C) Location 3

One significant point of interest under conditions such as those above in which axial diffusion is
dominant over radial diffusion, is that the trends observed in oxygen concentrations with varying nerve
to conduit diameter ratios were typically comparatively linear (or biphasic linear). The observed linearity
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is somewhat surprising given that the cross section of the model is cylindrical, and as such changes in
the radius of the conduit relative to the nerve results in changes in the cross-sectional area of the ISF
filled gap by r2. As such one would predict that the relationship between oxygen concentration and
nerve to conduit diameter ratios should have an r2 dependence in axial diffusion dominant regimes. One
potential reason that the observed data did not exhibit a strong r2 dependence is that the difference
between the oxygen diffusion coefficients in ISF and in the nerve itself is very small (see Table 11). In
order to test this hypothesis, the conduit wall oxygen permeability was set at zero (to force the system
into an axial diffusion dominant regime), and an artificially large difference in oxygen diffusion
coefficients for ISF and the nerve were implemented. Specifically, the diffusion coefficient of oxygen
through the ISF was increased by a factor of 100, and the nerve diffusivity was maintained at its base
value. Setting the parameters as indicated essentially made changes in conduit radii and hence the
cross-sectional area of ISF, the sole variable impacting oxygen concentration within the conduit. Figure
39 presents an analysis of oxygen concentration at Locations 1, 2, and 3 as a function of nerve to conduit
diameter ratio, in both a qualitative and quantitative manner.
Investigation of Figure 39 (a) indicates that when there is a substantial cross-sectional area of ISF
through which oxygen can readily diffuse (0.70:1.00 nerve to conduit diameter ratio) there is significant
oxygen concentration throughout the interior of the conduit. Conversely, when the nerve diameter and
the conduit diameter are equal and no cross-sectional area of ISF exists (Figure 39 (b)), oxygen can only
diffuse through the nerve tissue and as a result virtually the entire interior of the conduit is hypoxic with
essentially zero oxygen concentration. Figure 39 (c, d, e) present the plateau oxygen concentration
values as a function of nerve to conduit diameter ratios for Locations 1, 2 and 3 respectively. It is evident
that at all locations there is only a slight dependence of oxygen concentration on nerve to conduit
diameter ratio until a value of approximately 0.90:1.00, at which point a reverse logarithmic decay trend
is observed. It is noted that the final data points of Figure 39 (c, d, e) are plotted as negative oxygen
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concentrations, which hold no physical meaning - however they are included to illustrate that indeed
the model does predict a strong non-linear dependence of oxygen concentration on nerve to conduit
diameter ratio under axial diffusion dominant conditions.

Figure 39: Oxygen Concentration Plateau Profiles
Nerve to conduit diameter ratios (A) 0.70:1.00 ratio and (B) 1.00:1.00 ratio. Oxygen concentration vs nerve to conduit
diameter ratio for (C) Location 1 (D) Location 2 and (E) Location 3. Note that the conduit wall oxygen permeability was set
to zero and the ISF oxygen diffusion coefficient was increased to 100 times its baseline value. Negative oxygen
concentration values clearly have no physical meaning but are included to highlight the r 2 dependence of the data.
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6.4 GLUCOSE DIFFUSION AND DISTRIBUTION
In order to model the concentration and distribution of glucose, the primary energy source for
neural regeneration, within the CNF conduit, a series of parameters required definition. The physical
dimensions of the nerve and conduit remained the same as were employed for the oxygen modeling
study and are summarized in Table 11. Additional parameters that required definition included the
initial concentration of glucose within the conduit, the neural tissue and the ISF, the diffusion coefficient
of glucose through the conduit wall, within the neural tissue and through the ISF, and finally the
consumption rate of glucose by the conduit, the neural tissue and the ISF. Each of these parameters
were derived from literature, or experimentally determined as described below, and are summarized in
Table 13.
Table 13: Glucose Diffusion Related Parameters
Initial glucose concentration, diffusion coefficient and consumption rate for the conduit
neural tissue and interstitial fluid

Blood glucose levels of healthy individuals are known to be in the range of 4.2 to 8.3 mmol/L
[91], with most individuals having a blood glucose level of greater than 5 mmol/L [96]. In addition, it has
been shown that interstitial fluid glucose concentration is comparable to that of blood plasma, with no
measurable lag time [97]. As such a nominal value of 6 mmol/L was selected as the initial interstitial fluid
glucose concentration. The neural tissue was assumed to have equilibrated with the large glucose
reservoir of the body’s interstitial fluid and was therefore assigned an initial concentration of 6 mmol/L.
The CNF conduit was assigned an initial glucose concentration within the wall of 0 mmol/L.
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A literature value for the rate of consumption of glucose by peripheral neural tissue was
unavailable, as such a range was determined via known values for consumption of glucose by brain
tissue, and via application of a known relationship between neural oxygen consumption (which is well
established) and the rate of glucose consumption. First, Mergenthaler reported a value of 5.6 mg of
glucose consumed per 100 mg of human brain tissue per minute [88]. Employing average values for
brain volume [98] and weight [99], coupled with the molecular mass of glucose, enabled calculation of a
glucose consumption rate of 5.828 x 10-3 mol/(m3∙s). It is known that the brain consumes glucose at a
greater rate than peripheral neural tissue [100], although the precise proportionality is unknown, as
such this value should be considered a high (likely maximum) value. Second, Mergenthaler [88], and
separately Lim et al. [90], have reported that there is a direct relationship between the rate of oxygen
consumption by neural tissue and the rate of glucose consumption by the same tissue. Specifically, the
rate of glucose consumption is 5.5-5.8 times lower than that of oxygen consumption. Oxygen
consumption in a regenerating nerve has been found Lim et al, [90] to be approximately twice that of a
healthy nerve. Given the known linear relationship between neural oxygen and glucose consumption
rates [88, 101], it follows that the glucose consumption rate in a regenerating nerve should be double
the baseline value. Applying this scaling factor to known oxygen consumption rates of peripheral neural
tissue at baseline metabolic conditions and under active repair conditions (as reported by Lim et al. [86,
90] and Han et al. [93]) results in estimated values for glucose consumption rates of 1.673 and 3.345 x
10-4 mol/(m3∙s), respectively. It is noted that these values are approximately an order of magnitude
lower than those obtained employing the known glucose consumption rate of brain tissue (which are
certainly an over estimation for peripheral neural tissue) and are adopted here for the non-regenerating
regions of the nerve stumps, and the regenerating tip of the proximal nerve, respectively.
The permeability of the neural tissue was approximated via a value for the glucose diffusion
coefficient reported by Khalil et al. for epithelial tissue and dura mater as 2.64 x 10-10 m2/s [102]. It is
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noted however that the ends of the proximal and distal nerves not within the conduit were modeled as
impermeable to glucose since in vivo they would extend significant distances within the body and would
not be subject to glucose flux axially from an open end. The diffusion coefficient of interstitial fluid was
approximated via a value reported by Suhaimi et al. for glucose diffusivity in cell culture medium as 5.67
x 10-10 m2/s [103]. Lastly, the diffusion coefficient of glucose in the cellulose nanofiber conduit wall was
determined experimentally in the present work to be 1.7x10 -11 ± 0.9 x 10-11 m2/s see Section 3.11.
COMSOL Multiphysics® simulations were run for a duration of 1000 minutes, by which time
glucose concentrations had generally either plateaued, or had decreased below the hypoglycemic
threshold value of 4 mol/m3 [91].

6.4.1 EFFECT OF CONDUIT DIAMETER ON GLUCOSE CONCENTRATION AND DISTRIBUTION
An investigation into the effect of variation of the nerve to conduit diameter ratio on the
glucose concentration profile and distribution was performed for a 16mm conduit over a range of
0.70:1.00 to 1.00:1.00 in increments of 0.05, see Figure 40. It is evident that at all three locations within
the conduit the glucose concentration progressively decreases as the nerve to conduit diameter ratio
increases, that is, as the nerve and conduit diameters tend toward the same value. It is also noted that
glucose concentrations plateaued in the range of ~5-5.75 mol/m3, i.e. above the upper limit of
hypoglycemia of 4 mol/m3 [91]. The sensitivity of glucose concentration to nerve to conduit diameter
ratio at the three locations may be understood in terms of length of the diffusion path axially within the
conduit, the length of the radial diffusion pathway from the inner conduit wall to the nerve, and on the
relative glucose consumption rates at the given locations. Notably, at Location 1 the axial diffusion path
for glucose is the shortest of the three locations and hence axial diffusion is a significant contributor to
the instantaneous glucose concentration. The effect of nerve to conduit diameter ratio is greatest at
Location 1 (greatest range of plateau concentration values), a fact that may be attributed to the
decrease in volume of interstitial fluid between the inner conduit wall and the nerve as the conduit
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Nerve to Conduit Diameter Ratio
Figure 40: Glucose Concentration Profiles of a 16 mm Length Conduit
Variable nerve to conduit diameters at (A) Location 1, (B) Location 2, and (C) Location 3
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diameter approaches that of the nerve. The diffusion coefficient of glucose in interstitial fluid is
approximately twice that of neural tissue, and more than an order of magnitude greater than in the CNF
conduit wall, as such the effect of reduction of ISF volume is significant in regimes that have a
dependence on axial diffusion. It is expected that radial diffusion of glucose does contribute to the
instantaneous concentration at Location 1, although changes in nerve to conduit diameter are not
expected to result in large changes in glucose concentrations resulting from radial diffusion since the
change in diffusion distance from the inner conduit wall to the nerve is minor when compared to typical
axial diffusion paths. It is noted that the plateau glucose concentrations at Location 1 are intermediate
between those of Locations 2 and 3, a fact attributed to baseline neural glucose consumption, versus no
consumption at Location 2 and twice baseline consumption at Location 3. At Location 2 the axial
diffusion distance for glucose is the greatest of the three locations, as such it is expected that axial
diffusion will play a minor role in the instantaneous glucose concentration, and that radial diffusion will
dominate. The glucose concentration at Location 2 plateaued to the same value irrespective of the
nerve to conduit diameter, an observation attesting to the dominance of radial diffusion over axial
diffusion. As observed above, the instantaneous glucose concentrations at Location 2 are the highest of
the three locations, a fact attributed to the lack of neural consumption in the gap between the nerve
stumps. Location 3 resides at an axial distance from the end of the conduit that is intermediate between
that of Locations 1 and 2 and as such likely has instantaneous glucose concentrations that are influenced
by both axial and radial diffusion. Indeed, a similar but less strong dependence on nerve to conduit
diameter ratio is observed at Location 3 versus that at Location 1, suggesting not quite as strong an axial
diffusion dependence, and a greater radial diffusion dependence. It is noted that the glucose
consumption rate is twice that which occurs at Location 1, a fact reflected in the glucose concentrations
at Location 3 being the lowest of the three locations.
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6.4.2 EFFECT OF CONDUIT LENGTH ON GLUCOSE CONCENTRATION AND DISTRIBUTION
To assess the impact of the potentially confounding effect of changing conduit length on the
trends observed in glucose concentrations as a function of nerve to conduit diameter ratio, a similar
analysis to that performed in Figure 40 on the longest (16mm) conduit was performed on the shortest
(12mm) conduit, see Figure 41. It is evident from comparison of Figures 41 and 42 that the shorter
conduit resulted in higher glucose concentrations at Location 1, but invariant concentrations at
Locations 2 and 3. The findings suggest that axial diffusion is a significant contributor to the
instantaneous glucose concentration at Location 1. However, at Locations 2 and 3 radial diffusion
dominates over axial diffusion as evidenced by the negligible effect a significant reduction of the axial
diffusion distance had on the instantaneous glucose concentrations.
A comprehensive analysis of the effect of conduit length on glucose concentration profiles and
distributions was performed at a nerve to conduit diameter ratio of 0.70:1.00 over the full conduit
length range of 12 to 16mm in 1mm increments, see Figure 42. Investigation of Figure 42 reveals that at
all locations within the conduit the glucose concentration plateaus to a positive value, above 4 mol/m3,
for all conduit lengths. It is noted that the plateau concentrations follow the same trend as observed in
sensitivity to nerve to conduit diameter ratio as a result of axial diffusion path length, radial diffusion
path length, and rate of glucose consumption, namely highest at Location 2, intermediate at Location 1
and lowest at Location 3. Further, at each location the glucose concentration progressively decreases
with incremental increases in conduit length, a fact attributed to the increasing axial diffusion path
length for glucose to reach each of the three locations within the conduit.
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Nerve to Conduit Diameter Ratio
Figure 41: Glucose Concentration Profiles of a 12mm Length Conduit
Variable nerve to conduit diameter ratio at (A) Location 1, (B) Location 2, and (C) Location 3
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In order to test the dependence of the glucose concentration profiles on conduit length when
the luminal volume of interstitial fluid was minimized, simulations were run for conduit lengths varying
from 12 to 16mm in 1mm increments at a nerve to conduit diameter ratio of 1.00:1.00, see Figure 43.
Comparison of Figures 43 and 44 reveals that increasing the nerve to conduit diameter ratio from
0.70:1.00 to 1.00:1.00 decreases the glucose concentrations at all three locations and for all conduit
lengths, although the decreases are comparatively minor, particularly at Locations 2 and 3. The glucose
concentration at Location 1 decreased by approximately 0.3 mol/m3 upon increasing the nerve to
conduit diameter ratio. At Locations 2 and 3 minor decreases in glucose concentrations were observed
upon increasing the nerve to conduit diameter ratio, and the effect on glucose concentration of
modification of the length of the conduit was suppressed. The observed differences revealed that the
glucose concentration profiles at Location 1 were most sensitive to changes in conduit length and
diameter due to its comparatively short axial diffusion path and baseline consumption rate, however the
sensitivities at Locations 2 and 3 were far less pronounced, showing very minor, if any, shifts in
concentration. These data demonstrate the importance of axial diffusion of glucose through the
interstitial fluid resident in the gap between the nerve and the inner conduit wall, particularly at
Location 1. Specifically, if the gap and hence the interstitial fluid, are removed by employing a conduit
with the same diameter as the nerve, glucose concentrations are decreased as the only modes of
potentially active diffusion are axially through the nerve itself, and radially across the conduit wall. The
findings suggest that the minor decreases in glucose concentrations seen by both increasing the length
of the conduit and increasing the nerve to conduit diameter ratio are due to reduction of axial diffusion.
It is noted that glucose concentrations remain well above hypoglycemic conditions with axial diffusion
pathway reductions suggesting that diffusivity of glucose radially through the CNF conduit wall and/or
axially along the neural tissue itself is sufficient for maintaining healthy glucose levels.
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Figure 42: Glucose Concentration Profiles of a 0.70:1.00 Nerve-Conduit Diameter Ratio Conduit
Variable conduit length at (A) Location 1, (B) Location 2, and (C) Location 3
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Figure 43: Glucose Concentration Profiles of a 1.00:1.00 Nerve-Conduit Diameter Ratio Conduit
Variable conduit length at (A) Location 1, (B) Location 2, and (C) Location 3
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6.4.3 EFFECT OF CONDUIT WALL PERMEABILITY ON GLUCOSE CONCENTRATION AND
DISTRIBUTION
Clearly, limiting the axial diffusion of glucose through the interstitial fluid resident in the luminal
space between the nerve and the inner conduit wall via reduction of the conduit diameter has only a
minor effect on the glucose concentration and distribution within the conduit. Radial diffusion across
the CNF conduit wall, and/or axially through the neural tissue appear to be the dominant diffusion
modalities. As such an investigation of the effect of varying the permeability of the conduit wall to
glucose was performed to determine if a reduction in radial diffusion into the luminal space may lead to
hypoglycemic levels. Conduit parameters for the investigation were set at a nerve to conduit diameter
ratio of 0.70:1.00 and a conduit length of 16 mm. The baseline conduit diffusion coefficient employed in
the work to date has been 1.7 x 10-11 m2/s, a value based on the experimental measurement of glucose
diffusion through a cellulose nanofiber sheet. It is of interest to explore the effect of varying the conduit
wall permeability over a practical range. The highest obtainable conduit wall permeability would arise
from a wall material with a glucose diffusion coefficient equivalent to that of interstitial fluid, i.e. 5.7 x
10-10 m2/s, this value was therefore selected as the upper boundary of the glucose diffusion coefficient.
Two additional diffusion coefficient values were selected based on the application of one standard
deviation above and below the measured experimental value yielding values of 2.6 x 10-11 and 8.0 x 10-12
m2/s, respectively. Finally, a lower boundary value of 1 x 10-12 m2/s was selected given that it represents
the lowest value in the order of magnitude in which the experimental value minus one standard
deviation fell. Figure 44 presents the instantaneous glucose concentrations plotted as a function of time
at the three locations within the conduit employing the five selected conduit wall diffusion coefficients.
It may be seen from investigation of Figure 44 that employing a conduit wall diffusion coefficient
equivalent to that of interstitial fluid (5.7 x10-10 m2/s) results in glucose concentrations at all locations
that are only slightly lower than the baseline interstitial fluid concentration, a fact arising from the
absence of a barrier for radial diffusion across the conduit wall and therefore dominance of the radial
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diffusion mode over the axial diffusion mode. It is noted however that at the locations where glucose
consumption occurs (1 and 3), the plateau concentrations are lower than at Location 2. Decreasing the
diffusion coefficient of the conduit wall progressively to the experimental value plus one standard
deviation, the experimental value, and the experimental value minus one standard deviation is observed
to result in monotonic reductions in the plateau values of the glucose concentrations at all three
locations within the conduit, with the relative concentrations following the previously observed trend of
highest at Location 2, intermediate at Location 1, and lowest at Location 3. Reducing the diffusion
coefficient to the lower boundary value of 1 x 10-12 m2/s resulted in a dramatic decrease in the
instantaneous glucose concentrations and the lack of attainment of a plateau concentration in the
timescale investigated at all 3 locations. Running the simulation for a longer period of time indicated
that at Location 1, a plateau value of 3.8 mol/m3 was eventually reached (at ~ 3000 minutes). It is noted
that a concentration of 3.8 mol/m3 is below the threshold of hypoglycemia. At Locations 2 and 3, the
application of the lower boundary value of the diffusion coefficient resulted in a glucose concentration
profile that entered the hypoglycemic regime at 800 and 700 minutes, respectively. The data of Figure
44, coupled with the experimentally measured glucose diffusion coefficient for cellulose nanofiber
sheets, implies that under the conditions of the present study radial diffusion through the conduit wall is
the dominant pathway for glucose to enter the luminal space, and that axial diffusion, while present,
appears to have only marginal significance, primarily at Location 1.
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Conduit Permeability to Glucose
Figure 44: Glucose Concentration Profiles of a Conduit with Varied Conduit Permeability
0.70:1.00 nerve to conduit diameter ratio and conduit length of 16 mm with variable conduit
permeability at (A) Location 1, (B) Location 2, and (C) Location 3
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6.5 CONCLUSIONS OF FINITE ELEMENT ANALYSIS MODELING OF OXYGEN AND GLUCOSE
CONCENTRATIONS AND DISTRIBUTIONS WITHIN A CNF PERIPHERAL NERVE CONDUIT
In order to provide insight into the concentration and distribution of oxygen and glucose within
a peripheral nerve conduit, a COMSOL Multiphysics® model of a peripheral nerve injury comprising a 3
mm gap between the proximal and distal stumps was created. The injury site was enclosed within a
cellulose nanofiber conduit. The end of the regenerating proximal stump was modeled to consume
twice the oxygen and glucose per unit time vs baseline nerve consumption (as per literature). The
concentration and distribution of oxygen and glucose at three locations within the conduit were
analyzed as a function of the nerve to conduit diameter ratio, the permeability of the conduit wall to
oxygen and glucose, and the length of the conduit.
It was found that the lowest oxygen concentration within the conduit occurred at the end of the
proximal stump where regeneration was occurring. The end of the distal stump had the second lowest
oxygen concentration (with baseline oxygen consumption), with the gap in between the stumps having
the highest concentration (where no oxygen consumption occurs). Increasing the nerve to conduit
diameter ratio (effectively decreasing the ISF filled gap between the nerve and the inner wall of the
conduit) led to progressively lower oxygen concentrations for all conduit lengths and locations tested
and for conduit wall oxygen permeabilities in accordance with those used in in vivo studies. The findings
were attributed to the dominance of axial diffusion over radial diffusion of oxygen and the decreased ISF
filled axial volume as the nerve and conduit diameters approach each other. Increasing the oxygen
permeability of the conduit walls to values 10 times less than that of ISF (vs the baseline case of 100
times less permeable than ISF) resulted in the oxygen concentration at all locations within the conduit
being invariant with the nerve to conduit diameter ratio, implying that radial diffusion of oxygen across
the conduit wall is the dominant mechanism of oxygen migration for highly permeable conduits.
Progressively decreasing the conduit wall permeability led to reversion to the axial diffusion regime at all
locations. Increasing the length of the conduit employing the baseline wall permeability resulted in a
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consistent decrease in oxygen concentration at all locations within the conduit as the axial distance
required for oxygen diffusion increased. The model was shown to be internally consistent, and to follow
expected trends with regard to the effect of changes of conduit radii and concomitant change of the ISF
filled axial volume on oxygen concentration in an axial diffusion-controlled regime.
It was found that as the nerve to conduit diameter ratio increased, the glucose concentration at
all locations decreased, a finding consistent with decreased axial diffusion. It was noted however that
the small changes in glucose concentration that resulted suggest that axial diffusion was not the
dominant diffusion mode. Investigation of the effect of variation in conduit length revealed similar
trends. As conduit length increased, glucose concentrations progressively decreased, although again the
effects were comparatively minor in the nerve gap and proximal nerve, suggesting that radial diffusion is
the dominant regime at these locations. Lastly, the effect of variation of the glucose diffusion coefficient
of the cellulose nanofiber conduit wall was investigated. Progressively decreasing the glucose diffusion
coefficient of the CNF conduit wall consistently reduced the instantaneous glucose concentrations at all
locations. At a diffusion coefficient of 1 x 10-12 m2/s, more than an order of magnitude below the
experimentally determined value, the glucose concentrations at all locations were reduced below the
hypoglycemic threshold of 4 mol/m3, a finding attributed to inhibited radial diffusion of glucose. It is
concluded therefore, that under the experimental conditions employed, radial diffusion of glucose into
the luminal space of the conduit is the dominant diffusion modality at all locations, with axial diffusion
only contributing to a minor extent in the distal nerve stump due to the shorter axial distance from the
end of the conduit to the monitoring location.
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CHAPTER SEVEN
CONCLUSIONS
The present work developed conduits comprising cellulose nanofiber (CNF) which showed great
efficacy in promotion of peripheral nerve repair. CNF was produced from bleached softwood pulp via
mechanical segmentation and defibrillation. A recirculating flow supermasscolloider was constructed
within a temperature-controlled cleanroom at the University of Maine Technology Research Center. A
series of GMP/GLP based protocols were developed to ensure production of verifiable quality CNF.
Importantly, a cumulative energy meter was installed on the supermasscolloider to track the total
energy applied to the cellulose slurry, which was shown to correlate well with the resulting fines content
of the CNF.
Cylindrical neural conduits were created by rolling two layers of a sheet of CNF around a plastic
mandrel, followed by sealing of the outer flap. As such, it was critical that CNF sheets be reproducibly
created from the CNF slurry derived from the defibrillation process. It was found that dried CNF sheet
thickness was proportional to the percent solids content of the CNF slurry employed to cast the sheet,
as well as the thickness of the wet sheet spread by the casting knife film applicator. The CNF sheet
production process was optimized to produce sheets with a thickness of 56.2 ±1.3 m. Physical
characterization of the sheets was performed to determine strength, surface roughness,
porosity/permeability and transparency. Tensile strength testing revealed that the Young’s modulus of
the CNF sheets was of the order of 4.6 to 5.7 GPa. Due to the fact that the CNF sheets were cast on a
stainless steel plate and hence had two surfaces that dried in contact with different media (stainless
steel and air), the surface roughness of the two sides were considerably different. Specifically, the side
of the CNF sheet that dried in contact with the stainless steel plate was comparatively smooth with an
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average roughness, as determined by mechanical profilometry, of 0.5-1.0 m, while the side that dried
in contact with air was comparatively rough with an average roughness of 2.5-4.0 m.
Sheet porosity and permeability were characterized in order to understand the likely extent of
passage of pro and anti-regenerative species through the CNF walls of the neural conduits.
Measurement of air passage through the CNF sheets was unsuccessful, indicating that they were nonpermeable, at least in the dry state. Mercury porosimetry measurements of CNF sheets confirmed the
findings of the air permeability analysis; no evidence for sheet porosity was found down to the limit of
the technique of 10 nm. Sheet transparency was shown to increase with decreased sheet thickness, and
to increase with hot calendaring. Oxygen diffusion across the CNF sheets was measured as a function of
relative humidity in the range of 50-90 %RH. The data enabled extrapolation to a diffusion coefficient of
1.8 x 10-13 m2/s at the physiologically relevant condition of 100% relative humidity. The diffusion
coefficient of glucose through the CNF was experimentally determined to be 1.7 ± 0.9 x 10-11 m2/s,
approximately two orders of magnitude greater than that of oxygen. It was noted CNF sheets swell
significantly in aqueous solutions, expanding to approximately 70 m thickness in the wet state from an
initial dry thickness of approximately 50 m.
A significant amount of work was performed to develop an effective means of sealing the
internal and external flaps of the multi-layer CNF conduits, and to determine the optimal CNF sheet
properties. The efficacy of various sealing methods, CNF sheet thickness, and number of CNF sheet
layers were determined by evaluating the mechanical stability of conduits in a range of aqueous
solutions under both static and dynamic conditions. In terms of mechanical stability, it was determined
that the optimal number of CNF sheet layers was two and that sheets of approximately 52 m thickness
were most effective. Three different sealing methods were investigated. Applying an aqueous layer
beneath the flap was found to be ineffective for extended periods of time. Applying CNF slurry beneath
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the flap and coating the finished conduit in CNF slurry was found to produce a product with very good
stability for up to approximately 6 weeks. The final and most stable method developed for sealing the
conduit flaps was to employ mechanical interlocks on the inner and outer CNF layers; such conduits
maintained their integrity even under dynamic conditions far more extreme than would be experienced
in vivo.
CNF conduits were implanted in two murine sciatic nerve animal studies, and one non-human
primate tolerability study. The first murine trial demonstrated that the conduits were well tolerated by
the animals and were highly effective in promoting peripheral nerve regeneration when the sciatic nerve
was transected, and no tissue excised. Indeed grip strength measurements of the hindlimbs of the test
subjects 30 weeks post-surgery demonstrated approximately six times greater grip strength (~66%
functional recovery) in animals that received a CNF conduit vs animals that had the sciatic nerve
transected but did not receive a conduit. The second murine study investigated the efficacy of repair of
the sciatic nerve employing five different repair techniques. Specifically, Group 1 used a 3mm nerve gap
and no assistive repair intervention, Group 2 employed a suture to connect the nerve stumps across a
3mm nerve gap, Group 3 employed a 5mm conduit over a 3mm nerve gap, Group 4 employed a 5mm
conduit over a 1mm nerve gap, and Group 5 employed a 3mm conduit over a 1mm nerve gap. It was
concluded from the study that CNF conduits promote neural regeneration and do so over gaps that scale
to very large injuries in humans. In addition, and somewhat surprisingly, it was shown that the extent of
neural regeneration is dependent upon the length of the conduit employed and appears to be greatest
for shorter conduits. Histological analysis revealed the presence of significant tissue in the luminal space
of the conduit. Treatment with a cellulose specific stain revealed that the CNF conduit largely retained
its tubular geometry, although delamination of the inner and outer flaps was evident, suggesting the
need for a mechanical interlock design rather than solely a CNF slurry seal and coating. The non-human
primate study was undertaken to determine the ability of an animal species known to be very sensitive
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to foreign bodies to tolerate the CNF conduit. It was determined that conduits comprising CNF were
very well tolerated and histological examination showed no evidence of a foreign body/inflammatory
response, a finding consistent with a cell culture study. The suture employed in both the murine and the
non-human primate surgeries to implant the conduit, however, engendered a strong foreign
body/inflammatory response in the baboons.
The observation in the second murine study that the physical dimensions of the CNF conduit
employed directly impacted the extent of neural regeneration led to the development of a finite
element analysis model of the peripheral nerve-conduit system. Specifically, COMSOL Multiphysics® was
employed to model the peripheral nerve-conduit system, and to predict the concentration and
distribution of species likely to be important for neural regeneration as a function of the physical
dimensions of the conduit, and the permeability of its walls. Indeed the time-dependent concentrations
of oxygen, and separately, glucose were modeled throughout the nerve-conduit system as a function of
conduit length, the nerve to conduit diameter ratio, and the permeability of the CNF conduit wall to the
species of interest. It was found that all three parameters influenced the concentration and distribution
of oxygen and separately, glucose, throughout the nerve/conduit system. Oxygen concentrations within
the conduit were found to be heavily influenced by the conduit dimensions and to be dominated by
axial diffusion through the ISF filled luminal space between the nerve and the inner conduit wall; little
dependence on radial diffusion across the CNF wall of the conduit was found, a fact attributed to the
relative impermeability of CNF to oxygen. Conversely, glucose concentrations within the conduit were
found to be heavily influenced by radial diffusion across the CNF conduit wall, a fact attributed to the
high permeability of CNF to glucose; axial diffusion of glucose through the ISF filled luminal space
between the nerve and the inner conduit wall was found to be far less significant. The outcomes of the
COMSOL Multiphysics® modeling study are significant in that they demonstrate that oxygen
concentration within a CNF conduit in vivo may be modulated by the physical dimensions of the implant
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relative to the nerve; and further that glucose concentration within the conduit is mostly controlled by
the diffusion coefficient of glucose across the conduit wall. The in vivo murine studies revealed that
neural regeneration was greatest when a shorter conduit was implanted over a fixed neural gap, a
condition that the COMSOL model predicts would result in greater oxygen concentrations within the
conduit, and glucose concentrations well above the hypoglycemic threshold. It is concluded therefore
that the COMSOL model was predictive and explanatory of the in vivo results. Extension of the model to
determine the concentration and distribution of the primary waste product of metabolism, carbon
dioxide, would be an interesting future effort.
In addition to modeling the impact of conduit properties on carbon dioxide concentration, other
aspects of the CNF conduit that could modulate neural regeneration should be explored in future
studies to target an optimal regenerative environment. Indeed, although the first and second murine
studies demonstrated that conduit implantation resulted in greater neural regeneration than was
achieved in their absence, it was observed that the degree of regeneration decreased as the neural gap
increased. Research is therefore required to increase the extent of neural regeneration in CNF conduits
over large neural gaps. To this end, preliminary work was undertaken by the author and collaborators
to embed axial growth guidance cables in the inner wall of the CNF conduit that could potentially
support and direct neural regeneration. Further, chemical and/or biological modifications of the conduit
could be undertaken to convert the implant from an essentially inert construct into one which actively
promotes cellular proliferation. Indeed, the author and collaborators demonstrated the potential of the
extracellular matrix protein laminin to favorably modify CNF in such a manner. Such an approach could
be utilized to spatially template growth tracks for the regenerating neurons along the inner wall of the
conduit, and/or could be coupled with guidance cables to further enhance regeneration. In addition,
pro-regenerative species such as growth factors that are necessary to initiate regeneration could be
incorporated into the conduit to guarantee threshold concentrations are met. Finally, the ability of the
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CNF slurry/hydrogel itself to support cellular growth should be evaluated. If shown to be viable, CNF
conduits could be filled with CNF slurry comprising essential cells and growth factors prior to
implantation. Such a CNF construct could provide not only a microenvironment conducive to neural
regeneration, but also a reservoir of supportive cells and factors.
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APPENDIX
A1: CLEANROOM DESCRIPTION
A cleanroom was constructed off site at the Technology Research Center of the Forest
Bioproduct Research Institute to house a refining center and laboratory space for conduit development
from wood pulp feedstock. The overall cleanroom exterior dimensions of the cleanroom were 13’ wide x
17’ long x 12’ tall. The interior ceiling height was 10 ft, creating a 2 ft tall air chamber in the ceiling of the
entire cleanroom for air flow. Installed in the ceiling were four HEPA air filtration units as well as four
flat panel LED lights. The two longest sides of the cleanroom were constructed with a double wall with
approximately a 1-foot gap for air recirculation. The air flow in the room blew down from the ceiling and
was separated into two streams; airflow into the recirculation chambers of the double walled sides and
excess air pushed through a sweeper seal at the bottom of the entrances. The air flow created positive
pressure in the room meaning a constant flow of air outward from the room preventing unwanted
particles drifting into the room. A prefilter was installed in the roof of the cleanroom such that fresh,
filtered air could be pulled into the air chamber, mixed with recirculated air, and cycled into the
cleanroom. An 18,000 BTU air conditioner and heat pump (Home Depot, 309068909) was installed in
the ceiling space to maintain temperature of the cleanroom space.
The interior space was divided into two separate rooms, a working area and a gowning area.
Doors existed to partition the gowning area from the outside, and separately, the work area from the
gowning area. Only one should be opened at any given time to ensure maintenance of the clean positive
pressure environment. The gowning area, approximately 4’ x 12’, contained a storage shelf for personal
protective equipment (PPE), a coat rack, a shoe rack, and a bench. All PPE was donned while in the
gowning room with both doors closed. Once PPE was donned, an individual could enter the work area.
The work area was 10’ x 12’ with two 6’ x 3’ stainless steel work benches delineating two distinct work
areas (dry and wet). Dry work consisted of pulp preparation, sheet production, conduit production, and

134

other work in which water could potentially damage products. Wet work was performed on the second
bench which housed the supermasscolloider.
The supermasscolloider (SMC) setup was the centerpiece of the cleanroom and was employed
to refine bleached softwood kraft pulp into cellulose nanofiber. The SMC was configured to enable
continuous refinement. A food grade positive displacement pump was employed, sized appropriately to
move slurry prepared at 2% solids by weight. All contacting surfaces of the sanitary fittings were 316
stainless steel, joined with silicone gaskets, and were secured with quick lock fittings made of 304
stainless steel. The diameters of the fittings and lines ranged from 1” ID on the recirculation line,
sampling port, and waste line on the output side of the pump, 2” for the input of the pump, 3” on the
overflow, 4” on the pump reservoir and 6” for the SMC output receiver. The larger diameter on the
pump input side were necessary for the gravity-fed flow of viscous CNF slurry.
The ability to operate the SMC as a continuous, recirculating system relied upon the ability for
fluid flow to occur simultaneously in the pump and in the colloider. If either section of equipment were
to possess stagnant slurry, damage to the equipment and potential contamination of the slurry could
occur. It was critical to size each fitting volumetrically such that the entire volume of slurry in the system
(14 liters) could be held in the pump reservoir, and that the recirculation line and hopper volume
together were less than half of the system volume. Compliance with the volumetric restrictions meant
that with a full recirculation line, hopper and overflow line, neither the pump nor colloider were in
danger of dry operation. Optimizing the pump reservoir volume was key for consistent slurry production
as it maximized mixing of the slurry. Operationally it should be noted that as the viscosity of the slurry
increases with the extent of refining, the pump speed should be slowed to account for the decreased
flow from the gravity fed overflow line.
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Figure 1: Optimization of Continuous SMC System
Alterations were made to the pump speed and pump reservoir to increase the mixing capabilities
of the system. Sample aliquots were taken from the hopper and aggregate aliquots were taken
from the whole slurry after dispensing from the system.

The SMC is an open system that was designed for continuous refining of wood pulp dispersed in
water into a CNF slurry. Air quality was critical, hence the placement in a clean room. Similarly, water
quality was controlled via use of purification system. To ensure consistent, high quality CNF production
amenable to the creation of biomedical implants, Standard Operation Procedures and Protocols were
developed for each stage of the process from pulp preparation to conduit packaging. All protocols were
based on GMP and GLP protocols commonly used in the pharmaceutical industry. Quality Control
Checklists were developed for different stages of the process to ensure consistency and the prevention
of downstream complications. The Standard Operating Procedures and Quality Control Checklists may
be found in the subsequent appendices.
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A2: CLEANROOM BLUEPRINTS/DIAGRAMS

Figure 2: Technical Drawing of the Cleanroom

Figure 3: Image of the Constructed Cleanroom

137

Wet Manufacturing Table

Colloider
Controls
Colloider
Floor Mats

Cleaning Totes

Pump

2
File Cabinet
1

Sink

Storage Shelving

Gowning
Room
Bench
3

Dry Manufacturing Table

Shoe Rack

Coat Rack

Figure 4: Equipment Layout of Cleanroom with Three Distinct Working Areas
Dry Manufacturing of sheets and conduits (1), producing slurry (2), and sample storage (3)

Cellulose Pulp
Storage
CNF-SOP-01
CNF-QCC-01

Cellulose Pulp
Solution Prep
CNF-SOP-03
Colloider
Operation
CNF-SOP-04

Fiber Analysis

Gowning
area

Colloider
Cleaning
CNF-SOP-08

CNF-SOP-05
CNF-QCC-05

CNF-SOP-02

CNF conduit
production

CNF sheet
production

CNF-SOP-07
CNF-QCC-07

CNF-SOP-06
CNF-QCC-06

Labeling, Stability, Storage, and
Distribution
CNF-SOP-09 CNF-SOP-10 CNF-SOP-11

Figure 5: Workflow Diagram of Cleanroom Activities with Standard Operating Procedures and Quality Control Checks

138

A3: GMP/GLP-BASED PROTOCOLS DOCUMENT
GOOD MANUFACTURING PRACTICES (GMP) COMPLIANT METHOD TO PRODUCE CELLULOSE
NANOFIBRIL NEURAL CONDUITS

2/12/2018

Including All Standard Operating Procedures and Quality Control Checklists

(FOR RESEARCH PURPOSES ONLY)

Approved by:

Signature

Date

Originator

Nicklaus Carter and Mary Bourque

Manager

David Neivandt

Quality Assurance

David Neivandt and Caitlin Howell

139

SCOPE AND APPLICABILITY
The purpose of the following documents is to establish a clean process with multiple levels of quality
control and quality assurance to produce and distribute cellulose nanofibril (CNF) conduits. The methods
described in the Standard Operating Procedures (SOPs) enclosed are used to produce a medical-grade
CNF conduit from bleached cellulose pulp to be used for neural applications. The SOPs and Quality
Control Checklists (QCCs) do not include tests for pathogens, microbial growths, or sterility beyond
multiple visual inspections during production. The University of Maine has partnered with researchers in
the Eggan Laboratory at Harvard University, Nano Terra, and the Southwest National Primate Research
Center (SNPRC) of the Texas Biomedical Research Institute in San Antonio, Texas to test the conduits for
efficacy in vivo, and these teams have developed their own protocol to sterilize the conduits prior to
implantation.
Two specialized environments are needed to produce CNF conduits: A humidity-controlled environment
is required to store the cellulose pulp. A clean room with air filters and a gowning area prior to entry is
required for pulp suspension production, CNF slurry production, conduit production, and stability
studies (see Appendix A.1 and 2). The workflow plan for the cleanroom is presented in Appendix A.3.
The TAPPI-certified room in the University of Maine’s Process Development Center (PDC) stores the pulp
(see Appendix B.1 for PDC and TAPPI room floor plans) and a clean room housed in the University of
Maine’s Technology Research Center (TRC) is employed for production (see Appendix C for TRC floor
plan.) See Appendix D for further specifications and maintenance protocol of the clean room. The
analysis of cellulose pulp moisture content and the measurement of fines and fibers using a MorFi Fiber
Analyzer may take place in any laboratory environment. For the pilot operation described, separate
laboratory spaces in the facilities of the University of Maine in Orono are used (see Appendix B.2, and 3
for floor plans).
All operations and facilities are designed to adhere to the following Good Manufacturing Practices
(GMP): WHO GMP for active pharmaceutical ingredients stated as per Annex 2- WHO Technical Report
Series(TRS), No. 957, 2010; GMP guide for Active Pharmaceutical Ingredients ICH Harmonised Triplicate
Guideline stated as per ICH Q9; and GMP requirements as per Directives No. 2001/83/EC latest
amended vide Directive 2011/62/EU). See Appendix E for the whole-facility self-appraisal based on
these GMP guidelines. The whole-facility self-appraisal will be reevaluated on a yearly basis and all
revisions made will be documented.
See next page for a listing of the operation’s SOPs and QC checklists.
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SUMMARY OF METHOD
Nicklaus Carter, a Ph.D. candidate at the University of Maine (2017), has worked laboriously with
developing the process to product neural conduits. Therefore, Nicklaus was the originator of all SOPs
and QCCs. Mary Bourque, pursuing a B.S. in Chemical Engineering at Columbia University (2018), was a
participant of the NSF-funded Research Experience for Undergraduates (REU) in the Forest Bioproducts
Research Institute (FBRI) at the University of Maine and worked closely with Nicklaus to complete the
SOPs and QCCs. The SOPs and QCCs are numbered in the order they should be completed. The following
is a summary of methods detailed in each SOP document:

1. (CNF-SOP-01) Cellulose pulp sample is obtained, properly stored in a humidity-controlled
environment, and analyzed for moisture content, adhering to ISO 287 protocol.

2. (CNF-SOP-02) Personnel change into appropriate PPE prior to entering the clean room.
3. (CNF-SOP-03) Cellulose pulp is added to water and allowed to sit overnight. The pulp is agitated
and broken down into smaller particulates.

4. (CNF-SOP-04, CNF-SOP-05, CNF-SOP-06) The pulp suspension is circulated through a super mass
colloider (SMC) where it is refined until 90% fines is achieved. A calibration curve relating the
cumulative energy and fines content using a MorFi Fiber Analyzer is used to determine the level of
refinement while running the SMC. The SMC is cleaned after each batch.

5. (CNF-SOP-07) The slurry collected from the SMC is used to form CNF sheets by using a film
applicator and air drying.

6. (CNF-SOP-08) Dry sheets are measured for thickness before being rolled and employed as neural
conduits.

7. (CNF-SOP-09) The clean room and all equipment are cleaned regularly for quality control
measures.

8. (CNF-SOP-10) A detailed log of QCCs are kept to properly label each product. Example labels are
included.

9. (CNF-SOP-11) Products are tested for stability in different environments and timescales.
10. (CNF-SOP-12) The supervisor approves distribution of products, ensuring all QCCs are complete.
Quality Control and Quality Assurance
The following quality control checklists have been developed for applicable steps of production to
ensure consistent products as well as to create a traceable log of batch details and personnel
responsibility:

1.
2.
3.
4.

Cellulose Pulp (CNF-QCC-01)
Processed Fiber (CNF-QCC-06)
Sheet Production (CNF-QCC-07)
Conduit Production (CNF-QCC-08)
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1.0 Purpose
1.1. To store cellulose pulp in a temperature and humidity-controlled environment such that the
moisture content of an aliquot can be calculated.
2.0 Health and Safety Warnings
2.1. Take care when lifting or carrying large or heavy loads: Improper form or the inability to lift
heavy loads can cause strains and sprains.
2.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
2.3. Work in a well-ventilated laboratory area.
2.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
2.5. Hazardous waste must be disposed in designated waste container.
2.6. Be familiar with the MSDS/SDS for all chemicals employed in the procedure.
3.0 Cautions
3.1. The sample of cellulose pulp used for the pulp suspension must be stored in a temperature
and humidity-controlled environment in order for the calculated moisture content to be
representative of the entire sample.
3.2. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials, and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
3.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
3.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
4.0 Interferences
4.1. Improper storage of the pulp sample (malfunctioning temperature and moisture control,
improperly sealed bags, storage of the pulp sample in an open environment, etc.) will yield
inaccurate calculations of the weight percent solids of the pulp suspension.
5.0 Personnel Responsibilities and Qualifications
5.1. Supervisor:
●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed.

5.2. The Operator:
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●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

●

Must be able to lift up to 50 pounds.

6.0 Equipment and Materials
6.1. Equipment
6.1.1.

Laboratory scale (Fisher Scientific, 01-920-120)

6.1.2.

Heating/drying oven (Fisher Scientific, 15-10-0508)

6.2. Materials (as listed or equivalent)
6.2.1.

Bleached cellulose pulp (Vendor, Cat #XXXXX)

7.0 Quality Control and Quality Assurance
7.1. Complete the quality control checklist CNF-QCC-01 (Cellulose Pulp) for the pulp sample to
be stored in the TAPPI room. Remove a sample of approximately five sheets of pulp from
the lot and store in a temperature and humidity-controlled environment for a minimum of
24 hours prior to analysis of moisture content. Calculate the moisture content using the ISO
287 standard procedure using an aliquot of the sample. The moisture content calculated will
be representative of the entire sample removed from the lot and stored in a temperature
and humidity-controlled environment. Moisture content need only be recalculated if
storage conditions of the sample change or a new sample from the lot has been stored in
the TAPPI room to be used. While performing this SOP, record in the accompanying quality
control checklist CNF-QCC-01, Cellulose Pulp:
7.1.1.

Storage conditions in the TAPPI room

7.1.2.

Mass of sample

7.1.3.

Moisture content (%) of aliquot

7.1.4.

Visual inspection

7.1.5.

Notes

7.1.6.

Initials and date

8.0 References
8.1. CNF-QCC-01 (Cellulose Pulp Quality Control Checklist)
8.2. ISO 287 (Paper and board – Determination of moisture content of a lot – Oven-drying
method)
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8.3. CNF-SOP-09 (General Maintenance and Cleaning Protocol)
8.4. CNF-SOP-10 (Labeling Procedure for Stocks, Samples, and Products)
9.0 Procedures
9.1. Calculation of Moisture Content (as outlined in ISO 287)
9.1.1. Remove a pulp sample (five sheets) from the lot and store in the TAPPI room for a
minimum of 24 hours prior to analysis of moisture content
9.1.2. Transfer an aliquot of pulp (100g) from the sample to a dry container and obtain the
mass
9.1.3. Dehydrate the aliquot of pulp in a drying oven at a temperature of 105°C  2°C
9.1.4. Reweigh the pulp aliquot. Repeat drying and weighing until there is no change in mass
9.1.5. Obtain a moisture content value of the aliquot. The aliquot’s moisture content will be
representative of the sample stored in the TAPPI room
9.2. Cleaning and Maintenance
9.2.1. Clean the station as outlined in CNF-SOP-09. Record all maintenance and cleaning
performed in the maintenance and cleaning logs at the station.
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1.0 Purpose
1.1. To ensure that the cleanroom is entered by all personnel in a clean and consistent manner
2.0 Health and Safety Warnings
2.1. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
2.2. Work in a well-ventilated laboratory area.
2.3. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
2.4. Hazardous waste must be disposed in designated waste container.
2.5. Be familiar with the MSDS/SDS for all chemicals employed in the procedure.
3.0 Cautions
3.1. Improper execution of the gowning procedure may contaminate all products within the
room.
3.2. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
3.3. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
3.4. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.0 Personnel Responsibilities and Qualifications
4.1. Supervisor:
● Ensure operators are trained on this procedure.
● Ensure operators conduct procedures as instructed.
4.2. The Operator:
● Must be trained on all equipment and procedures prior to operation.
● Complete this procedure as instructed.
● Report any deviations to this procedure to Dr. Neivandt.
● Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the clean room.
5.0 Equipment and Materials
5.1. Materials (as listed or equivalent)
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5.1.1. Bouffant (Fisher Scientific, 17-624-136)
5.1.2. Clean room specific shoes (Vendor, Cat #)
5.1.3. Shoe covers (Fisher Scientific, 17-624-136)
5.1.4. Frocks (Fisher Scientific, 19-162-628)
5.1.5. Gloves (Fisher Scientific, 19-169-069)
5.1.6. Beard cover (Fisher Scientific, 17-100-925)
5.1.7. Hand sanitizer (Fisher Scientific, 12-544-105)
6.0 Quality Control and Quality Assurance
6.1. Visually inspect all materials to be brought into the clean room. Be sure all containers are
closed and sealed prior to entry.
7.0 Procedures
7.1. General Attire
7.1.1. Ensure that all personnel are NOT wearing open toed shoes, shorts, skirts, or dresses
7.1.2. Ensure that all personnel are following a regular schedule of hygiene
7.2. Before entering the gowning room
7.2.1. Remove bulky outerwear such as coats, scarves, sweatshirts, etc.
7.2.2. Remove shoes, hats, and any jewelry
7.2.3. Ensure that hair is tied back and that there are no dangling items of clothing or
jewelry
7.2.4. Turn the lights on to the clean room
7.2.5. Ensure filters have been on and running for at least 24 hours. If the filters have not
been on for at least 24 hours, ensure the filters are on and wait until a full 24 hours
has passed
7.2.6. Record the status of the HEPA filters and clean room and gowning pressures on the
clean room sign-in sheet. If the clean room pressure is not twice that of the gowning
room, do not enter the clean room
7.2.7. Close and seal all containers to be brought into the clean room
7.2.8. Enter the gowning room and close the door to the surrounding facility
7.3. Before entering the clean room
7.3.1. Ensure that the air filtration system is operating
7.3.2. Ensure that there is a supply of clean room garments in the gowning room
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7.3.3. Apply hand sanitizer
7.3.4. Put on clean room shoes stored in the gowning area and place shoe covers over them,
one pair per individual should be stored in the gowning room
7.3.5. Put on frock, bouffant, and beard cover as necessary
7.3.6. Put on gloves and be sure that the glove cuffs overlap the cuffs of the frock
7.3.7. Perform a self-review to ensure the individual entering is wearing a bouffant, clean
room shoes, shoe covers, frock, gloves, and beard cover (if applicable)
7.3.8. Make sure that the gowning room door is closed before entering the clean room
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1.0 Purpose
1.1. To prepare a cellulose pulp suspension: An unrefined dispersion of hardwood, softwood or
other cellulosic fibers in water
2.0 Definitions
2.1. CNF: Cellulose nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
3.0 Health and Safety Warnings
3.1. Take care when lifting or carrying large or heavy loads: Improper form or the inability to lift
heavy loads can cause strains and sprains.
3.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.3. Work in a well-ventilated laboratory area.
3.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.5. Hazardous waste must be disposed in designated waste container.
3.6. Be familiar with the MSDS/SDS for all chemicals employed in the procedure.
4.0 Cautions
4.1. The whole sample of cellulose pulp used for the pulp suspension must be stored in a
temperature and humidity-controlled environment for the calculated moisture content of
the aliquot to be representative of the entire sample.
4.2. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials, and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Interferences
5.1. Improper storage of the pulp sample (malfunctioning temperature and moisture control,
improperly sealed bags, storage of the pulp sample in an open environment, etc.) will yield
inaccurate calculations of the weight percent solids of the pulp suspension.
6.0 Personnel Responsibilities and Qualifications
6.1. Supervisor:
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●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed.

6.2. The Operator:
●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

●

Must be able to lift up to 50 pounds.

7.0 Equipment and Materials
7.1. Equipment
7.1.1. 5-Gallon plastic pail (ULINE, S-7914W)
7.1.2. Gamma seal lid for plastic pail (ULINE, S17945W)
7.1.3. Laboratory scale (Global Industrial, 240878)
7.1.4. Heating/drying oven (Fisher Scientific, 15-103-0508)
7.2. Materials (as listed or equivalent)
7.2.1. 280 g bleached cellulose pulp (Vendor, Cat #XXXXX)
7.2.2. 13.72 kg sterile deionized-distilled water (17.45-17.46 Megaohms-cm)
8.0 Quality Control and Quality Assurance
8.1. Before commencing the procedure in this document, complete the quality control checklist
CNF-QCC-01 (Cellulose Pulp) for the pulp sample to be used. Store the sample from the pulp
lot in the temperature and humidity-controlled environment of the TAPPI room for a
minimum of 24 hours prior to analysis of moisture content. Calculate the moisture content
using the ISO 287 standard procedure for an aliquot of the sample. The moisture content
calculated will be representative of the entire sample removed from the lot and stored in
the TAPPI room.
9.0 References
9.1. CNF-QCC-01 (Cellulose Pulp Quality Control Checklist)
9.2. ISO 287 (Paper and board – Determination of moisture content of a lot – Oven-drying
method)
9.3. CNF-SOP-09 (General Maintenance and Cleaning Protocol)
9.4. CNF-SOP-10 (Labeling Procedure for Stocks, Samples, and Products)
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10.0 Procedures
10.1. Preparation of the Cellulose Pulp Mixture
10.1.1. Visually inspect all containers prior to use: If an individual container does not pass
visual inspection, clean according to CNF-SOP-09, General Maintenance and Cleaning
Protocol.
10.1.2. Add 13.720 kg of DIW to the 5-gallon pail
10.1.3. Obtain 280 g pulp on a dry basis (or humid equivalent after obtaining moisture
content of the sample) to create a suspension of 2% solids by weight
10.1.4. Submerge the sample of cellulose pulp in the pail
10.1.5. Cover the mixture and allow the pulp to saturate for a minimum of 12 hours
10.2. Dispersing pulp in suspension
10.2.1. Agitate the saturated pulp
10.2.2. Repeat stirring/shearing until the suspension is a continuous dispersion
10.2.3. Break down any large particulates into particles smaller than 1” diameter to prevent
plugging lines in the SMC
10.3. Cleaning and Maintenance
10.3.1. Clean the station as outlined in CNF-SOP-09. Record all maintenance and cleaning
performed in the maintenance and cleaning logs at the station.
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1.0 Purpose
1.1. To operate a super mass colloider (SMC) to refine a cellulose pulp suspension into a
cellulose nanofibril (CNF) slurry
2.0 Definitions
2.1. CNF: Cellulose nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. SMC: Super mass colloider
3.0 Health and Safety Warnings
3.1. Do not put fingers or any other part of the body below the overflow inside the hopper,
inside of the discharge, or near the grinding stones of the SMC when in operation. Doing so
could cause personal injury.
3.2. Take care when lifting or carrying either large or heavy loads: Improper form or the inability
to lift heavy loads can cause strains and sprains.
3.3. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.4. Work in a well-ventilated laboratory area.
3.5. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.6. Hazardous waste must be disposed in designated waste container.
3.7. Be familiar with the MSDS/SDS for all chemicals employed in the procedure.
3.8. Must be able to lift up to 50 pounds overhead.
4.0 Cautions
4.1. The Moyno pump used during this operation must not be turned on when there is no fluid
in the holding tank. Operating the pump dry will cause damage to its internal components.
4.2. Do not operate the system with both the recirculation and sample port valves closed.
4.3. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials, and make note of any damaged or lost material in the corresponding
QC checklist as well as report the loss to Dr. Neivandt.
4.4. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.5. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Interferences
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5.1. If the pulp solution does not recirculate properly through the system, the refinement and
production of CNF will not be uniform.
6.0 Personnel Responsibilities and Qualifications
6.1. Supervisor:
●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed.

6.2. The Operator:
●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

●

Must be able to lift up to 50 pounds overhead.

7.0 Equipment and Materials
7.1. Equipment
7.1.1. Super mass colloider (Masuko, MKCA6-2)
7.1.2. Energy Measuring Universal Power Cell (Load Controls, UPC-KWH)
7.1.3. Digital Energy Meter (Load Controls, KWH-3)
7.1.4. Digital Load Meter (Load Controls, DM-100)
7.1.5. Stainless steel piping system, various fittings (McMaster Carr. See Appendix 8.1)
7.1.6. Moyno sanitary positive displacement pump (Atlantic Pump and Engineering,
MOFB1D-SSQ-SAA)
7.1.7. 4 oz. plastic portion cups with covers, (Uline, S-21201 and S21202)
7.1.8. 5-gallon pail (ULINE, S-7914W)
7.2. Materials (as listed or equivalent)
7.2.1. Cellulose pulp suspension (CNF-SOP-03, Creation of Cellulose Pulp Suspension)
8.0 Quality Control and Quality Assurance
8.1. Create a calibration curve of cumulative energy and total fines produced prior to running
the SMC for a product of end use. To create the calibration curve, follow the procedure
outlined in this SOP, collecting 50 mL samples of refined suspension from the SMC hopper
with a 100-mL container-with-cover for analysis of fines and fibers (CNF-SOP-06, Analysis of
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Fines and Fibers in CNF Slurry) every 15 minutes, noting the cumulative energy at each time
of sampling.
8.2. After a calibration curve has been created, the SMC can be run to produce CNF. Samples
should be collected every 15 minutes and analyzed for fines and fibers to validate the
calibration curve and identify possible interferences in the process. If parts are replaced in
the SMC, new materials are used, or other environmental changes occur, the calibration
curve should be reproduced.
8.3. Record the following data in the accompanying quality control checklist, CNF-QCC-06,
Processed Fiber:
8.3.1. Pulp sample used
8.3.2. Date produced
8.3.3. Cumulative Energy
8.3.4. Time elapsed during refinement
8.3.5. Final fines %
8.3.6. Weight percent of solids
8.3.7. Volume of slurry collected
8.3.8. Additional notes
8.3.9. Initial and Date
9.0 References
9.1. CNF-QCC-01 (Cellulose Pulp Quality Control Checklist)
9.2. CNF-SOP-03 (Creation of Cellulose Pulp Suspension)
9.3. CNF-SOP-05 (Protocol for Cleaning of the Colloider and Piping System)
9.4. CNF-QCC-06 (Processed Fiber Quality Control Checklist)
9.5. CNF-SOP-09 (General Maintenance and Cleaning Protocol)
9.6. CNF-SOP-10 (Labeling Procedure for Stocks, Samples, and Products)
10.0 Procedures
10.1. Calibration of the SMC grinding stones
10.1.1. Prior to operation of the SMC, the gap between the grinding stones needs to be
calibrated and the SMC must be visually inspected for cleanliness. If equipment is not
clean, follow the procedure outlined in CNF-SOP-05, Colloider Cleaning Procedure,
and CNF-SOP-09, General Cleaning Procedure
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10.1.2. Turn the stone-gap micrometer (see Appendix 11.2) counterclockwise a minimum of
5 full turns to open the gap, ensuring no contact between the stones occurs during
start up
10.1.3. Turn on the SMC and set stone rotation to 2,000 RPM
10.1.4. Carefully turn the stone-gap micrometer clockwise until the stones just slightly touch
while spinning. Contact is achieved when a slight clicking of the stones is heard
10.1.5. Mark position as the calibrated zero-point: Unlock the stone-gap micrometer handle
when the stones make contact and adjust such that the micrometer shows zero
when re-locked
10.2. Filling the SMC
10.2.1. Open the stone-gap to positive 5, relative to the zero point, while the SMC is running
at 2000 RPM
10.2.2. Slowly pour the 14 L of pulp solution into the SMC such that the hopper is not
overfilled into the overflow tube, ensuring all pulp uniformly passes through the
stones prior to circulation through the system
10.2.3. The Moyno pump used during this operation must not be turned on when there is
no fluid in the pump reservoir. Operating the pump dry will cause damage to its
internal components: When the pump reservoir is full, turn on the pump. Once
recirculation of the slurry is observed (i.e. slurry is pumping through all lines without
becoming plugged), adjust the stone-gap to negative 10 for continued refining
10.2.4. Begin a timer to record the elapsed time of refinement
10.3. Sampling from the SMC
10.3.1. Every 15 minutes a sample of slurry will be removed to measure fines for quality
control. Before removing the sample, open the stone-gap to plus 15 while the SMC is
still running to completely drain the hopper into the pump reservoir, mixing the
slurry contained in the SMC
10.3.2. Return the stone-gap to the zero point, refilling the hopper. Visually inspect to
ensure a clean sampling container to remove a 50-mL sample from the hopper and
record the cumulative energy at each time of sampling. Return the stone-gap to
negative 10. Do not put fingers or any other part of the body near the grinding stones
when the SMC is operating. Doing so could cause personal injury
10.3.3. Seal the sample for later measurement of fines content using a Techpap MorFi Fiber
Analyzer, located in the Process Development Center (CNF-SOP-06)
10.4. Collection of Slurry
10.4.1. Run the SMC until the energy reading corresponds to a fines percentage of 90%, as
determined by the calibration curve produced in Section 8.1
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10.4.2. Place a clean (visually inspected) 5-gallon bucket underneath the sample port. Open
the sample port valve and then close the recirculation line valve to begin pumping
slurry into the bucket
10.4.3. The Moyno pump used during this operation must not be turned on when there is
no fluid in the holding tank. Operating the pump dry will cause damage to its
internal components: Take caution to turn off the pump before the reservoir
empties and/or before the collection container becomes too full
10.4.4. Stop the timer and record the elapsed time of refinement and the cumulative energy
10.5. Determination of Weight Percent of Solids in CNF Slurry
10.5.1. Weigh the mass of a new, empty, 100 mL container
10.5.2. Fill the container with 100mL of newly refined slurry
10.5.3. Weigh the mass of the full container (full container mass minus the mass of the
empty container is equivalent to mass of CNF collected)
10.5.4. Place the container in the oven just as in the evaluation of moisture content (CNFSOP-01)
10.5.5. As the mass of the container of dry CNF plateaus, calculate the weight percent of
solids as seen below (subtracting container mass renders the mass of dried CNF):
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐷𝑟𝑦 𝐶𝑁𝐹
× 100 ~ 2% (𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑊𝑡 % 𝑜𝑓 𝑆𝑜𝑙𝑖𝑑𝑠)
𝑀𝑎𝑠𝑠 𝑜𝑓 𝐶𝑁𝐹 𝐶𝑜𝑙𝑙𝑒𝑐𝑡𝑒𝑑
10.6. Cleaning and Maintenance
10.6.1. Clean the station as outlined in CNF-SOP-09 and CNF-SOP-05. Record all maintenance
and cleaning performed in the maintenance and cleaning logs at the station
10.7. Assembly/disassembly of the SMC (if necessary)
10.7.1. To disassemble the system, remove the sections, starting at the highest points in
manageable portions: Start with the recirculation section, then the overflow section,
and finally the pump reservoir section
10.7.2. Break down each section into the individual fittings by removal of all quick clamps
and gaskets
10.7.3. Assemble the system in reversed order of disassembly
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11.0 Appendices
11.1. McMaster Carr Fittings
Quantity

Description

Item Code

4

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 1" Tube OD, 4" Long

50485K73

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 1" Tube OD, 6" Long

50485K73

4

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 1" Tube OD, 12" Long

50485K73

2

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 1" Tube OD, 18" Long

50485K73

7

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel 90
Degree Elbow Connector for 1" Tube OD

50485K111

2

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Inline
Tee Connector for 1" Tube OD

50485K141

2

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Adapter
for 1" Tube OD x 1" Barbed Hose ID

50485K773

3

On/Off Valve for Food and Beverage Sanitary Quick-Clamp for 1" Tube OD

44755K113

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Adapter
for 3" Tube x Butt-Weld, 1-13/16" Long

50485K185

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 3" Tube OD, 4" Long

50485K39

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 3" Tube OD, 12" Long

50485K39

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel 90
Degree Elbow Connector for 3" Tube OD

50485K115

2

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Connector for 4" Tube OD, 12" Long

50485K41

1

High-Polish Quick-Clamp Sanitary Tube Fitting, 316L Stainless Steel 90
Degree Elbow Connector for 4" Tube OD

50485K116

1

High-Polish Quick-Clamp Sanitary Tube Fitting, 316L Stainless Steel Inline
Tee Connector for 4" Tube OD

50485K146
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1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Reducer for 2" x 1" Tube OD

50485K232

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Reducer for 3" x 2" Tube OD

50485K237

2

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Reducer for 4" x 3" Tube OD

50485K239

1

High-Polish Quick-Clamp Sanitary Tube Fitting 316L Stainless Steel Straight
Reducer for 6" x 4" Tube OD

50485K242

25

High-Polish Quick-Clamp Sanitary Tube Fitting 304 Stainless Steel Clamp
with Wing Nut for 1" and 1-1/2" Tube OD

4322K152

2

High-Polish Quick-Clamp Sanitary Tube Fitting 304 Stainless Steel Clamp
with Wing Nut for 2" Tube OD

4322K153

5

High-Polish Quick-Clamp Sanitary Tube Fitting 304 Stainless Steel Clamp
with Wing Nut for 3" Tube OD

4322K155

6

High-Polish Quick-Clamp Sanitary Tube Fitting 304 Stainless Steel Clamp
with Wing Nut for 4" Tube OD

4322K156

25

High-Temperature Silicone Gasket for Quick-Clamp Fittings, for 1" Tube OD

4520K43

2

High-Temperature Silicone Gasket for Quick-Clamp Fittings, for 2" Tube OD

4520K45

5

High-Temperature Silicone Gasket for Quick-Clamp Fittings, for 3" Tube OD

4520K47

6

High-Temperature Silicone Gasket for Quick-Clamp Fittings, for 4" Tube OD

4520K48

3

Washdown Threaded-Rod-Mount Clamping Hanger Vibration-Damping
Silicone Rubber Cushion, 1" ID

8831T35

1

Washdown Threaded-Rod-Mount Clamping Hanger Vibration-Damping
Silicone Rubber Cushion, 3" ID

8831T41
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11.2. Colloider Diagram and Stone-Gap Micrometer Operation

Stone-Gap
Micrometer

Close
Gap

11.3. Colloider Piping System
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1. Purpose
1.1. To remove debris and sanitize the colloider system
2. Definitions
2.1. CNF: Cellulose nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. Fines: Cellulose nanofibrils that are less than 200 μm in length
2.4. SMC: Super mass colloider
3. Health and Safety Warnings
3.1. Acidic cleaning solution can cause irritation to eyes and skin: Wear gloves.
3.2. Take care when lifting or carrying either large or heavy loads: Improper form or the inability
to lift heavy loads can cause strains and sprains.
3.3. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.4. Work in a well-ventilated laboratory area.
3.5. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.6. Hazardous waste must be disposed in designated waste container.
3.7. Be familiar with the MSDS/SDS for all chemicals being employed in the procedure.
4. Cautions
4.1. Follow instructions for dilution of alkaline and acidic cleaners: Failing to do so may corrode
or damage to equipment.
4.2. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5. Interferences
5.1. Creating a cleaning solution that is too dilute may not clean and sanitize the equipment
effectively.
6. Personnel Responsibilities and Qualifications
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6.1. The Supervisor:
●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed

6.2. The Operator:
●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the clean room.

●

Must be able to lift up to 50 pounds.

7. Equipment and Materials
7.1. Equipment
7.1.1. 2 - 116 Qt. storage tote (Home Depot, SKU #1000030696)
7.1.2. PBW-Alkali Cleaner (Northern Brewer Homebrew Supply, SKU#U005)
7.1.3. Star San (Northern Brewer Homebrew Supply, SKU#U001)
7.1.4. 1 - 32 oz. Spray Bottle (Home Depot, SKU#255852)
7.2. Materials (as listed or equivalent)
7.2.1. Deionized Water (17.45-17.46 Megaohms-cm)
8. Quality Control and Quality Assurance
8.1. Cleaning of the SMC should occur after every batch production of slurry. The system has
been properly sanitized when it has demonstrated proper recirculation and there is no
visible debris or particulates on the equipment.
9. References
9.1. CNF-SOP-04 (Production of CNF Using a Super Mass Colloider)
10. Procedures
10.1. Preparation of alkaline scrub solution – Tote mix
10.1.1. Fill the tote marked “alkaline” with 10 gallons of water
10.1.2. Weigh 10 ounces of PBW powder and mix into the water
10.2. Preparation of acidic sanitary solution – Tote mix
10.2.1. Fill the tote marked “acidic” with 10 gallons of water
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10.2.2. Measure 2 ounces of Star San (Bettix bottle) and mix into the water
10.3. Cleaning the colloider system in place
10.3.1. Recirculate the PBW “alkaline” solution through the system in the same manner as
refining a cellulose slurry, but with the stone gap opened by 3 turns
10.3.2. After 30 minutes of PBW recirculation, drain the PBW solution and circulate DIW
through the system to rinse remaining PBW
10.3.3. Drain the DIW. Gently recirculate the Star San “acidic” solution (Turn off the
colloider and ensure that the gap is open by 3 full turns
10.3.4. Circulate the solution for 5 minutes, drain the Star San solution, and rinse a final
time with DIW
10.3.5. Allow the system to air dry for 12 hours
10.3.6. Record cleaning in the cleaning log at the wet table station
10.4. Cleaning stainless steel surfaces
10.4.1. Use the PBW solution to clean debris from surfaces.
10.4.2. Rinse surfaces with DIW and let dry
10.4.3. Apply the Star San via the 32 oz spray bottle solution
10.4.4. Let the Star San solution contact the surfaces for 2 minutes, then wipe dry
10.4.5. Apply a DIW rinse
10.4.6. Fill out the station’s cleaning log
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1.0 Purpose
1.1. To determine the level of refinement of cellulose nanofibrils (CNF) by analyzing the
percentage of fines present in a sample of slurry
2.0 Definitions
2.1. CNF: Cellulose Nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. Fines: Cellulose Nanofibrils that are less than 200 μm in length
2.4. SMC: Super mass colloider
3.0 Health and Safety Warnings
3.1. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.2. Work in a well-ventilated laboratory area.
3.3. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.4. Hazardous waste must be disposed of in the designated waste container.
3.5. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4.0 Cautions
4.1. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.2. Visually inspect all equipment prior to operation: If equipment does not pass visual
inspection, clean using protocol outlined in CNF-SOP-09, General Maintenance and Cleaning
Protocol.
4.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Interferences
5.1. Ensure the DIW in the wash beaker is replaced after every run. The wash beaker has a
designated position (position 6) on the MorFi Fiber Analyzer carousel and should not be
moved.
5.2. Improper calculations during the two dilutions of slurry will yield inaccurate concentrations
and percent total fines.
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6.0 Personnel Responsibilities and Qualifications
6.1. Supervisor:
●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed.

6.2. The Operator:
●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

7.0 Equipment and Materials
7.1. Equipment
7.1.1. 1 L Griffin Beakers, (Fisher Scientific, 14-379-019)
7.1.2. 100 mL sample containers with covers, (Uline, S-9934)
7.1.3. 1 L Graduated Cylinder, (Fisher Scientific, 14-379-140)
7.1.4. 100 mL Graduated Cylinder, (Fisher Scientific, 14-379-142)
7.1.5. Laboratory scale (Fisher Scientific, 01-920-120)
7.1.6. Laboratory spatula (Fisher Scientific, 14-357Q)
7.1.7. MorFi Fiber Analyzer (Techpap. MorFi Compact)
7.2. Materials (as listed or equivalent)
7.2.1. 100 mL samples of fully processed or partially processed CNF
8.0 Quality Control and Quality Assurance
8.1. Record the following data in the accompanying quality control checklist, Processed Fiber
(CNF-QCC-06):
8.1.1. Pulp sample used
8.1.2. Date CNF was produced
8.1.3. Cumulative Energy
8.1.4. Time elapsed during refinement
8.1.5. Final fines %
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8.1.6. Weight percent of solids
8.1.7. Volume of slurry collected
8.1.8. Additional notes
8.1.9. Initial and Date
9.0 References
9.1. CNF-SOP-04 (Production of CNF Using a Super Mass Colloider)
9.2. CNF-QCC-06 (Processed Fiber)
9.3. CNF-SOP-10 (Labeling Procedure for Stocks, Samples, and Products)
10.0 Procedures
10.1. Preparation of Sample
10.1.1. Measurement of the length and fines of the fibers requires a 50 mg/L solids content
of the slurry
10.1.2. Calculate the mass of slurry necessary to generate the 50 mg/L solids content, from
the 100 mL sample collected from SMC
10.1.2.1. 50 mg/L is divided by sample concentration (% solids content, estimated from
input of pulp mass/ water mass)
10.1.2.2. This value is then multiplied by ten to account for a dilution step
10.1.2.3. The final value, in grams, describes the mass of slurry from the sample that
must be used in the first 1L dilution.
𝑚𝑔
1
1𝑔
1000 𝑚𝐿
×
×
×
× 1𝐿
𝐿
% 𝑠𝑜𝑙𝑖𝑑𝑠 1000 𝑚𝑔 100 𝑚𝐿
= 𝑀𝑎𝑠𝑠 (𝑔) 𝑟𝑒𝑞𝑢𝑖𝑟𝑒𝑑 𝑓𝑟𝑜𝑚 𝑠𝑙𝑢𝑟𝑟𝑦 𝑠𝑎𝑚𝑝𝑙𝑒
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10.1.3. Dilute Sample to 50 mg/L
10.1.3.1. Measure out calculated mass of sample from 100 mL slurry sample container
into a small beaker using a spatula
10.1.3.2. Add sample to 1 L graduated cylinder, then fill to 1 L with DIW
10.1.3.3. Mix solution thoroughly between two 1L beakers and measure out 100 mL
into the 100 mL graduated cylinder; discard remaining material and rinse out
the empty containers
10.1.3.4. Add the 100 mL dilution to the 1 L graduated cylinder and fill to 1 L with DIW
once more
10.1.3.5. Mix thoroughly and pour contents into a 1 L beaker. The 1L dilution will be
used for fiber analysis
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10.1.3.6. Discard the remaining solutions by diluting with water: the slurry is safe to
discard down the floor drain
10.1.4. Loading samples on MorFi Fiber Analyzer carousel
10.1.4.1. The carousel has 6 positions correlating to 5 samples and 1 wash of DIW
10.1.4.2. The DIW in the wash beaker should be replaced each run
10.1.4.3. Up to 5 samples can be run at a time, and as few as one
10.1.4.4. The wash beaker has a designated position (position 6) and should not be
moved
10.1.4.5. The samples can be placed in any other carousel position
10.2. Operation of the MorFi Fiber Analyzer
10.2.1. Turn on the computer and open the “MorFi” software
10.2.2. Click the “Carousel” button in the bottom bar of the screen to open sample menu
10.2.3. In the sample menu the following information must be provided:
10.2.3.1. Family: Select “HR - Fibers and Fines”, preset measuring protocol selection
10.2.3.2. Consistency: Enter “50 mg/L”, the concentration of the sample
10.2.3.3. ID: Enter “Operator’s Initials and day/month/year”, the filename for the saved
file (i.e. NRC-8-14-17)
10.2.3.4. Coarseness: Enter “Material-timepoint of sample refinement”, additional file
differentiation (i.e. cotton-90mins)
10.2.3.5. Number: Enter “#”, correlates to the position of sample on the carousel
10.2.4. When all information is entered into the window, the measurement can be initiated
in one of two ways:
10.2.4.1. “Start with List Open”: Select this option if there are more samples to
measure. It will start measuring the first in line and keep the menu open to
add additional samples to the queue.
10.2.4.2. “Start and Close List”: Select this option if the info just entered is the only
sample or the last sample being analyzed.
10.2.5. The device will measure each sample, with a rinse in between, and save the data
according to the user provided ID and coarseness
10.2.6. Reports can be printed at the end of the measurement during a time delay between
samples or can be accessed from the saved files. All reports are to be printed and
stored in the clean room

171

10.2.7. After all measurements are complete discard solutions and clean all containers for
future samples

172

CNF-SOP-07 CNF SHEET PRODUCTION

Nanocellulose Conduit Production
Standard Operating Procedure #07
Cellulose Nanofiber Sheet Fabrication

Rev

Date

Description

1

1/19/2017

Draft Development Document-Nicklaus Carter

2

7/28/2017

Revision-Mary Bourque

3

8/14/17

Revision – Nicklaus Carter

Approved by:

Signature

Date

Originator

Nicklaus Carter

Manager

David Neivandt

Quality Assurance

David Neivandt and Caitlin Howell

173

1.0 Purpose
1.1. To spread CNF slurry to form a CNF sheet that is 50 µm thick
2.0 Definitions
2.1. CNF: Cellulose Nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
3.0 Health and Safety Warnings
3.1. Blades are sharp and can cause cuts: Use caution when using razor blades.
3.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.3. Work in a well-ventilated laboratory area.
3.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.5. Hazardous waste must be disposed of in the designated waste container.
3.6. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4.0 Cautions
4.1. Visually inspect all equipment prior to use: If equipment does not pass visual inspection,
clean using protocol outlined in CNF-SOP-09, General Maintenance and Cleaning Protocol.
4.2. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials, and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Interferences
5.1. Overloading the film applicator may create an uneven spread of slurry.
6.0 Personnel Responsibilities and Qualifications
6.1. Supervisor:
●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed.

6.2. The Operator:
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●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

7.0 Equipment and Materials
7.1. Equipment
7.1.1. Casting Knife Film Applicator, 8” wide, (Elcometer, K0003580M007)
7.1.2. Stainless Steel Plate, 12” x 18” x ⅜” thick, (McMaster Carr, 8983K252)
7.1.3. Single Edge Razor Blades, (Harbor Freight, 39748)
7.1.4. Benchtop Digital Micrometer, (Testing Machines Inc., 49-85)
7.1.5. 150 mL Griffin Beakers, (Fisher Scientific, 14-379-022)
7.2. Materials (as listed or equivalent)
7.2.1. CNF slurry (CNF-SOP-04, Production of CNF Using a Super Mass Colloider)
8.0 Quality Control and Quality Assurance
8.1. Record the following data in the accompanying quality control checklist, Processed Sheet
(CNF-QCC-07):
8.1.1. Slurry used
8.1.2. Date/Time spread
8.1.3. Date/Time lifted
8.1.4. Volume of slurry used
8.1.5. Casting thickness
8.1.6. Dried thickness
8.1.7. End use
8.1.8. Additional notes
8.1.9. Initial and Date
8.2. The final sheet thickness must be within  5% of the accepted dried sheet thickness
9.0 References
9.1. CNF-SOP-04 (Production of CNF Using a Super Mass Colloider)
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9.2. CNF-QCC-07 (Processed Sheet Quality Control Checklist)
9.3. CNF-SOP-09 (General Maintenance and Cleaning Protocol)
9.4. CNF-SOP-10 (Labeling Procedure for Stocks, Samples, and Products)
10.0 Procedures
10.1. Spreading the CNF slurry
10.1.1. Measure 100 mL of the CNF slurry in a griffin beaker
10.1.2. Pour the slurry onto a stainless steel plate in a line such that the length doesn’t
exceed the width of the film applicator (8”)
10.1.3. Set the height of the applicator blade to 0.075 inches (1.9 mm)
10.1.4. Drag the applicator down the plate to start spreading the slurry into a sheet with a
vertical chopping action
10.1.5. Use a smooth second pass of the film applicator to even out the ridges left from
chopping
10.1.6. Trim and discard irregular edges of the sheet with a new single edged razor blade
(razor blades are discarded daily in the sharps container)
10.1.7. Move the stainless steel plate to a secluded area on the dry table and leave to dry
for 24 hours (be sure it is away from items that may fall into the wet sheet)
10.2. Measuring CNF sheet thickness
10.2.1. Lift the dried sheet from the plate using a single edged razor blade: Slide the blade
approximately ¼” under the sheet around the entire perimeter
10.2.2. Remove the sheet from the plate and transfer it into a resealable bag for
transportation.
10.2.3. Transport the sheet to the TAPPI room, in the PDC, to adjust to the humidity for 24
hours and measure the thickness using the benchtop digital micrometer
10.2.4. Measure the sheet thickness at several points across the width of the sheet
10.2.5. Repeat this process as you move perpendicular to the measurement direction,
measuring 3 rows of 4 data points each (12 points total)
10.2.6. Calculate the average thickness and standard deviation of the measurements
10.2.7. Place the sheet in a labeled bag as described in CNF-SOP-10 (Labeling Procedure for
Stocks, Samples, and Products)
10.3. Cleaning and Maintenance
10.3.1. Clean the station as outlined in CNF-SOP-09. Record all maintenance and cleaning
performed in the maintenance and cleaning logs at the station.
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1.0 Purpose
1.1. To fabricate a neural conduit using a CNF sheet
2.0 Definitions
2.1. CNF: Cellulose Nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
3.0 Health and Safety Warnings
3.1. Blades are sharp and can cause cuts: Use caution when using razor blades.
3.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.3. Work in a well-ventilated laboratory area.
3.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.5. Hazardous waste must be disposed of in the designated waste container.
3.6. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4.0 Cautions
4.1. Take care not to damage the CNF sheets employed for the fabrication of conduits.
4.2. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials, and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Interferences
5.1. Visually inspect conduits after dipping in slurry: Ensure there is no buildup of slurry on the
top and bottom ends of the cylinder.
6.0 Personnel Responsibilities and Qualifications
6.1. Supervisor:
●

Ensure operators are trained on this procedure.

●

Ensure operators conduct procedures as instructed.

6.2. The Operator:
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●

Must be trained on all equipment and procedures prior to operation.

●

Complete this procedure as instructed.

●

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

7.0 Equipment and Materials
7.1. Equipment
7.1.1. 1 mL disposable syringe (Fisher Scientific, 14-823-30)
7.1.2. 20-gauge blunt tip needle, 304SS, 2” length (Fisher Scientific, 14-815-608)
7.1.3. Plastic mandrel, OD 1.6 mm (Vendor, Cat #XXXXX)
7.1.4. Utility knife (Fisher Scientific, 18-999-28)
7.1.5. Tubing Cutter (Fisher Scientific, 11-187-15)
7.1.6. Microspatula (Fisher Scientific, 14-357Q)
7.1.7. Acrylic Template (McMaster-Carr, 8589K41)
7.1.8. Rotating drying rack (Fisher Scientific, 05-450-127)
7.2. Materials (as listed or equivalent)
7.2.1. CNF sheet (CNF-SOP-07)
7.2.2. CNF slurry (CNF-SOP-04)
8.0 Quality Control and Quality Assurance
8.1. Visually inspect all equipment prior to use: If equipment does not pass visual inspection,
clean using protocol outlined in CNF-SOP-09, General Maintenance and Cleaning Protocol.
8.2. Visually inspect slurry prior to use: If slurry shows signs of mold or microbial contamination,
DO NOT USE. Label with red tape and remove from operation area for proper disposal.
Slurry may be used for up to 6 months after refinement.
8.3. Record the following data in the accompanying quality control checklist CNF-QCC-08,
Conduit Production:
8.3.1. Sheet Used
8.3.2. Slurry Used for Seal/Dip
8.3.3. Date rolled
8.3.4. Type of Seal
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8.3.5. Inner diameter
8.3.6. Number of layers
8.3.7. Length of conduit
8.3.8. End use
8.3.9. Additional Notes
8.3.10. Initials and Date
9.0 References
9.1. CNF-SOP-07 (CNF Sheet Fabrication)
9.2. CNF-QCC-08 (Processed Roll Quality Control Checklist)
9.3. CNF-SOP-09 (General Maintenance and Cleaning Protocol)
9.4. CNF-SOP-10 (Labeling Procedure for Stocks, Samples, and Products)
10.0 Procedures
10.1. Creating an acrylic template
10.1.1. Measure and draw out the desired conduit pattern on the acrylic platform
10.1.2. Score the template over the lines drawn on the acrylic with a utility knife (as
presented in Appendix 11.1)
10.1.3. Repeat the above step until a continuous notch is made around the designated
template
10.1.4. The utility knife must be able to freely travel within the notches of the template for
consistent cutting of the pattern from CNF sheets
10.2. Cutting a CNF conduit pattern
10.2.1. Place the sheet over an acrylic template of conduit size specifications (1.5 x 2.5 cm
rectangular pattern)
10.2.2. Position the sheet such that the direction of casting is in alignment with the longer
edge of the pattern.
10.2.3. Cut the CNF sheet using a utility knife and follow the notches in the acrylic template.
Blades are sharp and have potential to injure the operator: Use caution when using
razor blades
10.2.4. If the template requires intricate geometrical entities to be removed from inside the
rectangular outer shape, cut the interior geometry prior to the border
10.3. Rolling a CNF conduit
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10.3.1. Place the long edge of the conduit cutout over the plastic mandrel. This edge will be
noted as the starting edge, and the opposite edge will be the finishing edge
10.3.2. Roll the finishing edge overtop the start edge
10.3.3. Keep the successive wraps tight to the mandrel
10.3.4. Prior to completion of the final wrap, a seal of slurry is applied, via blunt tip needle,
to the last half of the wrap to prevent unraveling. Visually inspect slurry prior to use:
If slurry shows signs of mold or microbials, DO NOT USE. Label with red tape and
remove from operation area
10.4. Sealing a CNF conduit
10.4.1. Fill a 1 mL syringe connected to a 20 gauge blunt tip needle with CNF slurry
10.4.2. Apply the slurry to the interior facing side of the finishing edge in a zig zag pattern
10.4.3. Fold the flap over and onto the conduit and gently press to seal the conduit
10.4.4. Gently wipe off excess slurry from the seal with a microspatula
10.4.5. Leave conduit on the mandrel and let dry for 24 hours in a secluded area. Record
the batch of slurry used on the respective QCC
10.5. Coating a CNF conduit
10.5.1. Allocate the respective slurry into a separate container (100 mL beaker) such that
the depth of the slurry in the container exceeds the length of the conduit. Designate
this container as CNF slurry for conduit coating
10.5.2. Submerge the dried and sealed conduit in the designated container of CNF slurry
10.5.3. Remove conduit from the slurry, removing excess coating with a microspatula if
uneven
10.5.4. Repeat dipping thrice until a consistent coating can be attained
10.5.5. Leave the coated conduit on the mandrel and relocate to a secluded area. Rotate
the conduit during the drying process by fixing mandrel to the rotating drying rack.
10.6. Removing the CNF conduit
10.6.1. Cut the conduits to length, still on the mandrel, using tubing cutters
10.6.2. Inspect each conduit for a clean-edge cut and ensure there is no delamination of the
outer layer
10.6.3. Package in a sealable bag and label, as per CNF-SOP-10
10.7. Cleaning and Maintenance
10.7.1. Clean the station as outlined in CNF-SOP-09. Record all maintenance and cleaning
performed in the maintenance and cleaning logs at the station.
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11.0 Example of Notched Template on Acrylic platform
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1. Purpose
1.1. To outline routine cleaning and maintenance procedures and schedule
2. Definitions
2.1. CNF: Cellulose nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. Fines: Cellulose nanofibrils that are less than 200 μm in length
2.4. SMC: Super mass colloider
3. Health and Safety Warnings
3.1. Acidic cleaning solution can cause irritation to eyes and skin.
3.2. Take care when lifting or carrying either large or heavy loads: Improper form or the
inability to lift heavy loads can cause strains and sprains.
3.3. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety
glasses when applicable) while working in the laboratory.
3.4. Work in a well-ventilated laboratory area.
3.5. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.6. Hazardous waste must be disposed of in the designated waste container.
3.7. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4. Cautions
4.1. Follow instructions for dilution of alkaline and acidic cleaners: Failing to do so may cause
corrosion or damage to equipment.
4.2. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before
entry to prevent contamination due to airborne particles.
4.3. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5. Interferences
5.1. Producing a cleaning solution that is too dilute may not clean and sanitize the equipment
properly.
6. Personnel Responsibilities and Qualifications
6.1. Supervisor:
•

Ensure operators are trained on this procedure.
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•

Ensure operators conduct procedures as instructed.

6.2. The Operator:
●

Must be trained on all equipment and procedures prior to operation.

•

Complete this procedure as instructed.

•

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

•

Must be able to lift up to 50 pounds.

7. Equipment and Materials
7.1. Equipment
7.1.1. 2 - 116 Qt. storage totes (Home Depot, SKU #1000030696)
7.1.2. PBW-Alkali Cleaner (Northern Brewer Homebrew Supply, SKU#U005)
7.1.3. Star San (Northern Brewer Homebrew Supply, SKU#U001)
7.1.4. 1 - 32 oz. Spray Bottle (Home Depot, SKU#255852)
7.1.5. Cleanroom Wipe – part of a cleaning kit, (NCI, WW-MAINTK-1)
7.2. Materials (as listed or equivalent)
7.2.1. Deionized Water (17.45-17.46 Megaohms-cm)
8. Quality Control and Quality Assurance
8.1. This procedure is to be used for all dirty surfaces and stainless steel equipment. It should
be repeated after every station use.
9. References
9.1. All QC checklists and SOPs in the master binder
10. Procedures
10.1. Preparation of alkaline scrub solution - Tote mix
10.1.1. Fill the tote marked “alkaline” with 10 gallons of water
10.1.2. Weigh 10 ounces of PBW powder and mix into the water
10.2. Preparation of acidic sanitary solution - Tote mix
10.2.1. Fill the tote marked “acidic” with 10 gallons of water
10.2.2. Measure 2 ounces of Star San (Bettix bottle) and mix into the water
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10.3. Preparation of acidic sanitary solution - Spray bottle mix
10.3.1. Fill spray bottle with mix from tote if available
10.3.2. Fill the 32 oz spray bottle with water (0.25 gallons)
10.3.3. Mix 0.05 oz of Star San with the water
10.4. Cleaning stainless steel surfaces
10.4.1. Use the PBW solution to clean debris from surfaces.
10.4.2. Rinse surfaces with DIW and let dry
10.4.3. Apply the Star San via the 32 oz spray bottle solution
10.4.4. Let the Star San solution sit for 1-2 minutes, then wipe dry
10.4.5. Apply a DIW rinse
10.4.6. Fill out the station’s cleaning log
10.5. Cleaning Walls of the Cleanroom
10.5.1. It is recommended that the walls of the cleanroom are cleaned weekly
10.5.2. Use a cleanroom wipe and DI water to wipe down the acrylic panels.
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1.0 Purpose
1.1. To thoroughly label all materials, samples, and products to create a traceable account of all
materials through a comprehensive log
2.0 Definitions
2.1. CNF: Cellulose Nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. Fines: Cellulose Nanofibrils that are less than 200 μm in length
3.0 Health and Safety Warnings
3.1. Take care when lifting or carrying either large or heavy loads: Improper form or the inability
to lift heavy loads can cause strains and sprains.
3.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.3. Work in a well-ventilated laboratory area.
3.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.5. Hazardous waste must be disposed of in the designated waste container.
3.6. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4.0 Cautions
4.1. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.2. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Personnel Responsibilities and Qualifications
5.1. Supervisor:
•

Ensure operators are trained on this procedure.

•

Ensure operators conduct procedures as instructed.

5.2. The Operator:
●

Must be trained on all equipment and procedures prior to operation.

•

Complete this procedure as instructed.

•

Report any deviations to this procedure to Dr. Neivandt.
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●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

•

Must be able to lift up to 50 pounds.

6.0 Equipment and Materials
6.1. Equipment
6.1.1. Brady BBP33 Label Printer (Brady, BBP33-C)
6.1.2. Brady Workstation Labeling Software (Brady, Free Online)
6.2. Materials (as listed or equivalent)
6.2.1. Adhesive Paper Label Roll, 2in x 1in (Brady, B33-17-424)
6.2.2. Black Thermal Transfer Print Ribbon (Brady, B30-R4300)
7.0 References
7.1. All QC checklists and SOPs contained in master binder. Labeling procedure applies to all
stations of operation.
8.0 Procedures (Refer to respective quality control checklists)
8.1. Labeling raw material – in bags
8.1.1. Label the raw material as presented in Appendix 9.2.1
8.1.2. In respective log entry: source, lot#, quantity/mass, visual inspection results, etc. as
presented in Appendix 9.3.1
8.2. Labeling cellulose pulp solutions - in buckets
8.2.1. Label solution as “unrefined,” as presented in Appendix 9.2.2
8.2.2. In respective log entry: pulp type, amount of pulp/water, etc.
8.3. Labeling cellulose slurries - in buckets
8.3.1. Label slurry as “refined,” as presented in Appendix 9.2.3
8.3.2. In respective log entry: % fines, cumulative energy, etc. as presented in Appendix
9.3.2
8.4. Labeling cellulose sheets - in bags
8.4.1. Label sheets as presented in Appendix 9.2.4
8.4.2. In respective log entry: % fines, thickness, material composition, etc.
8.4.3. as presented in Appendix 9.3.3
8.5. Labeling cellulose conduits - in bags/vials
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8.5.1. Label conduits as presented in Appendix 9.2.5
8.5.2. In respective log entry: inner diameter, number of layers, length, etc. as presented in
Appendix 9.3.4
8.6. Labeling various other products
8.6.1. Material dependent, follow the examples seen in Appendix 9.2
8.7. Packaging cellulosic materials
8.7.1. Dry materials are stored individually in plastic bags that are sealable
8.7.2. Wet materials are stored in appropriate containers with sealable covers
8.8. Labeling Compromised Materials
8.8.1. Label any materials that do not pass visual inspection or materials that are past their
expiry date (6 months post-inception) with red tape; record the reason for product
removal and the date applied. Report to Dr. Neivandt.
8.9. Creating Labels
8.9.1. Turn on the printer and the connected laptop
8.9.2. Data from the QCC’s are entered into the Labeling Excel file, in the respective
sections.
8.9.3. Open the respective labeling file from the Brady Workstation profile.
8.9.4. Ensure that the Excel Import tool is refreshed by reopening the Excel file and
importing the data from the Labeling file.
8.9.5. Select the labels needed to print through the print menu, and select print
9.0 Labeling Examples
9.1. Sample Labeling Method

9.2. Examples of Sample Labeling for Tracking
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9.2.1. Labeling Pulp Samples

Sample: Pulp - Eucalyptus

5/1/17

Bleached Eucalyptus Pulp 200 g
Code: P01

NRC

9.2.2. Labeling Solution Samples

Sample: Pulp/Water - Eucalyptus

5/1/17

Eucalyptus Suspension, 200g in 14 L
Code: P01 – Unrefined

NRC

9.2.3. Labeling Slurry Samples

Sample: 89% fines and 2%wt

5/1/17

Eucalyptus CNF Slurry (E-89)
Code: P01 – R01

NRC

9.2.4. Labeling Sheet Samples

Sample: 52 micron

5/2/17

E-89 CNF Sheet – No visible defects
Code: P01 – R01 – S01
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NRC

9.2.5. Labeling Conduit Samples

Sample: 2WD Conduit

5/2/17

Two Layered Conduit – Slurry Sealed/
Dipped
Code: P01 – R01 – S01 – C01

NRC

9.3. Examples of Sample Logs for Tracking
9.3.1. Log for Raw Pulp
Sample from
lot
“P”

Storage
Conditions in
TAPPI room

Mass of
Sample

Moisture
Content (%)
Of Aliquot

Visual
Inspection

Notes

200 grams

10%

No
discoloration
of any sort

Eucalyptus

25 ºC
P01

50%
Humidity

Employee
Initials and
Date
NRC
5-1-17

9.3.2. Log for CNF Slurry
Sample #
“R”

Pulp
Sample
Used
(QCC-01)

R01

P01

Date CNF
was
Produced

Cumulative
Energy

5-1-17

4300
kW-hr

Time
Spent
Refining

Final %
Fines

1.5 hrs

89%

Weight
% of
Solids

Volume of
Slurry
Collected

(SOP-04)

(Estimation)

2.01%

15 Liters

Notes

Employee
Initials
and Date

NRC
5-1-17

9.3.3. Log for CNF Sheet
Sample #

Slurry
Used

“S”

(QCC-06)

S01

R01

Date/Time
Spread

Date/Time
Lifted

9 am

10 am

5-1-17

Volume
of Slurry
Spread

Casting
Thickness

120 mL

1.9 mm

Dried
Thickness
(Avg.  St. Dev.
Of 15pts)

52 µm

5-2-17
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 1.7 µm

End Use
(Destination)

Shipped to
Harvard
Mouse Trial

Notes

Employee
Initials
and Date

NRC
5-2-17

9.3.4. Log for CNF Conduit
Sample
#
“C”

(QCC-07)

Slurry
Used for
Seal/Dip

C 01

S01

R01

Sheet
Used

Date
Rolled

Type of
Seal

5-2-17

CNF
seal
and dip

Inner
Diameter

Number
of Layers

(QCC-06)

0.65mm

2 layers

Length
of
Conduit

2.5 cm

End Use
(Destination)

Shipped to
Harvard
Mouse Trial
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Notes

Employee
Initials
and Date

NRC
5-2-17

CNF-SOP-11 STABILITY STUDIES

Nanocellulose Conduit Production
Standard Operating Procedure #11
Material Stability Studies

Rev

Date

Description

1

6/30/2017

Draft Development Document-Nicklaus Carter

2

7/28/2017

Revision-Mary Bourque

3

8/14/17

Revision – Nicklaus Carter

Approved by:

Signature

Date

Originator

Nicklaus Carter

Manager

David Neivandt

Quality Assurance

David Neivandt and Caitlin Howell

194

1. Purpose
1.1. To test the material stability of all materials, samples, and products
2. Definitions
2.1. CNF: Cellulose Nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. Fines: Cellulose Nanofibrils that are less than 200 μm in length
3. Health and Safety Warnings
3.1. Take care when lifting or carrying either large or heavy loads: Improper form or the inability
to lift heavy loads can cause strains and sprains.
3.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.3. Work in a well-ventilated laboratory area.
3.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.5. Hazardous waste must be disposed of in the designated waste container.
3.6. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4. Cautions
4.1. Ensure stable conditions when storing each material for a predetermined amount of time.
Changing conditions may invalidate results.
4.2. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.3. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5. Interferences
5.1. All conditions must be carefully monitored and recorded.
6. Personnel Responsibilities and Qualifications
6.1. Supervisor:
•

Ensure operators are trained on this procedure.

•

Ensure operators conduct procedures as instructed.

6.2. The Operator:
•

Must be trained on all equipment and procedures prior to operation.
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•

Complete this procedure as instructed.

•

Report any deviations to this procedure to Dr. Neivandt.

•

Must be able to lift up to 50 pounds.

7. Equipment and Materials
7.1. Equipment
7.1.1. Shaker Table (Fisher Scientific, 11-676-339)
7.2. Materials (as listed or equivalent)
7.2.1. 50 ml centrifuge tubes (Fisher Scientific, 22170265)
8. Quality Control and Quality Assurance
8.1. Repeat tests to ensure no outliers in conditions. The stability studies in this SOP are meant
to ensure high quality products that can withstand different environments.
9. References
9.1. All SOPs and QC checklists in the master binder
10. Procedures
10.1. Slurry Stability
10.1.1. Dispense the desired amount of CNF slurry into a new sealed container and label
accordingly
10.1.2. Leave the slurry undisturbed for a predetermined amount of time in a
predetermined environment
10.1.3. Visually inspect the slurry for contaminants/growth
10.2. Sheet Stability - Dry Stability
10.2.1. Leave sheets of CNF in a predetermined environment for a designated amount of
time and label accordingly
10.2.2. Analyze sheets visually and record observations
10.2.3. Measure sheet thickness at each temporal observation
10.3. Sheet Stability - In Liquid
10.3.1. Submerge CNF sheets in desired solution and label accordingly
10.3.2. Visually inspect the sheets for degradation
10.3.3. Visually inspect the solution for increase in particulate concentration
10.4. Conduit Stability - Dry Test
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10.4.1. Leave CNF conduits in a predetermined environment for a designated amount of
time and label accordingly
10.4.2. Analyze conduits visually and record observations
10.4.3. Measure conduit diameter at each temporal observation
10.5. Conduit Stability - In Liquid
10.5.1. Fill centrifuge tubes with at least 3 inches of the predetermined solution to ensure
coverage of the conduit and label accordingly
10.5.2. Visually inspect conduits for degradation
10.5.3. Observe the solution for increase in particulate concentration
10.5.4. Leave tubes stationary or place on shaker table
10.6. Conduit Stability - Bending Test
10.6.1. Leave conduits in predetermined solution for a predetermined amount of time and
label accordingly
10.6.2. Remove conduit and fix at both ends using a mandrel: The mandrel is placed within
the conduit ends ¼” in
10.6.3. Place the conduit with mandrels assembly on a smooth platform where the conduit
can be bent by moving the mandrel ends
10.6.4. Bend the conduit and record the angle at the point of outer layer tearing or collapse
of the middle region
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1.0 Purpose
1.1. To ensure all products are properly packaged and the log reflects complete characterization
prior to distribution
2.0 Definitions
2.1. CNF: Cellulose nanofibrils
2.2. DIW: Deionized distilled water (17.45-17.46 Megaohms-cm)
2.3. Fines: Cellulose nanofibrils that are less than 200 μm in length
3.0 Health and Safety Warnings
3.1. Take care when lifting or carrying either large or heavy loads: Improper form or the inability
to lift heavy loads can cause strains and sprains.
3.2. Use appropriate personal protective equipment PPE (laboratory coats, gloves, safety glasses
when applicable) while working in the laboratory.
3.3. Work in a well-ventilated laboratory area.
3.4. PPE is worn only in laboratory areas and removed before entering non-laboratory areas.
3.5. Hazardous waste must be disposed of in the designated waste container.
3.6. Be familiar with the MSDS/SDS for all chemicals being used in this procedure.
4.0 Cautions
4.1. Improper storage of materials could result in damage or degradation of samples.
4.2. Do not process recovered, re-conciliated, or damaged materials or equipment. Visually
inspect all materials and make note of any damaged or lost material in the corresponding
QC checklist as well as reporting the loss to Dr. Neivandt.
4.3. Ensure filters have been on and running for at least 24 hours. If the filters have not been on
for at least 24 hours, turn the filters on and wait until a full 24 hours has passed before entry
to prevent contamination due to airborne particles.
4.4. If the clean room pressure is not twice that of the gowning room, do not enter the clean
room, for this may indicate end of the filter life.
5.0 Interferences
5.1. Be sure all materials are packaged properly with the correct labels and log sheets included.
6.0 Personnel Responsibilities and Qualifications
6.1. Supervisor:
•

Ensure operators are trained on this procedure.

•

Ensure operators conduct procedures as instructed.
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6.2. The Operator:
•

Must be trained on all equipment and procedures prior to operation.

•

Complete this procedure as instructed.

•

Report any deviations to this procedure to Dr. Neivandt.

●

Follow Safety and Environmental Management (SEM) lock-out tag-out procedure for
equipment that needs repair. Remove broken equipment from the room.

•

Must be able to lift up to 50 pounds.

7.0 Equipment and Materials
7.1. Equipment
7.1.1. Tabletop impulse sealer with cutter (ULINE, H-161)
7.2. Materials (as listed or equivalent)
7.2.1. Pre-designed labels (CNF-SOP-10)
7.2.2. Flat sealable polypropylene bags, 4mil 4x6” (ULINE, S-11585)
7.2.3. Resealable plastic bags, 2mil 10x13” (ULINE, S-596)
7.2.4. Glass jar with metal lids, 16 oz. or ~500mL (ULINE, S-17984M)
7.2.5. Glass jar with metal lids, 32 oz. or ~1L (ULINE, S-19316M)
8.0 Quality Control and Quality Assurance
8.1. Quality Assurance Supervisor MUST approve all QC checklists prior to distribution.
8.2. Visually inspect all packaging and storage materials prior to use: If packaging materials are
dirty or damaged, discard immediately and report to Dr. Neivandt.
9.0 References
9.1. All QC checklists and SOPs contained in master binder.
10.0 Procedures (Refer to respective quality control checklists)
10.1. Packaging cellulose pulp slurries
10.1.1. Fill screw top glass containers with slurry (500mL or 1L container depending on the
amount of slurry being packaged)
10.1.2. Cover and label containers accordingly
10.1.3. If the log corresponding to the slurry is complete, notate in the log the amount
removed and the receiving organization in the “end use” column
10.2. Packaging cellulose sheets
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10.2.1. Label bag accordingly
10.2.2. Package cellulose sheets in resealable plastic bag
10.2.3. If the log corresponding to the sheet is complete, notate the receiving organization
in the end use column
10.3. Packaging cellulose conduits
10.3.1. Label bag accordingly
10.3.2. Place one conduit in the unsealed bag
10.3.3. Seal the bag using the impulse heat sealer, making sure to not crimp the conduit
10.3.4. If the log corresponding to the conduit is complete, notate the receiving
organization in the end use column
10.4. Distribution of Products
10.4.1. When an order is received, the products are procured in the order in which they
were made (line clearance methodology).
10.4.2. All log sheets must be collected for the procured products
10.4.3. Ensure that the log sheets are filled out thoroughly
10.4.4. Ensure that all products of acceptable quality (yields, visually inspect, etc.)
10.4.5. Final approval of shipment must be given by Dr. Neivandt.
10.5. Recalled/Defective Products
10.5.1. Recalls will be dealt with on a case-to-case basis with Dr. Neivandt to establish an
acceptable procedure for future occurrences.
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A4: GLUCOSE DIFFUSION COEFFICIENT
The glucose concentration in the receiver chamber of the bi-chambered tanks was measured as a
function of time until either failure of the CNF sheet was observed, or the concentration approached
that of the donor chamber. Aliquots of receiver chamber solution (50 μL) were taken at a given time and
the absorbance of the samples measured employing a UV-Visible spectrometer (Thermo Scientific,
GENESYS 10S) at a wavelength of 340 nm. The glucose concentration of each sample was obtained
employing the calibration curve of Section 3.11, see below.

Tank
#1

Time
3hrs

Absorbance
0.033

Concentration (mmol/L)
0.107

#2

3hrs
6hrs
9hrs
3days
4days

0.023
0.216
0.145
0.870
0.953

0.073
0.729
0.488
2.955
3.237

#3

3hrs
6hrs
9hrs
27hrs
33 hrs

0.131
0.194
0.404
0.714
0.754

0.440
0.655
1.369
2.424
2.560

#4

3hrs

0.114

0.382
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A5: STATISTICAL ANALYSES FOR COMPARISONS
Statistical analyses were performed in Minitab 19 Statistical Software. Several comparisons were made
regarding CNF sheets in both the tensile testing and surface roughness measurements. In tensile testing
samples were taken both the with and cross to the direction of sheet casting. Surface roughness analysis
compared the two surfaces of CNF sheets when plated on a stainless-steel plate: the air-exposed surface
versus the steel contacting surface. The following readouts are resultant of Minitab’s assistant function
for statistical hypothesis testing.

STATISTICAL ANALYSIS FOR COMPARISONS OF TENSILE STRENGTH

Samples used for tensile testing were taken from both with and cross to the direction of sheet casting,
noted as parallel and perpendicular respectively. From the t test directly above, it can be confirmed that
samples taken in the parallel direction statistically had a higher Young’s modulus value than those taken
in the perpendicularly.
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STATISTICAL ANALYSIS FOR COMPARISONS OF SURFACE ROUGHNESS

Duplicate CNF samples were taken from two sheets in both with and cross casting directions and
mounted on glass slides with either the presumed rough or smooth side exposed. Each combination of
variables was measured in triplicate resulting in 48 total measurements. All samples with the rough side
exposed were grouped, regardless of other parameters, and compared to group of samples with the
smooth side exposed. From the readout directly above, the average roughness of the air-exposed
surface (rough side of the sheet) was statistically greater than the average roughness of the steelcontacting surface (smooth side of the sheet).
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Duplicate CNF samples were taken from two sheets in both with and cross casting directions and
mounted on glass slides with either the presumed rough or smooth side exposed. Each combination of
variables was measured in triplicate resulting in 48 total measurements. All samples with the airexposed surface were grouped (24), and comparisons were made between samples taken cross-casting
direction against those taken with-casting direction (12 each). From the readout directly above, the
average roughness of the air-exposed surface samples did not significantly differ as an effect of casting
direction.
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Duplicate CNF samples were taken from two sheets in both with and cross casting directions and
mounted on glass slides with either the presumed rough or smooth side exposed. Each combination of
variables was measured in triplicate resulting in 48 total measurements. All samples with the steel
contacting surface (smooth) were grouped (24), and comparisons were made between samples taken
cross-casting direction against those taken with-casting direction (12 each). From the readout directly
above, the average roughness of the steel-contacting surface samples did not significantly differ as an
effect of casting direction.
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A6: VARIOUS CNF CONDUIT DESIGNS AND CNF RELATED DEVICES
Over the course of conduit development a range of sealing techniques and device designs were reduced
to practice for a range of potential applications, see the table below.
Title

Image

Production

Potential Application

Simple
Conduit

4.5x2.5cm rectangle of CNF sheet
was rolled onto a mandrel and
then sealed with CNF

Severed nerves

Mechanical
Interlock
Conduit

Uses various slits and tabs to
reinforce the closure of the
conduit for increased stability
within solution. The tabs are
inserted through the slits during
rolling. This allows for the sealing
method to be applied as in
previous conduits

Physically ‘locked’
conduit for severed
nerves with
increased stability

Collared
Conduit

4.5x2.5cm rectangle of CNF sheet
with two integral rectangles with
triangular tops removed, then
rolled onto a mandrel and sealed
with CNF

Reinforces suturing
of severed nerves

Web and
Guiding
Cable
Conduit

Simple conduit rolled and sealed
accordingly. It was then threaded
with a needle and thread to add
webs to both ends and then an
inner connecting thread

Directional guidance
of nerve
regeneration,
severed nerves

Suture
Conduit

Created a wet sheet of CNF as
established. The wet sheet was
then shaped into a 4.5x2.5cm
rectangle. Sutures were added
across the top of the wet sheet
and then the sheet was left to dry.

Directional guidance
of nerve
regeneration,
severed nerves
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It was then rolled and sealed with
CNF

Branched
Conduits

Three simple conduits were
produced and then the ends were
trimmed to form the branch. CNF
was used to seal the conduits and
the point of branching. Branching
can used to create tees, 90-degree
bends, etc.

Experimental

Curved
Conduits

Wrapped a rectangular sheet of
CNF around a curved mandrel and
sealed with CNF. Alternatively, a
mold could be used, and the two
halves could be sealed together
with CNF

Experimental

Hinged
Conduits

Simple conduit cut down the
middle, then a strip of a CNF sheet
was sealed along the inside of the
conduit which left two flaps that,
when pulled on, would open the
conduit

Nerve crush injuries

Windowed
Conduits

Simple conduit with squares
removed equidistant from one
another. When rolled on a
mandrel, the cut-out squares line
up perfectly with each other and
create a window

Visualization of
regeneration or aid in
surgery
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Double-Layer
Conduits

Simple conduit made of one
material rolled and dried on a
mandrel, then a second layer is
wrapped around the dried conduit
of a different material to create a
conduit with two different layers

Tapered-End
Conduits

Created a simple conduit and then
fused the two ends together by
wetting with water and then
sealed the ends together with
Drug delivery
CNF. To reduce sharp edges, once
dried the edges were trimmed and
the slurry seal reapplied.

Capsules

Using hermetic alodined pans as
molds, CNF was poured over the
pans to create sheets with indents
when dried. Two sheets were then
sealed together with DNF and the
edges were cut away to create a
capsule.
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Enhance
regeneration by use
of two materials

Drug delivery

A7: MURINE STUDIES AVERAGE DATA
To gauge functional recovery in both murine studies, grip strength analysis was performed. Grip
strength was measured in grams for both the control hindlimb and the hindlimb which had been
operated upon. Measurements were recorded in triplicate; the following data represents the averages
of the triplicate measurements.

MURINE STUDY 1 – AVERAGE GRIP STRENGTH DATA
Data below are those available from the first murine study. All recorded grip strength measurements are
in grams.

Group

Week 2

Week 6

Week 8

Conduit 16.36

39.08

42.82

Sham

18.86

19.84

9.16
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MURINE STUDY 2 – GROUP 1 AVERAGE GRIP STRENGTH DATA

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
2188
1
2189
1
2192
1
2194
1
2199
1
2183
1
4
1
25
1
32
1
39
1
46
1
53
1
54
1
55
1
67
1
68
1
70
1
98
1
103
1
105
1
116
1
27.50
31.80
36.50
27.30
35.20
37.30
24.00
32.60
23.20
38.10
31.80
42.10
39.50
36.10
48.50
45.50
55.00
45.93
41.73
40.93
48.40

Week 0
24.90
24.50
36.90
30.50
39.00
22.80
15.40
37.80
20.60
37.80
27.50
41.20
41.60
40.80
37.80
39.50
36.90
41.23
43.10
28.17
42.07

wk 0
21.90
18.00
20.20
17.60
34.30
25.30
23.60
35.20
17.60
34.80

1.40
1.53
1.07
1.70
0.93
1.23
0.80
1.77

2.37

1.70
1.70
1.70
1.20
1.70
0.80
1.70
1.27

29.63
53.40
36.93
43.43
41.90
34.90
34.77
35.03

38.80

26.20
21.00
23.60
20.60
30.90
16.30
30.90
38.07

wk 1

Week
1
1.70
0.80
1.20
3.40
0.40
1.20
1.20
3.80
1.20
1.20
28.60
20.47
18.00
28.03
34.63
33.47
35.77
31.63
31.43
43.23

1.20
1.20
0.80
1.20
0.80
2.10
2.23
1.40

1.80
1.23
2.37
3.67
2.40
0.97
2.10

36.50
17.60
27.90
32.60
45.90
34.07
27.60
35.63

37.90
34.33
33.33
44.37
38.63
37.33
39.77

2.23
1.50
1.63
1.37
9.97
1.23
1.70
1.83

3.27

1.37
1.50
1.40
3.67
1.27
1.07
1.83
2.23

41.93
49.20
47.10
39.50
33.07
38.47
41.50
35.37

31.90

34.20
24.03
28.30
36.30
28.90
32.60
21.73
35.20

0.53
0.40
0.97
1.97
12.83
6.70
1.40
1.23

5.83

1.37
0.80
1.59
2.50
1.23
1.53
1.80
1.70

34.90
45.67
46.40
39.80
41.47
41.63
36.20
40.07

39.20

48.27
37.33
37.27
41.10
33.50
40.63
26.17
36.63

0.93
2.53
2.10
1.20
9.27
7.10
1.47
1.83

5.27

1.40
1.83
1.70
3.67
1.07
1.10
1.20
1.53

39.20
43.67
47.67
37.80
45.10
39.23
45.63
40.93

44.10

48.23
36.17
37.90
45.80
36.20
37.07
31.03
42.23

Week wk 2 Week wk 4 Week wk 6 Week wk 8 Week
wk
2
4
6
8
10
10
1.20 18.00 2.50 24.00 1.07 23.30 1.37 28.30 1.67 34.77

1.53
1.63
1.97
0.93
0.80
1.37
1.23
1.67
1.23
0.80
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MURINE STUDY 2 – GROUP 1 AVERAGE GRIP STRENGTH DATA (CONT.)

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
2188
1
2189
1
2192
1
2194
1
2199
1
2183
1
4
1
25
1
32
1
39
1
46
1
53
1
54
1
55
1
67
1
68
1
70
1
98
1
103
1
105
1
116
1
wk
12
35.03
0.80
4.80
0.93
10.13
0.97
0.93
0.83
2.10

Week
14
1.53
10.95
9.65
18.00
13.25
12.65
18.00
9.65
18.03

1.07
5.40
1.53
5.40
1.07
1.50
1.97
2.10

24.82
19.42
19.33
22.38
17.38
20.85
14.00
19.43

0.80
3.67
1.80
7.40
1.53
1.23
0.83
2.53

22.93
29.90
21.22
22.58
27.67
24.58
20.93
25.38

23.73
21.28
20.48
22.88
21.32
19.37
8.58
21.37

1.80
7.10
1.93
2.23
11.40
1.67
1.50
1.23

0.93
6.27
1.67
1.67
0.93
0.67
0.67
1.67

36.77
42.37
54.03
35.90
43.53
31.93
38.77
44.63

44.83
46.37
42.07
35.47
32.33
41.37
22.43
37.20

wk
Week
wk
Week
wk
Week
wk
14
16
16
18
18
20
20
11.55 1.53 14.68 0.67 18.28 1.10 42.73

Week
12
1.23
46.67
37.77
40.03
35.63
41.67
37.80
16.33
40.63

1.80
4.67
0.97
5.10
8.97
2.23
1.67
1.53

2.40
3.67
1.23
9.70
0.53
0.80
1.37
1.80

18.57
23.58
24.02
20.58
25.72
21.43
18.95
20.95

44.67
1.93
7.70
1.37
4.23
11.27
5.97
1.53
4.73

2.27

9.70
14.78
17.85
17.58
18.35
16.43
16.12
22.50

44.77
48.97
41.07
40.90
45.33
38.07
40.07
49.07

1.10
10.83
1.37
4.27
10.00
11.10
1.80
1.70

1.93
7.27
1.40
4.53
12.40
7.83
1.67
1.53

212

MURINE STUDY 2 – GROUP 2 AVERAGE GRIP STRENGTH DATA

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
2190
2
2191
2
2198
2
5
2
31
2
34
2
36
2
41
2
43
2
44
2
49
2
52
2
56
2
66
2
72
2
75
2
108
2
111
2
115
2
43.80
27.90
32.60
15.40
30.50
33.90
41.60
36.50
34.30
32.60
40.40
34.80
40.80
37.80
49.40
46.80
45.27
39.07
42.77

Week 0
24.00
30.50
33.50
12.80
33.90
30.90
33.50
29.60
23.20
36.50
33.50
45.20
44.70
28.30
36.50
39.50
43.93
37.33
30.83

wk 0
wk 1

27.30
27.90

26.60
22.30
29.60
15.40
37.80
30.90
29.60

1.63
1.53

24.57
28.33
28.77
39.20
35.47
35.90

Week
1
1.70
1.20
1.20
1.20
3.00
1.20
1.70

0.93
0.93
0.97
0.67
0.97
0.97

23.60
14.10
18.00
29.20
42.10
33.00
33.77
27.30

2.37
3.67
0.97
2.67
1.80
3.40

0.97

Week
4
1.70
2.10
2.10
0.80
1.80
3.13
2.97
1.07

37.63
39.07
35.63
48.23
45.50
32.47

37.20

32.20
32.20
34.80
39.20
41.20
30.00
35.93
36.17

wk 4

Week
2
1.20
1.20
0.80
1.20
1.70
3.00
1.53
1.80

41.07
24.60
26.60
26.00
39.20
41.77
38.10
43.63
37.50
35.03

wk 2

2.93
1.23
2.27
0.53
1.23
1.67
1.37
1.07
2.10
1.23

42.20
30.03
30.33
26.30
31.47
39.23
45.93
41.80

1.83
1.23
5.40
1.23
2.70
7.83
1.83
2.67
5.97
9.73

Week
8
1.53
1.20
2.40
3.10
8.70
8.97
11.70
2.37

46.77
43.77
42.50
42.50
41.93
45.53
38.20
50.23
39.50
48.63

28.90
33.20
37.07
33.03
45.07
34.77
37.00
35.90

1.07
1.23
3.67
1.97
3.53
1.80
1.67
2.57
8.23
8.40

Week
10
1.07
1.83
4.77
2.37
2.70
8.53
14.27
1.97

43.93
46.30
40.90
35.77
41.50
39.20
41.47
41.80
41.80
49.10

wk
10
41.97
41.67
38.63
39.67
42.80
40.90
34.50
40.93

wk 8

Week
6
1.23
1.07
1.40
1.53
6.27
11.57
9.57
1.80

41.50
38.77
43.97
44.20
44.53
39.10
37.07
41.07
49.23
38.07

wk 6

2.13
1.50
2.80
1.93
1.50
4.97
1.83
1.83
3.53
8.13
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MURINE STUDY 2 – GROUP 2 AVERAGE GRIP STRENGTH DATA (CONT.)

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
2190
2
2191
2
2198
2
5
2
31
2
34
2
36
2
41
2
43
2
44
2
49
2
52
2
56
2
66
2
72
2
75
2
108
2
111
2
115
2
Week
12
1.37
1.53
4.23
4.23
1.67
2.93
15.30
1.93
46.93
38.10
45.07
38.93
40.80
46.20
33.77
36.30
40.50
41.50

wk
12
44.10
33.17
40.63
47.77
46.77
40.37
34.47
37.07

2.80
5.97
14.13
7.57
6.23
9.67
10.40

4.07

Week
14
0.80
1.23
3.40
3.10
2.10
1.93
14.30
2.37

0.53
12.90
15.00
15.07
20.13
18.78
18.57

2.93

1.37
5.37
11.13
4.40
4.57
7.83
8.30

3.80

wk
Week
14
16
13.90 1.23
11.75 1.40
15.20 4.23
8.30
3.67
19.75 3.23
16.95 1.93
15.57 18.43
1.80
3.97

22.22
21.72
25.25
20.02
26.03
21.52
28.38

24.45

1.67
5.83
11.77
3.97
3.67
8.70
10.83

4.80

20.87
23.38
30.17
20.67
21.27
25.08
25.95

25.50

4.40
6.97
12.70
3.70
2.53
4.53
11.35

4.83

wk
Week
18
20
22.45 1.20
17.20 1.70
22.02 3.37
25.43 5.10
24.43 2.67
21.15 2.97
24.38 23.43
19.72 2.10

48.40
48.13
40.37
41.33
38.20
36.63
47.10

47.23

wk
20
44.20
37.90
20.17
53.97
44.10
39.93
39.77
35.03

wk
Week
16
18
15.07 0.80
17.13 0.97
19.23 3.67
17.28 6.53
25.67 2.67
23.17 2.23
23.28 19.60
18.85 3.23

1.97
0.80
4.13
2.37
3.83
13.80
3.80
4.23
8.13
7.53
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MURINE STUDY 2 – GROUP 3 AVERAGE GRIP STRENGTH DATA

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
3
2193
3
2195
3
2196
3
2184
3
3
3
26
3
28
3
29
3
33
3
37
3
42
3
50
3
60
3
61
3
63
3
65
3
71
3
80
3
84
3
87
3
107
3
112
32.20
34.80
27.90
34.30
32.20
33.90
42.50
29.20
22.30
25.30
21.40
44.20
34.80
43.40
35.20
39.50
42.10
34.82
36.07
36.72
52.93
36.77

Week 0
24.90
28.70
30.00
37.80
21.00
38.60
30.00
27.90
35.20
35.60
35.20
40.80
34.80
47.20
39.90
36.90
47.70
34.82
32.86
35.49
45.40
42.80

wk 0
27.90
20.20
17.60
23.20
26.20
41.20
40.50
31.30
36.50
25.80

1.67
1.07
1.37

0.67
1.40
0.83
1.97
1.23
1.23
2.70

Week
2
0.80
0.40
0.00
2.50
1.20
2.10
1.20
1.70
2.10
1.37

35.47
30.87
36.80

30.63
27.17
29.60
41.33
44.20
38.07
43.07

18.90
26.20
28.70
25.30
36.50
46.80
35.60
31.80
38.20
34.13

wk 2

Week
1
1.20
1.70
0.40
1.70
0.80
3.70
3.00
0.80
3.00
1.70
24.03
20.00
24.77
30.33
31.30
24.30
39.50
42.07
38.63
40.63
28.77

wk 1

1.23
1.83
1.97
0.67
0.67
0.97
1.23
1.23
1.70
1.07
1.37

Week
6
2.23
2.27
1.63
2.13
3.53
1.40
5.53
2.27
3.37
4.93

35.33
34.93
38.50
47.23
36.63
40.23
36.20
37.33
40.20
42.07
43.93

34.47
29.90
30.03
25.03
29.17
36.03
37.77
32.33
29.57
40.20

5.83
8.57
0.93
5.57
1.20
6.23
13.83
4.50
3.23
10.00
1.67

Week
8
1.70
1.50
2.63
10.00
5.83
2.40
6.53
2.50
5.00
5.97

37.97
33.60
42.37
49.37
39.23
38.50
41.50
46.10
41.67
42.07
32.73

32.17
39.27
38.37
37.50
43.10
46.37
37.50
38.90
35.77
37.20

6.53
8.40
1.40
4.80
6.27
6.10
11.80
5.53
4.23
15.00
2.10

Week
10
1.40
1.67
6.83
12.47
8.53
3.97
7.10
3.50
3.97
8.97

38.33
39.63
42.60
49.67
47.80
40.77
43.07
43.50
45.63
37.03
45.80

wk
10
37.07
37.80
43.23
38.37
35.93
41.47
41.67
41.50
35.60
35.03
wk 8
24.50
25.30
33.50
26.60
46.80
29.33
27.77
27.30
41.07
41.93

4.33
6.70
1.23
3.80
1.80
5.13
0.93
2.93
2.23
7.83
1.67

wk 6
Week
4
1.70
3.00
1.70
2.50
2.50
1.67
2.23
2.10
1.83
1.67

42.00
41.67
36.20
44.77
43.63
42.80
37.20
46.53

wk 4

2.80
1.50
3.67
3.27
2.10
1.67
1.50
2.13
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MURINE STUDY 2 – GROUP 3 AVERAGE GRIP STRENGTH DATA (CONT.)

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
2193
3
2195
3
2196
3
2184
3
3
3
26
3
28
3
29
3
33
3
37
3
42
3
50
3
60
3
61
3
63
3
65
3
71
3
80
3
84
3
87
3
107
3
112
3

Week
12
1.93
2.10
9.13
14.40
8.83
1.97
11.13
1.93
1.97
8.10
39.20
38.93
36.33
49.50
34.63
38.50
46.80
46.83
47.40
39.23
34.90

wk
12
30.17
40.07
49.97
41.77
39.63
45.77
35.90
37.20
40.93
46.80
4.83
6.40
1.50
5.37
2.40
7.97
21.43
7.23
6.83
12.57
1.80

Week
14
0.83
0.80
7.10
7.93
8.97
2.10
10.40
3.23
2.40
9.83
12.35
10.70
12.80
16.15
16.27
12.77
21.10
42.07
20.15
20.85
15.07

wk
Week
14
16
14.35 0.67
10.30 1.23
8.80
4.50
12.85 12.97
13.70 8.13
21.65 2.10
20.85 12.43
16.50 4.10
19.30 1.80
13.58 5.97
10.70
8.53
2.27
8.27
3.07
11.27
25.03
7.27
2.80
8.43
2.10

5.70
6.67
1.10
5.67
2.97
10.10
23.73
10.70
5.97
14.27
2.13

7.13
1.97
8.27
4.97
9.13
23.47
11.15
6.10
15.57
2.40

wk
Week
16
18
17.20 0.93
20.77 1.40
20.00 3.67
19.82 9.70
23.32 10.10
23.88 3.50
21.52 12.43
20.58 4.53
19.57 2.10
21.07 10.70
21.15
20.15
21.80
26.58
20.52
21.82
21.22
24.52
21.95
24.95
17.20

13.27
9.53
3.10
5.23
4.27
11.70
29.33
5.27
4.50
6.53
2.67

wk
Week
18
20
15.50 0.97
20.43 1.67
28.53 4.97
24.85 5.97
24.30 12.30
23.93 4.37
23.15 11.13
20.22 2.67
21.67 5.10
28.32 8.13

43.93
37.03
44.20
54.40
53.37
40.37
41.53
38.77
51.23
32.17
38.70

wk
20
39.03
46.93
45.97
41.10
47.07
49.83
37.93
40.63
38.37
40.37
22.02
22.67
18.92
27.43
18.52
23.23
34.12
27.03
27.12
25.90
18.35
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MURINE STUDY 2 – GROUP 4 AVERAGE GRIP STRENGTH DATA

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
4
2197
4
2185
4
1
4
2
4
27
4
30
4
35
4
38
4
40
4
45
4
51
4
59
4
62
4
64
4
69
4
74
4
81
4
85
4
89
4
90
4
106
4
114
29.20
38.20
22.70
22.70
42.90
38.20
30.90
34.80
29.20
35.60
43.80
25.30
41.20
39.00
39.90
36.10
31.46
31.66
34.48
32.96
50.80
42.50

Week 0
24.50
31.30
19.30
17.10
31.30
35.60
30.00
37.80
36.50
43.40
39.10
30.50
47.20
25.70
39.50
28.30
32.62
35.42
36.78
32.99
43.63
45.97

wk 0

Week
4
1.70
1.20
0.80
1.20
2.23
1.73
1.23
0.67
0.67
1.20

40.93
32.77
40.93
40.53
39.50
40.93

32.20
27.00
38.60
34.80
37.27
32.47
37.37
38.50
36.77
44.97

2.93
1.53

Week
6
1.10
1.53
5.10
2.07
1.63
5.53
3.37
4.10
1.97
3.10
2.40
1.07
1.93
2.53
1.93
1.93
7.80
2.40
1.93

39.80
39.17

27.17
26.20
28.73
29.17
35.20
36.77
38.77
42.53
31.60
42.07
42.50
31.43
45.50
39.20
36.90
39.77
38.50
38.37
36.17

4.13
2.83

Week
8
2.80
4.23
12.83
2.97
2.40
4.40
2.13
6.97
2.40
4.23
1.53
1.97
4.23
2.50
1.80
4.97
3.27
2.10
2.27

39.63
45.80

43.37
43.67
45.80
42.80
40.63
37.93
37.93
40.90
34.73
48.77
42.63
33.17
43.93
38.63
37.63
43.23
44.80
37.03
39.37

5.10
3.23

Week
10
5.43
6.67
12.00
5.67
5.40
8.27
4.43
6.97
2.07
8.70
2.10
1.40
3.40
4.40
5.67
7.53
9.83
4.53
2.83

37.33
49.57

wk
10
43.17
35.80
42.67
41.93
36.63
39.20
42.83
39.27
37.77
50.97
41.07
29.20
50.23
46.10
34.07
41.77
41.37
42.07
39.60
wk 8

18.90
26.60
26.60
27.00
28.70
26.60
38.33
38.33
29.33
36.63
39.63
22.30
31.17
35.60
47.53
36.20
38.63

2.53
1.80
1.80
1.83
1.67
1.20

46.67
36.33

wk 6

Week
2
0.40
0.80
1.20
1.20
2.50
1.70
2.10
2.23
2.37
1.97
0.93
1.07
1.10
1.53
1.23
1.23
2.13

36.60

2.27
3.83

wk 4

1.93

36.20
41.93

wk 2

31.73
16.30
22.43
32.30
29.77
25.77
39.33
40.07
31.83

1.23
1.53

wk 1

Week
1
1.20
0.80
0.80
1.70
2.80
3.00
1.70
1.70
1.20
2.10
1.10
1.67
1.83
1.10
0.67
0.93
1.67
1.53
2.10
35.50
40.93

22.70
28.30
24.50
19.70
34.30
34.80
48.10
33.50
27.00

0.80
1.67
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MURINE STUDY 2 – GROUP 4 AVERAGE GRIP STRENGTH DATA (CONT.)

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
2197
4
2185
4
1
4
2
4
27
4
30
4
35
4
38
4
40
4
45
4
51
4
59
4
62
4
64
4
69
4
74
4
81
4
85
4
89
4
90
4
106
4
114
4

Week
12
5.80
5.70
10.53
7.70
6.67
2.80
2.83
5.80
2.53
11.57
1.80
4.80
5.53
4.50
5.27
8.97
13.00
8.70
8.13
27.73
38.90

wk
12
41.93
36.60
49.50
44.67
48.80
41.50
40.80
34.37
35.20
51.53
41.63
42.37
45.23
37.47
40.73
39.93
44.77
34.50
41.77
10.83
3.10

Week
14
5.83
8.70
8.10
9.57
3.40
5.23
2.23
4.37
1.53
12.67
2.97
13.40
7.70
2.80
6.13
13.27
22.10
11.00
9.53
18.37
21.23

wk
Week
14
16
11.55 1.67
14.55 4.80
12.85 6.23
10.45 13.27
18.40 10.97
18.25 2.53
25.10 4.23
17.87 4.70
14.68 2.23
1.97 12.57
16.33 4.50
8.68
2.20
11.77 4.50
16.92 3.67
15.50 5.70
13.50 14.83
20.73 18.13
40.07 7.53
16.88 4.83
5.07
1.53

8.27
2.67

5.10
3.07

wk
Week
16
18
22.23 2.10
22.60 6.53
25.45 8.53
22.43 9.00
21.13 13.57
21.73 2.97
20.65 3.10
22.50 7.27
18.35 2.23
25.93 10.57
22.52 3.13
17.12 1.40
22.93 5.23
20.58 3.67
19.78 6.97
22.58 12.00
26.30 12.40
19.72 4.53
20.65 11.70
21.28
23.67

4.40
2.80

wk
Week
18
20
23.88 2.80
22.65 7.53
28.80 7.27
27.12 15.10
26.10 12.97
23.37 3.80
21.52 3.67
19.37 7.10
18.37 2.37
32.10 12.60
22.30 3.27
27.88 7.37
26.47 15.00
20.13 6.20
23.43 9.70
26.60 14.27
33.43 15.70
22.75 6.93
25.65 9.67

35.90
40.37

wk
20
41.50
39.37
44.07
39.37
50.83
43.93
45.73
37.63
37.47
43.90
37.50
44.20
45.83
49.53
51.27
52.10
42.90
35.77
45.40
19.28
21.00
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MURINE STUDY 2 – GROUP 5 AVERAGE GRIP STRENGTH DATA

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
78
5
79
5
82
5
83
5
86
5
88
5
91
5
94
5
95
5
96
5
97
5
99
5
100
5
101
5
102
5
104
5
109
5
110
5
113
5
34.14
33.58
31.53
35.21
36.61
33.60
44.84
44.93
44.53
47.10
55.67
47.37
42.97
45.23
37.80
35.77
48.40
44.07
47.67

Week 0
31.56
34.79
32.33
35.62
32.53
35.47
38.87
39.07
39.47
40.07
50.40
45.23
45.23
39.93
50.33
37.50
38.03
41.63
32.77

wk 0
Week
1
1.97
1.83
1.37
1.50
1.10
1.23
1.53
1.53
1.67
2.53
1.23
1.07
0.27
1.07
1.97
1.23
1.10
1.67
0.97
wk 1
36.37
43.43
39.20
32.47
39.07
33.20
37.20
35.17
36.07
40.50
37.63
32.33
39.07
43.93
34.73
30.40
34.60
33.73
32.47

41.63
42.07
42.40
44.67
41.10
36.90
42.23
35.63
44.10
46.37
44.67
41.20
43.67
43.67

wk 4

Week wk 2 Week
2
4
1.67 28.97 1.70
2.23 24.30 1.50
1.70 37.07 1.53
1.53
1.23
1.07
7.23
2.10
4.53
1.67
4.40
1.23
1.37
1.53

41.50
38.47
44.23
33.47

40.20
36.67
38.93
25.77
33.90
31.03
36.07
35.63
39.57
36.90
34.73
34.47
33.03
34.17
37.20

1.50
2.97
2.80
1.67

1.97
2.07
1.67
0.67
0.93
1.10
1.53
0.53
0.80
0.80
1.37
0.67
1.07
1.53
1.40

7.87

Week
6
2.50
1.67
1.37
6.40
3.53
3.23
21.87

37.07
37.93
36.47
41.63
41.63
44.10
45.23
37.07

54.43

35.63
40.07
40.53
34.60
42.63
43.93
33.20

wk 6

2.67
3.80
7.27
3.13
4.80
2.80
5.97
1.67

Week
8
3.67
2.67
1.67
5.43
5.37
5.10
1.97

48.67
45.53
44.23
45.93
51.10
40.20
55.00
35.73

42.63
44.93
47.97
47.80
33.47
43.23
38.67

5.40
8.00
9.87
3.10
6.27
2.53
12.40
1.20

Week
10
8.57
1.40
2.27
14.83
4.37
8.40
19.43

42.93
49.07
45.80
46.53
45.80
43.67
46.77
37.20

wk
10
47.17
44.07
44.07
44.80
40.90
46.10
41.63

wk 8

3.80
7.27
11.00
4.40
6.40
4.80
9.30
1.37
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MURINE STUDY 2 – GROUP 5 AVERAGE GRIP STRENGTH DATA (CONT.)

‘Week’ denotes operated leg data, ‘wk’ denotes control leg data. All measurements reported in grams.
Animal Group
ID
78
5
79
5
82
5
83
5
86
5
88
5
91
5
94
5
95
5
96
5
97
5
99
5
100
5
101
5
102
5
104
5
109
5
110
5
113
5
Week
12
13.70
9.97
0.67
20.17
9.13
10.83
20.60

38.77
46.37
34.77
41.00
46.53
48.67
39.20
44.33

wk
12
48.53
43.97
40.77
40.80
50.53
38.77
44.67

9.67
10.57
9.40
4.10
11.23
3.67
5.40
2.10

Week
14
11.27
12.73
1.93
17.00
10.57
10.53
24.60

16.43
19.93
22.37
18.05
15.53
17.83
17.63
16.93

wk
Week
14
16
19.02 10.40
22.83 7.97
20.45 1.07
32.47 20.60
20.52 11.57
17.63 10.80
19.43 22.30

15.00
11.40
12.60
3.37
7.27
2.53
11.40
1.10

7.40
12.57
12.13
3.23
5.67
5.53
10.40
1.10

7.70
6.83
9.83
2.80
6.97
2.67
7.10
1.23

wk
Week
16
18
22.57 8.37
23.30 8.97
24.67 1.23
27.10 19.47
18.50 11.53
23.23 11.83
30.27 21.90

25.67
24.67
25.75
24.53
27.95
21.50
30.48
18.70

3.97
8.27
8.53
2.10
5.40
2.80
15.13
1.20

wk
Week
18
20
29.90 7.83
28.35 7.70
21.35 1.93
28.90 19.70
30.55 9.13
24.65 10.87
34.63 22.30

48.10
45.93
44.07
39.63
44.80
41.20
38.07
40.90

wk
20
36.03
37.10
44.93
43.23
36.90
41.80
42.20

24.22
28.47
22.08
22.55
28.88
26.17
22.30
23.22
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MURINE STUDY 2 – WEIGHT TRENDS
The weights of subjects in the 2nd murine study were measured at the same time as grip strength
measurements were made. Weights were averaged per group for each week and trends were plotted,
see below. At the pre-surgery time point, weights were grouped closely. The no treatment group
showed steadily increasing weights over the course of 28 weeks. Groups 1-5 showed a slight initial
decrease in the first week after surgery, but thereafter recovered and all groups maintained similarly
increasing trends in weight as the no treatment group for the remainder of the study duration.
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